健全経済 healthy economy – ページ 25 – ワールドソルーションズLLC

U.S.A. アメリカ Vol.123（New Jersey ニュージャージー州 Vol.4: pharmaceutical corporations 製薬会社）

All the below link and tweets are in English.

Vol.122 (New Jersey ニュージャージー州 Vol.3: pharmaceutical corporations 製薬会社）の続き

ツイッター検索で上記製薬会社名及び Japan や日本の5製薬会社各社名を入れて出て来たもの

Japan's PeptiDream to work with Merck in developing COVID-19 therapies https://t.co/GzIqX0LbZQ pic.twitter.com/T8MxO4ZuZu

— Reuters (@Reuters) June 12, 2020

CDC Director Brenda Fitzgerald bought stock in Japan Tobacco, Merck and Humana– *AFTER* she became the nation's top public health official.

The investigation from @SarahKarlin
& @Briannaehley: https://t.co/gHNHqOP8IG

— Adam Cancryn (@adamcancryn) January 30, 2018

During COVID, the growing dangers and threat posed by antibiotic-resistant bacteria outweigh the global level of preparedness. Meanwhile, antibiotic R&D is suffering for investment. Forge applauds @Merck and Kyorin for supporting @PewCharitableTrust https://t.co/i0ToNjccgt

— Forge Therapeutics (@ForgeThera) October 23, 2020

New data from Merck, Kyorin shared to Pew's SPARK @pewtrusts @Merck https://t.co/ibg9R6JXFn

— The Science Advisory Board (@ScienceBoard) October 21, 2020

“Our hope is that the data from @Merck’s research will help catalyze discovery of new #antibiotics for Gram-negative pathogens,” @pewhealth’s @KathrynTalking says of the pharmaceutical company’s recent data contribution to SPARK. https://t.co/qd6oOf3y15

— Save Antibiotics (@saveantibiotics) October 21, 2020

Japan Prize / Merck-Banyu Lectureship for Naoya Kumagai / DECHEMA Prize for Timothy Noeel (News) https://t.co/npKfaLlQBg pic.twitter.com/6Q1xQyXK11

— Angewandte Chemie (@angew_chem) April 26, 2018

@MSD_JAPAN

In today's News Briefing: Two years unveiling a flop in their first PhIII trial of guadecitabine as a frontline treatment, Otsuka is back with 2 more pivotal setbacks. And the #FDA approved an expanded indication for Merck’s best-seller Keytruda. https://t.co/5svHdzG7UG

— Endpoints News (@endpts) October 16, 2020

Merck adds to lung cancer wall with Otsuka deal https://t.co/l9RW0Njibg pic.twitter.com/GnYs2TWMeI

— HealthIT and Biotech (@UCCharting) January 9, 2020

Merck adds to lung cancer wall with Otsuka deal | BioPharma Dive https://t.co/k063lZ3W8E

— Mr. Brian Uberig (@Brian_Uberig) January 8, 2020

MSD enlists Otsuka units Taiho and Astex to develop KRAS therapies https://t.co/2QOB4obxMj #pharma #healthcare

— PharmaTimes (@PharmaTimes) January 8, 2020

Merck and Otsuka enter into a research and development pact for a drug that targets a dangerous subset of cancers https://t.co/8ESVh069oT

— Bloomberg (@business) January 7, 2020

Merck & Co. partners with Otsuka units Taiho, Astex on cancer drug development https://t.co/qu7yCDMN5P $MRK $ASTX

— FirstWord Pharma (@fwpharma) January 6, 2020

Industry Insight of Oncolytic Virus Market Research Segment, In-depth Analysis | Merck, Otsuka Pharmaceutical Co, Pfizerhttps://t.co/lnfmzWgTWA #news #pharma #pharmiweb

— Pharma News (@pharminews) December 24, 2019

Oncolytic Virus Market Analysis and Reviews 2019 to 2025 | Merck, Otsuka Pharmaceutical Co, Pfizer, Roche, Cold Genesys, Genelux https://t.co/5MnJLhS6t2 pic.twitter.com/4THnWUqxql

— Science Examiner (@ScienceExaminer) October 7, 2019

Analyst Keshalini Sabaratnam @Pharma_GD on the #sales #forecast for @Merck and #Otsuka 's #Keytruda (pembrolizumab) projected to be top drug by 2023 and what does this mean for their #contractmanufacturers #CDMO #CMO @AstraZeneca @BoehringerDE https://t.co/R6Wmwcm2Qb

— GlobalData PharmSource (@PharmSource) October 2, 2019

The $200 discount for the Marketing Disruption Summit ends Friday! Explore the full agenda and get your tickets here: https://t.co/sueo5mBZEd #sanofi #BMS #ferring #boehringeringelheim #merck #teva #gsk #abbvie #astrazeneca #pfizer #bayer #otsuka #us #pharma #marketing #data #it pic.twitter.com/u9P8j4mLcn

— Reuters Events Pharma (@RE_Pharma) August 14, 2019

Otsuka buying Waltham, Mass.-based antibody specialist Visterra for $430 million, all-cash. https://t.co/FIwi2S4VeB

Last valuation was $188 million, per Pitchbook. Omega, Alexandria, Cycad Group, Gates Foundation, Merck, Vertex, Temasek, Alexandria among investors.

— Matthew Herper (@matthewherper) July 11, 2018

"Editor’s note: The author did not initially disclose having received payments from Boehringer Ingelheim, Eli Lilly, Hoffmann-La Roche, Lundbeck, Merck, Sharpe, and Dohme, Otsuka, Pfizer, and other companies." You have to ask – why the delay? @AmerGeriatrics https://t.co/RWpZYRJ7zK

— James Richardson, MD, MPH (@DocRock54) March 10, 2018

Merck and Otsuka US agree: Misalignment in healthcare is our biggest cha… https://t.co/H2U3iCqVZ1 via @YouTube

— Tim Nolan (@TimNolan1941) August 17, 2017

ESMO: Where will Merck, Eisai take Keytruda-Lenvima next? Ovarian and colorectal cancer could be good options, data show https://t.co/mjqD8dcsru

— cafepharma (@cafepharma) September 20, 2020

Chasing Merck, Eisai launches insomnia drug Dayvigo in Japan https://t.co/e3JM6pAqPX

— cafepharma (@cafepharma) July 7, 2020

https://twitter.com/LRamseu/status/1312391912956010498

Merck, Eisai's Keytruda-Lenvima combo stonewalled in liver cancer after Roche's first-in-class green light #livercancernews https://t.co/uJyJ0rpuoG

— Blue Faery (@BlueFaeryLiver) September 16, 2020

US rejects MSD/Eisai's Keytruda Lenvima combo https://t.co/U6bwJRTYcK #lifesciences #news

— PharmaTimes (@PharmaTimes) July 9, 2020

Merck, Eisai's Keytruda-Lenvima combo stonewalled in liver cancer after Roche's first-in-class green light https://t.co/fCgfHt2mPc

— FiercePharma (@FiercePharma) July 8, 2020

Merck, Eisai to put experimental cancer combination in new clinical trial https://t.co/LuQoPj699g

— MarketWatch (@MarketWatch) July 8, 2020

Merck, Eisai to put experimental cancer combination in new clinical trial https://t.co/uoyKGe8up0

— MMC Anchor (@MMCAnchor) July 8, 2020

ASCO: Merck, Eisai pad case for liver cancer nod with Keytruda-Lenvima combo data https://t.co/f6piWgmPOf

— EIPG (@EIPGeu) June 1, 2020

.@Merck/@Eisai's Keytruda/Lenvima combo 1st to win simultaneous approvals from @US_FDA, @GovCanHealth & @TGAgovau under new international regulatory program for #cancer drugs, writes @biotechvisigoth. $MRK #oncology https://t.co/nAfqQ8mUqL

— MedCity News (@medcitynews) September 18, 2019

New #paediatric treatments recently launched for #HIV #soiltransmittedhelminths #epilepsy and #pneumonia from 4 companies detailed in #atmi2018 today: @GSK @JNJNews @Merck @eisai …. #worldChildrensDay2018 #WorldChildrensDay https://t.co/qnb3DoC0m1

— Danny Edwards (@dannyjedwards) November 20, 2018

#Eisai, #MSD start marketing activity for #LENVIMA https://t.co/qGiJ2CwZx0 via @AsiaBioSpectrum

— Sudam Walekar (@sudam_walekar) October 23, 2018

Eisai and MSD Japan Commence Collaboration on Commercialization Activities for LENVIMA (Lenvatinib) in Japan https://t.co/oLX4MT3Vnu

— EIN Presswire: Merck Newswire (@EINMerckNews) October 22, 2018

Eisai/MSD’s Lenvima approved in Europe for liver cancer https://t.co/pPxoYTKCzG pic.twitter.com/Itatzdg438

— PIR International (@PIR_Intl) August 28, 2018

Merck, Eisai win FDA approval for Lenvima to treat unresectable HCC https://t.co/5tlVxTAiLO

— NGT Consulting (@NextGeneTherapy) August 20, 2018

Eisai and MSD team up to combine Lenvima and Keytruda in cancer https://t.co/K7XtG4RWnv pic.twitter.com/R9fukbkYeX

— Pharmamarketeer (@Pharmamarketeer) March 13, 2018

Merck partners with Eisai's Tyrosine Kinase inhibitor drug Lenvatinib with apotential deal of over 5 billion dollars#merck #Eisai #Checkpointinhibitor #Tyrosinerkinaseinhibitor #combination #billiondollar #deal #treat #malignancies https://t.co/NXsLRtc17N

— Neil Sankar (@SankarNeil) March 12, 2018

Merck and Eisai Ink $5.76B Cancer Deal https://t.co/bKH5FnuCC9 pic.twitter.com/RI1iJIIqLI

— Biotech World (@BiotechWorld) March 9, 2018

Eisai and MSD will jointly develop and commercialize a thyroid cancer therapy – https://t.co/Z1TfQSlksY pic.twitter.com/QVLB0ppzJT

— GMPnews.Net (@GMPnewsNet) March 8, 2018

Our final panel session at @PharEast2018 features Representatives from @JNJCares, Eisai Japan, MSD Singapore and Fosub-kite discussing on using real world evidence (RWD) to support the rational use of medicine in Asia. #phareast pic.twitter.com/LD4Y0kmqE4

— Phar-East (@PharEast2018) March 2, 2018

@gatesfoundation , @wellcometrust & @Mastercard Launch Initiative to Speed Development and Access to Therapies for COVID-19#COVID19TherapeuticsAccelerator #Covid19 https://t.co/ATA8tRBLc7 #BD #BI #Eisai #EliLilly #Gilead #GSK #JandJ #MSD #Merck #Novartis #Pfizer #Sanofi

— Claude Waddington (@Mr_C_Wadd) March 30, 2020

MSD and Eisai announce meaningful objective response rates for Keytruda+Lenvima combo in two cancer patient populations https://t.co/dRtWAbK5fk #pharma pic.twitter.com/2YDFuIMvrs

— Pharmafocus (@Pharmafocus) May 29, 2020

Eisai and MSD's Lenvima recommended for NHS Scotland in advanced or unresectable #LiverCancer https://t.co/bhdX1Yb5qR #cancer #pharma #NHS pic.twitter.com/H2qvj5SrrE

— Pharmafocus (@Pharmafocus) April 8, 2019

Thank you to our No One Fights Alone Virtual Gala Celebration sponsors, including Platinum Ribbon Sponsors, Amgen, Merck, Oncosec Immunotherapies, and Silver Ribbon Sponsors, Eisai and Immunomedics. Your generosity and support make it all possible. https://t.co/B8RsqHB5bW pic.twitter.com/KungeoGTTb

— TNBC Foundation (@TNBCFoundation) October 23, 2020

These pharma fleecers, including Takeda, Eisai, Merck, and Genentech, choose to sell their expensive oncology drugs in excessively large drug vials that lead to waste. They got my second #PharmaFleeceAward today.

— Senator Dick Durbin (@SenatorDurbin) March 14, 2019

Daiichi Sankyo signs clinical trial collaboration deal with Merck and Pfizer: Daiichi Sankyo has entered into a clinical trial collaboration agreement with Merck and Pfizer to evaluate the combination of its [fam-] trastuzumab deruxtecan (DS-8201) with… https://t.co/N83w7zGYxv

— cafepharma (@cafepharma) October 26, 2018

Daiichi-Merck partnership lines up Keytruda combo therapy https://t.co/YnoL7Sa9B6 pic.twitter.com/9Ocwq2ei5F

— JackLeckerman (@JackLeckerman) October 9, 2018

Daiichi Sankyo has entered into a clinical trial collaboration agreement with a subsidiary of MSD to evaluate a potential new combination therapy for breast or lung cancershttps://t.co/i08ieVPnZY pic.twitter.com/F3ZuKh8KUs

— Bio_Talent (@bio_talent) September 28, 2018

Unfortunately message is suspect bc of COI. F. Schiele reports personal fees from Board membership, consultancy, or lecturing from Sanofi, Amgen, Pfizer, AZ, MSD, BMS, Bayer & Daiichi-Sankyo. Steen Dalby Kristensen has recd lecture fees from AZ, Bayer, BMS/Pfizer and Boehringer- https://t.co/mKikYa72D9

— Ram Charan (@RamCharanji) January 11, 2018

Global Fibromyalgia Drugs market 2020: focuses on companies, opportunities, market size, growth, revenue & forecast 2026 | COVID19 Impact Analysis | Key Players: Pfizer, Eli Lilly, Actavis, Merck Sharp and Dohme, Daiichi Sankyo, etc. | InForGrowth – The … https://t.co/Z61iSQQlKs

— FMS News bot (@fmsbot) October 2, 2020

Hyperlipidemia Market: Market Data, Industry Analysis, Size,Share 2027 | Leading Players- AstraZeneca, Sanofi, Merck & Co., Pfizer, Daiichi Sankyo Company https://t.co/Wbz8agTS65

— Harshad Ramesh Borde (@BordeHarshad) August 25, 2020

The Next Boom Sector: Cancer

Physiomics #PYC is a leading oncology consultancy using its proprietary state of the art Virtual Tumour technology to predict and better understand effects of cancer treatments

Clients:
Merck, Astellas, Bicycle, Valirx, Cyclacel, CellCentric etc pic.twitter.com/djRsMNxJsc

— Stockonomist (@Stockonomist) September 28, 2020

Thanks to our @ANZUPtrials #bestofGUoncology #ANZUPGU19 sponsors – @IpsenGroup Astellas Oncology @AstraZeneca @MSD_Aus pic.twitter.com/WtTfQE1djd

— ANZUP (@ANZUPtrials) November 6, 2019

.@NICEComms has been busy with announcements today, rejecting Astellas’ #Xospata for a certain type of acute myeloid leukaemia (AML) and querying evidence for MSD's #Keytruda in head and neck cancer https://t.co/vFcLhQXJnT

— pharmaphorum (@pharmaphorum) January 15, 2020

MSD acquires Takeda’s Dunboyne manufacturing facility https://t.co/zOsjPUDhHN

— Silicon Republic (@siliconrepublic) August 10, 2020

MSD buys Takeda biologics medicines plant in Dunboyne https://t.co/IflH6PU1MF via @IrishTimesBiz

— Irish Times Business (@IrishTimesBiz) August 7, 2020

MSD to takeover Takeda's Dunboyne facility https://t.co/ACUOaUBlOd

— RTÉ Business (@RTEbusiness) August 7, 2020

This is a very welcome announcement from MSD and Takeda. https://t.co/C6aqYapp57

— Martin D Shanahan (@MartinDShanahan) August 7, 2020

Takeda acquired Tim Clackson's prev company, ARIAD, in '17 for $5.2 Billion. He had originally joined ARIAD in 1994. In addition to Takeda & Merck/MRL, German Merck's M Ventures & Ipsen's venture fund are also corporate VCs that invested in the B round. They moved 2 Waltham, MA https://t.co/OxT4HM5RxL

— Pearl Freier (@PearlF) March 2, 2020

Takeda & Merck (MRL Ventures) r 2 of the investors in #CambMA-based immuno-oncology Xilio Therapeutics fka Akrevia. $100.5M B. Originally launched by @atlasventure & F-Prime. CEO is @OtherReneRusso & Tim Clackson is Prez & EVP R&D.MRL Ventures @dud3k BOD https://t.co/JaUnc6UUXD

— Pearl Freier (@PearlF) March 2, 2020

Takeda, Merck invest in cancer startup's Xilio Therapeutics $100M Series B round – Bizwomen https://t.co/GBIVu54ivm #venturecapital #earlystageinvestors #angelinvestors #startups

— Red Trait Ventures (@RedTrait) March 4, 2020

PharmaScrip: Executives On The Move: Exits From Takeda Vaccines And Novartis Institutes To CMO Positions And Board Changes At Merck & Co. https://t.co/1Ah2xcjDQI #PharmaScrip https://t.co/3BT9hqerzu pic.twitter.com/ON8dj4Klug

— ZorgNL (@zorgnl) February 13, 2020

Impact of COVID-19 on Colorectal Cancer Therapeutics Market Latest trending report is booming globally by Top Leading Players Taiho Pharma, Merck KGaA, Amgen, Takeda https://t.co/Xud5IlkmE0

— mednetnews (@mednetnews) October 17, 2020

Colorectal Cancer Therapeutics Market 2020-2026 | Comprehensive Study COVID19 Impact Analysis | Worldwide Key Players: Taiho Pharma, Merck KGaA, Amgen, Takeda, Roche, etc. https://t.co/rJMqyCbJPm

— mednetnews (@mednetnews) September 5, 2020

Global Innovative Drug Market Expected to Reach highest CAGR: Pfizer,Gilead Sciences,Johnson & Johnson,Roche,AbbVie,Sanofi,Amgen,Novartis,Merck & Co. (MSD),GlaxoSmithKline (GSK),Bayer,Takeda,AstraZeneca,Novo Nordisk https://t.co/An4NCt3fo9

— @ReportsandMarkets (@ReportsMarkets) October 13, 2020

#VaccinesEurope represents drugmakers including #AstraZeneca, #GlaxoSmithKline, #Janssen (which belongs to Johnson & Johnson), #Merck, #Novavax, #Pfizer, #Sanofi, #Takeda, #Abbott and #CureVac. Covid-19 vaccine makers #LobbyEU for #LegalProtection.https://t.co/FNImlmq8yE

— Riikka Kevo (@riikka_kevo) August 26, 2020

Lipid Metabolism Disease Drug Market Latest updates and Coronavirus (COVID-19) Impact on Global Market in 2020-2029 Merck, Takeda Pharmaceutical and Novartis – The Loop 21 https://t.co/xazRpkLaZ2

— Dr Jitesh Arora (@drjitesharora) July 29, 2020

Who would want a simple solution?

"thank the leadership of AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eisai, Eli Lilly, Evotec, Gilead, GlaxoSmithKline, Johnson & Johnson, KSQ Therapeutics, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda, and Vir"https://t.co/V20z6DAu2U

— sandeep chakraborty (@sanchak74) June 12, 2020

Global #pharmaceuticals unprecedented collaboration in the search for effective #COVID19 therapies. IFPMA press conference on 30 April 2020 with key speakers across MSD, Takeda, CSL, Pfizer, AstraZeneca, Sandoz and Merck.https://t.co/Blg8sI0uHX @IFPMA @ThomasCueni @MedicinesAus

— Rozalina Sarkezians (@RozalinaRS) May 1, 2020

Pray to Merck, Pfizer, Sanofi, Takeda, J&J, Lilly. Pray to all the start up biotechnology firms throughout the world. Pray to science. An imaginary friend in the sky will not help you. https://t.co/jGz1Ga4fID

— The Grackle ☠ (@LanceMa89524580) March 20, 2020

Takeda, Merck invest in Waltham cancer startup's $100M round https://t.co/KOtqmEQWpy

— Matthew Liptak (@mattliptak) March 2, 2020

Global Drugs for Lipid Metabolism Disease Market 2020 Raises During Pandemic Phase 2021 | Merck, Novartis, Takeda Pharmaceutical – Best News Monitoring https://t.co/6mUdaMY12P

— Dr Jitesh Arora (@drjitesharora) July 29, 2020

Skyhawk Therapeutics, one of GGC's first portfolio companies, recognized by BostInno as one of the 20 Boston Startups to Watch in 2020! Great progress on HUGE dollar contracts with Celgene / Bristol-Myers Squibb, Biogen, Merck, Takeda and Genentech. https://t.co/cktw5pUivN

— Good Growth Capital (@goodgrowthvc) December 23, 2019

U.S.A. アメリカ Vol.122（New Jersey ニュージャージー州 Vol.3: pharmaceutical corporations 製薬会社）

All the below link and tweets are in English.

取り急ぎ以下貼っておきます。Vol.123（New Jersey ニュージャージー州 Vol.4: pharmaceutical corporations 製薬会社）もご覧ください。

New Jersey Vol.10 (corporations: Merck (Merck Sharp & Dohme (MSD) outside the U.S. & Canada))

上記リンク内に無い本日までのツイート

Earlier this week at the #HLTH2020 virtual conference, Mike Nally and Dr. Julie Gerberding spoke about #COVID19 and the importance of building trust within the community. pic.twitter.com/apenJ82Pt6

— Merck (@Merck) October 15, 2020

Learn more about our latest #infectiousdiseases update being announced during #IDWeek2020: https://t.co/Y8iz2dQfDG $MRK pic.twitter.com/NZNdVVG0Md

— Merck (@Merck) October 21, 2020

“@Merck executives, some of whom have been skeptical of unproven technologies some rivals are using in their #vaccines, have noted in public that their own #COVID19 vaccines rely on proven technologies currently used to fight other diseases.” #compliance #competition #IP #Pharma https://t.co/cWNZDFVm06

— Mark Warner (@MAAWLAW) October 23, 2020

.@Merck, one of the largest pharmaceutical companies in the world, is testing the delivery of vaccines via drone to get them to patients fasterhttps://t.co/NGgvfI9QvH

— FierceHealthIT (@FierceHealthIT) October 23, 2020

BIO-BREAKING: @IAVI, @SerumInstIndia & @Merck have joined hands to develop #SARSCoV2 neutralizing monoclonal antibodies (#mAbs) co-invented by IAVI and @scrippsresearch as innovative interventions to address the #COVID19 pandemic.

More: https://t.co/BIr9fn9uq2 via @BioVoiceNews

— BioVoice (@BiovoiceNews) October 23, 2020

Quite an intriguing account of the dynamics leading to Oxford U's (and its for-profit spin-offs') deal with @AstraZeneca (vs @Merck) re research, development, distribution, and pricing of a hoped-for vaccine.https://t.co/uqEOle6whi

— Alani Golanski (@alanigolanski) October 22, 2020

We’re at #IDWeek2020, presenting data on combination #vaccines with @Merck. Read more about the presentations here: https://t.co/fISWZ4h4aG pic.twitter.com/IHbGFg2CM4

— Sanofi US (@SanofiUS) October 20, 2020

@volans_i , @Merck and @Vidant_Health team up to bring the future of healthcare one step closer with the 1st ever temperature-controlled drone medicine and vaccine delivery program in the United States! https://t.co/RpFtJZhXto

— Volansi (@volans_i) October 20, 2020

When John contracted #COVID19, our community stepped up to help in incredible ways. Learn how the support and compassion he received made a powerful difference. #PatientsAreOurPurpose

— MSD (@MSDInvents) October 9, 2020

https://twitter.com/FriendsOfSheba/status/1318279650842464259

As leaders convene for #IDWeek2020, we are committed to collaborating with the scientific community and investing our expertise and resources to address global antimicrobial health issues. Learn more: https://t.co/tDe64Bdmer pic.twitter.com/AbFsjVmAM5

— Merck (@Merck) October 21, 2020

"Clark, thanks for giving me eyes. Thanks for donating your life for the sake of mine. We don’t walk the streets; we fly!” Hear more from our own Darley Oliveira who has been blind since childhood & how his guide dog, Clark is helping him break down barriers. #PoweredbyInclusion

— Merck (@Merck) October 15, 2020

#DYK there’s a field where technology can help determine what the next big thing in pharmaceuticals could be? Hear inspiring messages from our #WomenInSTEM to encourage the next generation of inventors. #NationalSTEMDay pic.twitter.com/WrU8PzjmxB

— Merck (@Merck) November 8, 2019

Through the 2019 Fellowship for Global Health, a select group of our determined inventors will bring their diverse set of skills to locations in need of specific healthcare solutions. Follow the Fellows as they begin their ambitious journeys across the globe. #FellowInventors

— Merck (@Merck) October 1, 2019

We’re excited to be (virtually!) joining healthcare professionals from across the country at #NPWH2020. Click here to learn more about how you can help grow the conversation about her birth control options: https://t.co/O8KIUcO9uU pic.twitter.com/w1ZiylDlOD

— US Merck Products (@USMerckProducts) October 1, 2020

We’re excited to be (virtually!) joining healthcare professionals from across the country at #AAFPFMX. Click here to learn more about how you can help grow the conversation about her birth control options: https://t.co/bjIRYqEGNf pic.twitter.com/70IjkRENQV

— US Merck Products (@USMerckProducts) October 1, 2020

September is Gynecologic Cancer Awareness Month—talk to your patients about a treatment option for certain types of #EndometrialCarcinoma. Learn more: https://t.co/j1drUEdg6C pic.twitter.com/IjGj8p8LEO

— US Merck Products (@USMerckProducts) September 16, 2020

Biosimilars offer doctors more treatment options, and that may create more competition. #Biosimilars may help more people get access to biologic medicines. They may also help reduce costs in the health care system. https://t.co/5UL4ySDr7p pic.twitter.com/k9H7Yf1vuH

— US Merck Products (@USMerckProducts) September 2, 2020

Check your skin for melanoma. It's important! pic.twitter.com/TQVR7hN1as

— US Merck Products (@USMerckProducts) August 12, 2020

Check your skin for melanoma. It's important! pic.twitter.com/euc7ldQppS

— US Merck Products (@USMerckProducts) August 12, 2020

Take a closer look at ZINPLAVA™ (bezlotoxumab) in Washington, DC. Visit booth 410. pic.twitter.com/POUHwRC60t

— US Merck Products (@USMerckProducts) October 1, 2019

We’re here getting prepped for the first day of American Diabetes Association 2019 Scientific Sessions! Stop by Booth 1525 tomorrow when ADA 2019 kicks off. pic.twitter.com/bmbztGrQG9

— US Merck Products (@USMerckProducts) June 6, 2019

Hello, Music City! We’re excited to be joining OB-GYNs from across the country at ACOG. pic.twitter.com/AvhJ4xh7MJ

— US Merck Products (@USMerckProducts) April 26, 2019

Fourteen years ago this month, I was sworn in as @HHSGov Deputy Secretary. Very grateful @POTUS gave me the opportunity to come back to this amazing department to serve the American people – it’s the honor of a lifetime. pic.twitter.com/lH7flhQzhO

— Secretary Alex Azar (@SecAzar) July 28, 2019

“Over the course of my career, I’ve been touched by so many women bravely battling triple-negative #breastcancer.” Dr. Gursel Aktan shares what drives her to pursue #breastcancer research. #BCAM

— MSD (@MSDInvents) October 23, 2020

We're proud to unveil our next center of innovation – the London Discovery Research Centre. This state-of-the-art facility will become our research and business hub in the heart of London’s “Knowledge Quarter.” Learn more. #InventingForLife

— MSD (@MSDInvents) October 13, 2020

NICE recommends @Merck’s Keytruda for untreated metastatic or unresectable recurrent #headandneck squamous cell #carcinoma, but only as monotherapy, creating division in access within UK https://t.co/0ViUMLd329

— pharmaphorum (@pharmaphorum) October 23, 2020

Phase 3 trials in adults bolster @Merck challenge to @Pfizer’s Prevnar 13 vaccine to prevent pneumococcal disease, and keep filing before year-end on track https://t.co/f8DGI7kTcA

— pharmaphorum (@pharmaphorum) October 21, 2020

This #BCAM, I encourage you to listen to Paula Schneider, @susangkomen CEO & breast cancer survivor, as she reflects on her cancer experience in a #WithLoveMe letter. Hear other inspirational stories & explore resources at @Merck’s Your Cancer Story: https://t.co/3nYsDCwZA1 pic.twitter.com/mHIfxSo6cv

— Katie Couric (@katiecouric) October 21, 2020

Merck announced positive data regarding 2 studies, one examining pembrolizumab in combination with chemotherapy and another in combination with quavonlimab in combination to treat advanced non-small cell lung cancer. | @Merck https://t.co/uj7MTofcwf

— Cancer Network (@CancerNetwrk) October 20, 2020

.@Merck Receives Excellence in Health & Well-Being award from Business Group on Health https://t.co/09aeVV41Ak pic.twitter.com/tYLA3jh4Cf

— 3BL Media News (@3BLNews) October 15, 2020

@US_FDA expands Keytruda @Merck approval for classical Hodgkin lymphoma https://t.co/ddhDIHTGDJ pic.twitter.com/z5qokOweQs

— HemOnc Today (@HemOncToday) October 15, 2020

Experimental Antiretroviral Has Potential for Once-Weekly HIV Treatment #NNRTI #HIV #mk8507 #antiretrovirals #UequalsU #Glasgow2020 #islatravir @Univ_Paris @pozmagazine @pozglobal @JHUNursing @MDHealthDept @BMore_Healthy @BaltCityLGBTQ @lgbtqnation @Merck https://t.co/vZMCGvj3sr

— REACH Initiative (@HopkinsREACH) October 21, 2020

Support for melanoma patients-'Melanoma Matters' is 4-part patient support video series. A video & resources will be released weekly. See more & stories to come: https://t.co/TNTrgFtkkx. Thanks to melanoma support groups, @melanomasupport, @PeterMacCC & @bmsnews @Novartis @Merck

— Melanoma Institute (@MelanomaAus) October 23, 2020

No matter where you are in your #cancer journey, no one should have to walk alone. Check out the latest #melanoma resources on @Merck’s cancer support program, Your Cancer Story, developed to help patients & caregivers from diagnosis through survivorship, & beyond. #MerckPartner pic.twitter.com/mbqLrKPNQI

— Melanoma Research (@MelanomaReAlli) October 15, 2020

Keytruda (@Merck) has received an expanded label use from @FDAOncology as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma. https://t.co/wKkASOdmKf pic.twitter.com/RRCdGdShZI

— The Cancer Letter (@TheCancerLetter) October 20, 2020

Bristol Myers, Exelixis get in FDA fast lane for Opdivo-Cabometyx combo in kidney cancer | @Bristol_Myers @ExelixisInc @Merck @pfizer #Cancer #kidneycancer #renalcellcarcinoma #NewYorkCity #Alameda #California #NewJersey #Biotech https://t.co/teZXz0JZxk

— Pharm2Market (@pharm2market) October 21, 2020

@AmerUrological @Merck announced plans to construct a new TICE BCG manufacturing facility in the USA and anticipates the build to take up to 6yrs to complete.

expects 3x its current capacity.

Until, Merck has no plans to change the current dosing of BCG pic.twitter.com/iMDYZogO56

— @DocMeetings – Urology (@docmeetings) October 20, 2020

Check out part 2 of @Okerainc CEO @NickHalsey's discussion with @Merck's Chief Data & Analytics Officer Sol Rashidi on her journey to becoming a #CDO and the evolving role for #CDOMagazine's #TechTalks. Check it out here —> https://t.co/NyfRoQkXXb

— Okera (@okerainc) October 19, 2020

FDA puts ‘black box’ warning on popular asthma medication; teens speak out about side effects https://t.co/b8qp15Kccb @USMerckProducts @USMerckProducts @Merck

— Donnie USMC (@don2569603) September 9, 2020

Getting ready for a FB Live today 1pm/2pm CST/EST: 7 Things Women Should Know About Heart Failure. Through partnership w/ @AAHFN and sponsorship by @Amgen @Novartis @Cytokinetics @AstraZenecaUS & @USMerckProducts, experts discuss risks you might not know. https://t.co/e75amFOG4H pic.twitter.com/Mbg5p7RMCi

— WomenHeart (@WomenHeartOrg) June 28, 2019

How can #data and action can drive improvement in D&I? Join our #paneldiscussion at #HRTechConf moderated @slupusho who will talk to our customers at @Merck, @Panasonic, and @Uber about how data and #analytics enables them to move the needle on D&I. https://t.co/5Li46RolKJ pic.twitter.com/W5A4LScbMG

— Visier (@visier) October 23, 2020

Thank you @Merck for being an #AMWA2020 celebratory sponsor and exhibitor! We appreciate your partnership and support. https://t.co/v1VoQ3BNIK pic.twitter.com/mvcOW9CHUT

— AMWA (@AmMedWriters) October 23, 2020

MDP is proud to work with @Merck to ensure our work toward #riverblindness and #lymphaticfilariasis elimination can continue safely during the #COVID19 pandemic. https://t.co/ass7B42Kei

— Mectizan Donation Program (@MectizanMDP) October 22, 2020

.@Merck donates $500K to #NGOs working to eliminate #RiverBlindness (#onchocerciasis) & lymphatic #filariasis

Funds to be administered by @MectizanMDP & address suspensions of #CommunityHealth interventions due to #COVID19 https://t.co/qASLxxFNYg #parasitology #GlobalHealth pic.twitter.com/lKoJQpboBJ

— DDNews Online (@DDNewsOnline) October 22, 2020

See yourself in STEM. Biotechnology alumna Monica Roberson shares how her experience with STEM Mentorship Partner @Merck prepared her for graduate school and beyond. Learn more at https://t.co/q1DYfpprrS #BHCCSTEM #MassSTEMWeek #MACommCollege #CommunityCollege pic.twitter.com/0Q2vF2RF9Z

— BHCC Boston (@BHCCBoston) October 22, 2020

https://twitter.com/APSForg/status/1318913714825940992

We are proud to announce our #internalcommunications work with @Merck has received honorable mention in @PRSANJ's Pyramid Awards! We worked with our client to develop and execute an #employeeengagement campaign that raised money for cancer research. Great job, team! pic.twitter.com/eeQXUe6YkB

— The SPI Group (@spigroup) October 21, 2020

Thanks to our Bronze Sponsors @Merck and @genentech for their support of our event, "Health Equity in the Fight to End Cancer in Rural Montana." pic.twitter.com/nHHb1iq6mV

— ACS CAN Montana (@ACSCANMT) October 21, 2020

$ENZC penny Flippers Gonna regret selling ANY Shares these next 6 months!! @BioClonetics is Arriving @#BioPharma is Taking Notice! Look at those Numbers! Who will get us in #Partnerships READ THIS LINK: https://t.co/AqcZQD7upT I like @Merck & #AI like @BioClonetics Also $GLD #HIV pic.twitter.com/4omlyuWN9A

— Mike (@crabbermike) October 21, 2020

U.S.A. アメリカ Vol.121（Final (2nd) US Presidential Debate 10/22/2020 ― 米国大統領選挙テレビ討論会）

All the below tweets (@newsmax, @MotherJones, @amconmag, @RawStory, @FDRLST, @Newsday, @StarTribune, @WSJ) are in English. @BelmontUniv

FULL-LENGTH: Re-watch the final Trump-Biden showdown in its entirety. #Debates2020 https://t.co/XDzS5gB8kj

— Newsmax (@newsmax) October 23, 2020

"The moderator doesn't know how to ask follow up questions."@AlanDersh on @kwelkernbc's 'disappointing' job at holding both candidates responsible. https://t.co/VlT7z8drtO pic.twitter.com/RszZ7OsXpn

— Newsmax (@newsmax) October 23, 2020

FINAL DEBATE: @kimguilfoyle on President Donald Trump's performance – "he was decisive, informative – he was able to go through the list of his accomplishments." https://t.co/VlT7z8drtO pic.twitter.com/jloKjTWa2l

— Newsmax (@newsmax) October 23, 2020

"Joe Biden tried to dance away from [Hunter Biden's laptop]," @RichardGrenell tells Newsmax TV's @SchmittNYC.

"He can't go after China – he's going to upset the people that have been paying him." https://t.co/VlT7z8drtO #Debates2020 pic.twitter.com/VPHes9Cr8a

— Newsmax (@newsmax) October 23, 2020

BLOWOUT: "I'll stop giving them federal subsidies – I will transition from the oil industry," which Trump slams as destroying American industry. #Debates2020 pic.twitter.com/l0dMJ11V7u

— Newsmax (@newsmax) October 23, 2020

.@JoeBiden admits that crime bills he once supported were a 'mistake,' and President Trump brands him a typical 'all talk' politician. #Debates2020 https://t.co/VlT7z8drtO pic.twitter.com/QGp1UAjUKd

— Newsmax (@newsmax) October 23, 2020

RUSSIA, RUSSIA, RUSSIA: Joe Biden calls Hunter Biden's laptop a 'hoax' – only believed by Trump and @RudyGiuliani. #Debates2020 pic.twitter.com/sZ4Te9zA5S

— Newsmax (@newsmax) October 23, 2020

.@realDonaldTrump pushes Joe Biden 10 times on the US-Mexico border cages reportedly built by the Obama administration. https://t.co/VlT7z8drtO pic.twitter.com/kUicj2S8d9

— Newsmax (@newsmax) October 23, 2020

'C'mon Joe, you can do better.'

President Donald Trump on Joe Biden's 'rehearsed' response, "I'm not a typical politician, that's why I got elected." #Debates2020 pic.twitter.com/MLJuCyvqW1

— Newsmax (@newsmax) October 23, 2020

Trump recalls his chat with President Obama about North Korea, and touts his good relationship with "very different kind of guy" Kim Jong Un. #Debates2020 https://t.co/VlT7z8drtO pic.twitter.com/V6gbw2K1cN

— Newsmax (@newsmax) October 23, 2020

Trump brings up the 'horrible emails' that allege Joe Biden raked in millions from foreign nations, and calls for Biden to come clean to the American people. #Debates2020 https://t.co/VlT7z8drtO pic.twitter.com/pOZXYdLdNz

— Newsmax (@newsmax) October 23, 2020

.@realDonaldTrump says Democrat virus response 'killed' his wonderful city of New York. #Debates2020 pic.twitter.com/VOQq9gBkMX

— Newsmax (@newsmax) October 23, 2020

Joe Biden slams Trump's mentality on the COVID-19 pandemic, and Trump responds by calling out Biden's criticism for his initial China travel bans. #Debates2020 https://t.co/VlT7z8drtO pic.twitter.com/bzuRRRrg5P

— Newsmax (@newsmax) October 23, 2020

"We're about to go into a dark winter," @JoeBiden on President Trump having 'no real clear plan.' #Debates2020 pic.twitter.com/LxZV4CN9ww

— Newsmax (@newsmax) October 23, 2020

Yes, Trump was calmer. He's still a narcissist with no sense of empathy. https://t.co/z6UovzR1fr

— Mother Jones (@MotherJones) October 23, 2020

No, Biden won't ban fracking https://t.co/Zgoch0uFpr

— Mother Jones (@MotherJones) October 23, 2020

Kristen Welker asked Donald Trump about immigration. His answer was both racist and false. #Debates2020 https://t.co/yprrQhX0Cc pic.twitter.com/8kBK0V1YBS

— Mother Jones (@MotherJones) October 23, 2020

Donald Trump just said 1 percent of immigrants show up for court dates. It's actually 99 percent –> https://t.co/BEl0WfsXU5 pic.twitter.com/EmpcfmjHnA

— Mother Jones (@MotherJones) October 23, 2020

Donald Trump just said at the #Debates2020 that he is "the least racist person in this room."

Fact-check: No. pic.twitter.com/4ektSs6GLA

— Mother Jones (@MotherJones) October 23, 2020

.@JoeBiden: "[Donald Trump] pours fuel on every single racist fire. This guy has a dog whistle about as big as a foghorn." #Debates2020 pic.twitter.com/rxtFpeALkc

— Mother Jones (@MotherJones) October 23, 2020

After a rambling answer on health care filled with non-sequiturs and false claims, Donald Trump's mic was cut off. Watch: pic.twitter.com/11KxLfQJhR

— Mother Jones (@MotherJones) October 23, 2020

Wow. Donald Trump just said that only immigrants "with the lowest IQ" come back for court hearings under 'catch and release' #Debates2020 pic.twitter.com/GP0jfDcd4H

— Mother Jones (@MotherJones) October 23, 2020

"You guys were one of the outlets who got singled out to balance the ledger." That's what a former Facebook employee told us after we started digging into recent news that the platform was throttling traffic to certain publishers, including Mother Jones. https://t.co/hqY9LBVDQD

— Mother Jones (@MotherJones) October 23, 2020

Donald Trump just mocked Joe Biden for wanting to discuss ordinary people's worries. #Debates2020 pic.twitter.com/EX5oFshf1X

— Mother Jones (@MotherJones) October 23, 2020

.@realDonaldTrump: “We’re learning to live with [COVID].”@JoeBiden: “People are learning to die with it.” https://t.co/mdShjuSucn pic.twitter.com/jYEV0TN6Ah

— Mother Jones (@MotherJones) October 23, 2020

https://t.co/R3db8xhNhS pic.twitter.com/YabV0s7ENe

— The American Conservative (@amconmag) October 23, 2020

As the election has drawn closer the Russian position has only hardened as they realize that they are far more likely to have real arms control discussions with a Biden administration. Larison: https://t.co/4tnoU1DkEw

— The American Conservative (@amconmag) October 23, 2020

https://t.co/M3IQkZOqCn pic.twitter.com/TWTGwIHPpA

— The American Conservative (@amconmag) October 23, 2020

https://t.co/t41BAfvNif pic.twitter.com/EixX8bmnlR

— The American Conservative (@amconmag) October 23, 2020

"Given the Biden family’s humble, middle-class character—so proudly touted on the campaign trail—the obvious career move was to buy a hedge fund." https://t.co/Mvdd5JP94Z

— The American Conservative (@amconmag) October 23, 2020

How a small, Trump-skeptical outfit like FDD wrote Iran policy in Trump’s first term is a story that can be investigated for years. It will be all the more relevant for anyone looking to change that in future administrations. https://t.co/wKjUwsBg9a

— The American Conservative (@amconmag) October 23, 2020

Climate change and Trump voters mix in this poignant piece about a vanishing waterman culture in the Chesapeake Bay: https://t.co/k9IodpsQ6k

— The American Conservative (@amconmag) October 23, 2020

Sure. While we're on the subject, here's what happened when a progressive woman dated a Proud Boy: https://t.co/mvqujLBcIC

— The American Conservative (@amconmag) October 23, 2020

Biden does not have a reputation for honor and telling the truth. https://t.co/kf0OR5CdCL

— The American Conservative (@amconmag) October 23, 2020

And here's a fun piece to check back on every year or so: https://t.co/XzAUVAzI6C

— The American Conservative (@amconmag) October 23, 2020

‘He just sounds ridiculous’: Trump called out for ‘really, really problematic’ debate moment
https://t.co/mA8K0RkQDx

— Raw Story (@RawStory) October 23, 2020

'Fantasies are not facts': Trump ridiculed for his meltdowns at final presidential debate https://t.co/z2T7sOkxCp

— Raw Story (@RawStory) October 23, 2020

Rick Santorum brags about Trump after debate: ‘We’re not keeping kids in cages anymore’
https://t.co/Z3RjXfpoID

— Raw Story (@RawStory) October 23, 2020

‘This guy is a dog whistle’: Biden lights Trump up after he claims to be ‘least racist’ person at debate
https://t.co/9sj1tEOhRD

— Raw Story (@RawStory) October 23, 2020

‘It’s criminal’: Biden accuses the Trump administration of crimes during debate
https://t.co/oo5K5ZplqN

— Raw Story (@RawStory) October 23, 2020

Biden slams Trump as ‘a very confused guy’ for forgetting who he is running against
https://t.co/6483jgl6hq

— Raw Story (@RawStory) October 23, 2020

‘Trump’s brain is ricotta cheese’: Internet mocks president’s attack on Biden calling him ‘the big man’
https://t.co/DMDwHXndoe

— Raw Story (@RawStory) October 23, 2020

WATCH: Trump immediately caves at debate after moderator fact checks him on having vaccine ‘within weeks’
https://t.co/Vckm9kT98Q

— Raw Story (@RawStory) October 23, 2020

Trump claims he was ‘kidding’ about injecting bleach — CNN’s Jim Acosta says that was a lie
https://t.co/IJrvyvCp0E

— Raw Story (@RawStory) October 23, 2020

Trump admits the swine flu pandemic was ‘far less lethal’ — but claims Biden’s management of it was a ‘disaster’https://t.co/KrXJC4EwSS

— Raw Story (@RawStory) October 23, 2020

Trump on coronavirus: ‘I take full responsibility – it’s not my fault’ | Raw Story

Which one is it? https://t.co/qDrCMZN6hV

— Girly Girl (@whatifisaidit) October 23, 2020

Biden Blames GOP For Failed COVID Relief Bills As Dems Keep Stonewalling Over Pet Projectshttps://t.co/G1zzT1cmwR

— The Federalist (@FDRLST) October 23, 2020

Joe Biden Finally Admitted He Wants To End The Oil Industryhttps://t.co/FvryiuyU88

— The Federalist (@FDRLST) October 23, 2020

Yes, Joe Biden Called Young Black Men ‘Predators’ https://t.co/CfKz45Kfo1

— The Federalist (@FDRLST) October 23, 2020

Biden Lied When He Said He Doesn’t Oppose Fracking. Here’s The Proofhttps://t.co/o9VfBcyPgI

— The Federalist (@FDRLST) October 23, 2020

Watch @JusticeTristan Explain Biden Family Corruption In 5 Minutes https://t.co/1UHSlB9ssX

— The Federalist (@FDRLST) October 23, 2020

Joe Biden Promised No Coal Power Plants Will Ever Be Built In America If He Wins https://t.co/a44HlgtwKB

— The Federalist (@FDRLST) October 23, 2020

The Green New Deal isn't just un-American, it's also completely bonkers. https://t.co/HIyoJXODE4

— The Federalist (@FDRLST) October 23, 2020

Why The Green New Deal Would Destroy The Environment https://t.co/qfJma09Cts

— The Federalist (@FDRLST) October 23, 2020

FLASHBACK: Joe Biden Says ‘Poor Kids Are Just As Bright’ As White Kids https://t.co/TcVG3iGTT6

— The Federalist (@FDRLST) October 23, 2020

Joe Biden Repeats Debunked Claim That Latest Email Scandals Are Russian Election Interference https://t.co/KQxAoP8rCR

— The Federalist (@FDRLST) October 23, 2020

The Obama administration actually denied clemency to over 20,000 people. https://t.co/5GByNAKDVk

— The Federalist (@FDRLST) October 23, 2020

Here's the thing about #fracking: Joe Biden doesn't need to endorse a ban if he pledges to regulate it to death. #Debate2020 https://t.co/snxlPVrLjQ

— Tristan Justice (@JusticeTristan) October 23, 2020

TRUMP on the toll of COVID-19 in the U.S.: "So as you know 2.2 million people, modeled out, were expected to die." FACT: This was his first line in the debate, and it is false. The U.S. death toll from the pandemic was not expected to be that high. https://t.co/98kk7PVWtO

— Newsday (@Newsday) October 23, 2020

For Trump, the matchup was perhaps the final opportunity to change the dynamics of a race dominated by his response to the pandemic and its economic fallout. For Biden, it was 90 minutes to solidify an apparent lead less than two weeks before the election. https://t.co/cUzrw3KCBY

— Newsday (@Newsday) October 23, 2020

Now that we have seen the final presidential debate. Here's your guide on voting: read all about the candidates. #LIVotes #debate2020 #Election2020 https://t.co/4ttlYboNN0

— Newsday (@Newsday) October 23, 2020

Watch the presidential debate tonight with @Newsday's editorial board @RitaCiolli @mjchiusano @MatttDavies @mwdobie @lanefiller @randimarshall and columnists @wfbor @CathyYoung63 https://t.co/fnSJ0tWFX3

— Newsday Opinion (@NewsdayOpinion) October 23, 2020

Trump posts unedited '60 Minutes' interview before it airs. https://t.co/ffV5KSYzY7

— Star Tribune (@StarTribune) October 23, 2020

Whether because of the new mute button or terrible reviews from their first debate, Donald Trump and Joe Biden interrupted each other far less frequently this time, even as they clashed on a range of issues. https://t.co/csueLODart pic.twitter.com/WRWsmEJpDZ

— Star Tribune (@StarTribune) October 23, 2020

President Donald Trump and Democratic challenger Joe Biden offered sharply different visions of how to handle the surging pandemic and fought over how much Trump pays in taxes during their final debate of the campaign. https://t.co/QaaiVs2QHo

— Star Tribune (@StarTribune) October 23, 2020

The Trump campaign has been videotaping people as they deposit ballots in drop boxes in Philadelphia in what it says is an attempt to catch violations. But the state attorney general suggests that surveillance could amount to illegal intimidation. https://t.co/VnF4eckIvd

— Star Tribune (@StarTribune) October 23, 2020

President Donald Trump's promise of $200 drug-discount cards was presented as a centerpiece of his health care agenda. Now officials acknowledge that Medicare recipients will not be getting cards this month. https://t.co/4ah6nZFr5C

— Star Tribune (@StarTribune) October 23, 2020

With two weeks to go before Election Day, U.S. Postal Service officials said they’re undertaking extraordinary measures to ensure that all ballots are delivered on time and counted. https://t.co/DtBFBoc2nd

— Star Tribune (@StarTribune) October 23, 2020

It's on: Trump, Biden face off in campaign's final debate, starting with the U.S. response to the coronavirus pandemic. https://t.co/QaaiVs2QHo

— Star Tribune (@StarTribune) October 23, 2020

From @WSJopinion: Biden has placed his bet that a campaign based almost entirely on character and Covid-19 is enough to take the White House. It’s paid off—so far, writes The Editorial Board https://t.co/0B12mHlE10

— The Wall Street Journal (@WSJ) October 23, 2020

Watch: Trump and Biden disagree over the timeframe for a widely available coronavirus vaccine https://t.co/PxssSyb3CD

— The Wall Street Journal (@WSJ) October 23, 2020

Watch the entire final presidential debate between President Trump and Democratic nominee Joe Biden #Debates2020 https://t.co/5lF2UjLxeo

— The Wall Street Journal (@WSJ) October 23, 2020

Hunter Biden's ex-business partner alleged Joe Biden was part of talks around his son’s efforts to form a venture with a Chinese oil company. Biden's campaign denied the former vice president's involvement, and records reviewed by WSJ show no role for him. https://t.co/98mcZHE63J

— The Wall Street Journal (@WSJ) October 23, 2020

President Trump and Joe Biden faced off in their last presidential debate, challenging each other over the handling of the coronavirus, their family business ties and Barack Obama’s legacy in a more orderly encounter after their first debate https://t.co/O2xoEyhU6o

— The Wall Street Journal (@WSJ) October 23, 2020

In the final question of #Debates2020, President Trump and Joe Biden took very different approaches when asked what they would say in their inauguration day address to Americans who did not vote for them https://t.co/NUH4zwGJ6b

— The Wall Street Journal (@WSJ) October 23, 2020

Joe Biden said it's the right time to raise the minimum wage to $15 an hour, even though businesses are struggling. President Trump said he would “consider to an extent” raising the minimum wage, but that it should be decided by states. #Debates2020 https://t.co/QzhUqEKnHO

— The Wall Street Journal (@WSJ) October 23, 2020

Joe Biden tried to show clear distance with liberal members of the Democratic party at #Debates2020. When President Trump brought up Bernie Sanders, Biden responded: "I beat all those other people because I disagreed with them.” https://t.co/XzoYdhvBQK

— The Wall Street Journal (@WSJ) October 23, 2020

Joe Biden criticized President Trump for touting U.S. relations with North Korea under his watch. "That’s like saying we had a good relationship with Hitler before he invaded Europe," Biden said. #Debates2020 https://t.co/ZusRB15Le7

— The Wall Street Journal (@WSJ) October 23, 2020

“We’re not going to shut down and we have to open our schools,” President Trump said during #Debates2020, while Joe Biden said he would not rule out future shutdowns due to the pandemic https://t.co/BSGLs4IgfY

— The Wall Street Journal (@WSJ) October 23, 2020

Joe Biden criticized President Trump at #Debates2020 for his handling of the pandemic and called for a more muscular federal response. Trump said recent spikes in Covid-19 cases will “soon be gone” and “it’s going away.” https://t.co/2b2OQ4NpF6

— The Wall Street Journal (@WSJ) October 23, 2020

What has President Trump said about Dr. Anthony Fauci? Read transcripts of the candidates' comments from speeches, interviews and more using our #talk2020 search tool https://t.co/0tnM44vZ2v

— The Wall Street Journal (@WSJ) October 23, 2020

Joe Biden, after President Trump alleged that he was taking money from foreign sources, responded: “I have not taken a penny from any foreign source ever in my life.” https://t.co/gJLywfcWss

— Kate Milani (@KateMilani) October 23, 2020

Joe Biden pressed President Trump at the debate on his refusal to release his tax returns and on reports he paid $750 in federal income taxes for 2016 and 2017. On the $750, Trump described that as a filing fee, but there is no such fee. https://t.co/O1MpG4iqnU

— Richard Rubin (@RichardRubinDC) October 23, 2020

Here’s what you need to know about fracking and where Trump and Biden fall on the campaign issue https://t.co/oXHOptQTSU #Debates2020

— Becky Bowers (@beckybowers) October 23, 2020

U.S.A. アメリカ Vol.120（Final (2nd) US Presidential Debate 10/22/2020 ― 米国大統領選挙テレビ討論会）

All the below tweets (@latimes, @EpochTimes, @dailykos, @WashTimes, @thedailybeast, @theblaze, @FortuneMagazine, @Forbes) are in English. @BelmontUniv

Review: The final Trump-Biden debate was a study in exasperation https://t.co/K6igDwuHEm

— Los Angeles Times (@latimes) October 23, 2020

Editorial: Trump was less unhinged in the second debate, but Biden still scored https://t.co/QUwreoFyru (via @latimesopinion)

— Los Angeles Times (@latimes) October 23, 2020

Column: Joe Biden finds a way to handle a brat like Trump https://t.co/I9IchiN8c3 (via @latimesopinion)

— Los Angeles Times (@latimes) October 23, 2020

Coronavirus Today: 'COVID, COVID, pandemic, COVID' https://t.co/JeZF8i0OVa

— Los Angeles Times (@latimes) October 23, 2020

Our journalists assessed the candidates’ performances, round by round. Here's what they had to say about #Debates2020: https://t.co/vkUPy17UfH

— Los Angeles Times (@latimes) October 23, 2020

In Georgia, long lines to vote — but determined optimism, too https://t.co/bz2wIaYXkf (via @latimesopinion)

— Los Angeles Times (@latimes) October 23, 2020

Key takeaways from the second and final Trump-Biden debate https://t.co/BanTEMITxT

— Los Angeles Times (@latimes) October 23, 2020

Watching U.S. presidential vote, much of the world sees a less-strong America https://t.co/YFPReIEahO

— Los Angeles Times (@latimes) October 23, 2020

“We’re not going to have fracking” if Biden is elected, President Trump said during tonight's #Debates2020.

Fact check: No, Biden wouldn’t ban fracking https://t.co/sFzoCeuYrq

— Los Angeles Times (@latimes) October 23, 2020

This is where President Trump and Joe Biden stand on immigration #Debates2020 https://t.co/w9YVeosMEa

— Los Angeles Times (@latimes) October 23, 2020

"I'm going to be an American president. I don't see red states and blue states. What I see is America, the United States," Joe Biden says during #Debates2020 https://t.co/TNjGZDJ9G6

— Los Angeles Times (@latimes) October 23, 2020

"If this stuff is true, about Russia, Ukraine, China … then he's a corrupt politician. So don't give me the stuff about how you're this innocent baby! … Take a look at the laptop from hell!"#Trump says he ran for president because of #Biden at the final #PresidentialDebate pic.twitter.com/ZPf45BNTd8

— NTD News (@news_ntd) October 23, 2020

Trump: “They did it, we changed the policy. They built the cages. Who built the cages, Joe?”#Trump responds to #Biden’s claim that the Trump admin built cages and separated families at the border during the final #PresidentialDebate pic.twitter.com/B6dbLb17jZ

— NTD News (@news_ntd) October 23, 2020

Trump: “Nancy Pelosi does not want to approve it. It’s near the election because she thinks it helps her politically. I think it hurts her politically.”

Trump says #Pelosi doesn’t want #StimulusBill due to election proximity at the final #PresidentialDebate pic.twitter.com/YsjfMtV1np

— NTD News (@news_ntd) October 23, 2020

President Donald #Trump said that he does not want to shut down the country over the #CCPvirus pandemic, arguing, “You can’t close up our nation or you won’t have a nation.” https://t.co/qKui5mw0Kz

— NTD News (@news_ntd) October 23, 2020

“The bank account was in 2013 … it was closed in 2015 i believe … I was thinking of doing a deal in China like millions of other people … I decided I’m not going to do it, didn’t like it. I had an account open and I closed it.”#Trump on his bank account in #China. pic.twitter.com/9SYUv1GgfU

— NTD News (@news_ntd) October 23, 2020

#Biden: "What I’m gonna do is pass Obamacare with a public option. (It’ll)become Bidencare … if you qualify for medicaid, and you do not have the wherewithal in your state to get medicaid, you’re automatically enrolled, providing competition for insurance companies." pic.twitter.com/r2ZqqIuzkp

— NTD News (@news_ntd) October 23, 2020

#Trump: "We have to open our country. I’ve said it before, the cure cannot be worse than the problem itself.”#Biden: “We ought to be able to safely open. We need the resources to open."

Trump, Biden on reopening the economy at final #PresidentialDebate. pic.twitter.com/cIFDl8RLG2

— NTD News (@news_ntd) October 23, 2020

“There’s some pretty… disgusting things this family was involved with.”@RudyGiuliani promised “there’s more coming out” after @NYPost’s report on alleged communication about a meeting between #JoeBiden and an official from #Burisma. https://t.co/1AsbxJGAex

— The Epoch Times (@EpochTimes) October 23, 2020

#GOP senators proposed a bill that would stop Democrats from passing any new #CourtPacking laws in the Senate.

This comes after Democrats threatened to expand the #SupremeCourt if Senate Republicans fill Justice #RuthBaderGinsburg’s seat. https://t.co/Gwd1QgtRKP

— The Epoch Times (@EpochTimes) October 23, 2020

#Senate investigators obtained #SecretService logs including dates and locations matching those discussed in the alleged #HunterBidenEmails.

The alignment of the dates is significant as the authenticity of the emails is the subject of a heated debate. https://t.co/SBtrSsaGew

— The Epoch Times (@EpochTimes) October 23, 2020

The newest Republican attack: Joe Biden supports Amtrak! https://t.co/h7RzyyTLVy

— Daily Kos (@dailykos) October 23, 2020

Trump's promise to give everyone free antibody treatments isn't just a lie, it's impossible https://t.co/6I89ONOJME

— Daily Kos (@dailykos) October 23, 2020

New study continues to debunk Trump's lie that so-called sanctuary cities are dangerous https://t.co/xtCg6iXxFd

— Daily Kos (@dailykos) October 23, 2020

Your blow-by-blow recap of the mute-button presidential debate, with a little help from Twitter https://t.co/R0tRpT3mDE

— Daily Kos (@dailykos) October 23, 2020

Trump blamed children for family separation: ‘A lot of these kids come out without the parents’ https://t.co/vXv9dLWlAb

— Daily Kos (@dailykos) October 23, 2020

Sticking the landing: 'I'm running as a proud Democrat but I'm going to be an American president' https://t.co/RVo327L1yu

— Daily Kos (@dailykos) October 23, 2020

Biden rose above as Trump reined in the yelling, but not the lies, at final debate https://t.co/CApZr85xHb

— Daily Kos (@dailykos) October 23, 2020

'I don't understand why this president is unwilling to take on Putin': Biden debate slam goes viral https://t.co/NoZs1IXbki

— Daily Kos (@dailykos) October 23, 2020

Biden: ’Anyone responsible for that many deaths should not remain the president of America' https://t.co/XCQ5S7bfEQ

— Daily Kos (@dailykos) October 23, 2020

'People are learning to die with it!' Biden hits Trump hard on COVID-19 https://t.co/sFGTKWth9E

— Daily Kos (@dailykos) October 23, 2020

Biden stunner: Democrat pledges to 'transition' from oil-and-gas industry https://t.co/cQZlCCgQC3

— The Washington Times (@WashTimes) October 23, 2020

U.S. has many files on Hunter Biden's money trail, congressional source sayshttps://t.co/MuW1GkZtxc pic.twitter.com/vEprp8AzX6

— The Washington Times (@WashTimes) October 23, 2020

JUST IN: Winners and losers from the final debate https://t.co/N34j0sUtyM

— The Washington Times (@WashTimes) October 23, 2020

Trump on Hunter Biden's 'laptop from hell:' 'Here we go again with Russia’ https://t.co/2nVuXoB6cZ

— The Washington Times (@WashTimes) October 23, 2020

Biden: Nothing 'unethical' about Hunter's dealings with Burisma https://t.co/0cnqxfJ9dP

— The Washington Times (@WashTimes) October 23, 2020

'He's a very confused guy': Joe Biden says Trump thinks he's running against somebody elsehttps://t.co/AQHU1S6pxr pic.twitter.com/mxqmlp2BoH

— The Washington Times (@WashTimes) October 23, 2020

“My fellow evangelicals are so focused on winning this election, they don’t realize that the data shows we’ve already lost all elections after this one.” @drjeffmyers @WashTimesOpEd https://t.co/CI4OY5tNpW

— The Washington Times (@WashTimes) October 23, 2020

Biden blames Obama for deportations https://t.co/FhVUzA5FTa

— The Washington Times (@WashTimes) October 23, 2020

Biden: Red and blue states are going to go bankrupt without fed money https://t.co/Nuz2wP9VI1

— The Washington Times (@WashTimes) October 23, 2020

Trump: There will be 'better healthcare' if Supreme Court strikes down Obamacarehttps://t.co/QiZTxalz3m pic.twitter.com/oBCn3QbfuP

— The Washington Times (@WashTimes) October 23, 2020

Biden bucks Bernie Sanders, far left on health care https://t.co/Le0ni5IkjL

— The Washington Times (@WashTimes) October 23, 2020

Joe Biden deflects Hunter Biden questions: 'I have not taken a penny from a foreign source in my life'https://t.co/OCylhu8L9c pic.twitter.com/w0WhsJRJlP

— The Washington Times (@WashTimes) October 23, 2020

Biden: ‘I have not taken a penny from any foreign source’ https://t.co/c86BovlVNC

— The Washington Times (@WashTimes) October 23, 2020

Even when he’s courting us, Trump keeps insulting Black folks, writes @kalihollowayftw https://t.co/3l66s1SZuB

— The Daily Beast (@thedailybeast) October 23, 2020

“We would hope that they recognize that until COVID arrived, the only national health crisis was around substance use disorders,” said one addiction treatment advocate https://t.co/4eDrU0HmwF

— The Daily Beast (@thedailybeast) October 23, 2020

Just hours after a pro-Trump WSJ columnist accused Hunter of trying to rope his dad into a business deal, the outlet’s reporters said documents revealed “no role for Joe Biden.” https://t.co/Nhfad2m73n

— The Daily Beast (@thedailybeast) October 23, 2020

CNN flies off the rails when Rick Santorum tries to claim Trump was “never called racist” before his presidency https://t.co/F93KAh6UkM

— The Daily Beast (@thedailybeast) October 23, 2020

"Bleeding badly and in need of a knockout, Donald Trump inched out the 9th round of a 10 round heavyweight fight—on points," writes @MattKLewis. "Trump, the flailing incumbent who has been losing the referendum on Trump, made the election about Joe Biden." https://t.co/hKKUuVWSgK

— The Daily Beast (@thedailybeast) October 23, 2020

The president, like Joe Biden, is taking advantage of loopholes in campaign finance laws to score huge checks. From there, however, the money trail gets bizarre. https://t.co/xyKRlLzKCc

— The Daily Beast (@thedailybeast) October 23, 2020

Trump trails Biden by substantial margins in polls. COVID-19 cases have increased in the past two weeks. A second stimulus package is being threatened by his own party, and there are only a dozen days until the election. https://t.co/GdbakqEPPQ

— The Daily Beast (@thedailybeast) October 23, 2020

“Well, first of all I’m jealous,” Chris Wallace said on Fox News immediately following the final debate between Trump and Biden. “I would have liked to have been able to moderate that debate and to get a real exchange of views.“ https://t.co/OkOxh9hBPr

— The Daily Beast (@thedailybeast) October 23, 2020

President Trump said migrant children separated from their parents at the U.S.-Mexico border were “so well taken care of” during the presidential debate against former Vice President Joe Biden https://t.co/etLP71lgso

— The Daily Beast (@thedailybeast) October 23, 2020

Once again, President Trump expressed his concern for all the poor birds being killed by windmills https://t.co/slyEreCpr6

— The Daily Beast (@thedailybeast) October 23, 2020

“I know more about wind than you do,” says the president who thinks windmills primarily cause cancer and kill birds. #debates2020 https://t.co/O4ZoXCXcPg

— The Daily Beast (@thedailybeast) October 23, 2020

VIDEO: Former Hunter Biden associate makes explosive allegations against Biden family https://t.co/CnInmLpNKQ

— TheBlaze (@theblaze) October 23, 2020

Biden campaign lashes out after Trump invites Hunter Biden's former business partner as guest to final debate https://t.co/xfNzxx70lK

— TheBlaze (@theblaze) October 23, 2020

If Trump mentions Hunter Biden's emails, Joe Biden likely to cry 'Russian misinformation' at debate https://t.co/ONIRbAWTOF

— TheBlaze (@theblaze) October 23, 2020

Post-debate media roundup: Poor boys, Abraham Lincoln and Hunter Biden #Debates2020 https://t.co/nGvTxgTSRD

— TheBlaze (@theblaze) October 23, 2020

'Who built the cages?!': @realdonaldTrump pummels Biden at final debate over migrant children separated at the border #debates2020 https://t.co/mb5vlDQ3ni

— TheBlaze (@theblaze) October 23, 2020

The media now claims that the Hunter Biden/CEFC story is part of a 'disinformation campaign.' But many of the details were reported in 2018 by… the New York Times https://t.co/0vo9SdoHi5

— TheBlaze (@theblaze) October 23, 2020

Uh-oh, Joe #Debates2020 https://t.co/hgMjMzouSl

— TheBlaze (@theblaze) October 23, 2020

Trump to bring Hunter Biden's former business partner to final debate as his special guest https://t.co/30WX2D2WUL

— TheBlaze (@theblaze) October 23, 2020

Former never-Trumper James Lindsay on why he just CAN'T vote for Joe Biden https://t.co/9HK2Pj5AY0

— TheBlaze (@theblaze) October 23, 2020

New Hunter Biden texts appear to show Joe Biden directly involved in setting up Chinese business deal https://t.co/LoFxXa62tB

— TheBlaze (@theblaze) October 23, 2020

Unlike Trump, Biden’s allegations against the President have their basis in fact—specifically, vetted claims, made by a publication of record, which were confirmed by Trump’s own attorney. https://t.co/LidmyEgBHh

— FORTUNE (@FortuneMagazine) October 23, 2020

What happens if Trump or Biden dies before the election? https://t.co/jHf5XbLwmt

— FORTUNE (@FortuneMagazine) October 23, 2020

Trump's statements during tonight's debate flies in the face of the actions he has actually taken during his presidency. https://t.co/z0vFyWpLEm

— FORTUNE (@FortuneMagazine) October 23, 2020

During the Obama administration, Senate majority leader Mitch McConnell and the GOP made a “no compromise pledge” to “kill, stop, or slow down” any piece of legislation the White House backed or court seat they attempted to fill. https://t.co/nhhbgBkcBU

— FORTUNE (@FortuneMagazine) October 23, 2020

Only a third of Americans plan to vote in person on Election Day https://t.co/Pp2Frz4AWh

— FORTUNE (@FortuneMagazine) October 23, 2020

Are you entitled to time off work to vote? Depends where you live https://t.co/DjhHPsW7E1

— FORTUNE (@FortuneMagazine) October 23, 2020

The President doesn’t actually impact the economy that much. Here's why: https://t.co/MqY7Jx9ipP

— FORTUNE (@FortuneMagazine) October 23, 2020

During the final presidential debate, President Donald Trump and former Vice President Joe Biden expressed diametrically opposite views on the severity of the coronavirus pandemic https://t.co/uNelxFirfN by @AndrewSolender pic.twitter.com/HobwuojKCX

— Forbes (@Forbes) October 23, 2020

https://t.co/BmtGnhrgNy

— Forbes (@Forbes) October 23, 2020

President Trump insisted that Biden is pining to knock down buildings and shrink their windows, a bizarre and inaccurate riff on Biden’s climate plan that has quickly turned into one of Trump’s go-to attack lines. Read more about it here https://t.co/XBi3SQ8imE

— Forbes (@Forbes) October 23, 2020

At the debate, Trump kept saying that Biden got $3.5 million from Russia. That’s not exactly true. He also mentioned that Biden's family is getting rich, that "they're like a vacuum cleaner" https://t.co/O7FoaBKZV2 by @rachsandl pic.twitter.com/CZfK90xGP0

— Forbes (@Forbes) October 23, 2020

In an exchange with Democratic challenger Joe Biden, Trump insisted Fauci and other experts underestimated the threat of Covid-19 in the spring, claiming the infectious disease expert described Covid-19 as “no problem” and predicted it would “go away soon” https://t.co/HvPDGMysmM pic.twitter.com/BcQGxuVUAt

— Forbes (@Forbes) October 23, 2020

https://t.co/QnCfCnpJkM

— Forbes (@Forbes) October 23, 2020

https://t.co/HRvhanqJGD

— Forbes (@Forbes) October 23, 2020

https://t.co/55x9vDhrQR

— Forbes (@Forbes) October 23, 2020

Is Trump right that Dr. Fauci discouraged wearing masks? Yes—but early on and not for long https://t.co/nKmVDwwiVE pic.twitter.com/n8S66XGBAv

— Forbes (@Forbes) October 23, 2020

President Trump has claimed repeatedly that the disease expert, Dr. Anthony Fauci, was against his decision to implement travel restrictions on China back in January and that Biden called the restrictions “xenophobic.” Here's why that's a problem: https://t.co/gI7raMFoDL pic.twitter.com/SWWwOJs36G

— Forbes (@Forbes) October 23, 2020

U.S.A. アメリカ Vol.119（California カリフォルニア州 Vol.3: pharmaceutical corporations 製薬会社）

All the below link and tweets are in English.

取り急ぎ以下貼っておきます。
California Vol.26 (corporations: Gilead Sciences)

上記リンク内に無い本日までのツイート

Read an open letter from our Chief Medical Officer about today's @US_FDA approval of our antiviral treatment for COVID-19. https://t.co/JAyK3zJGD7

— Gilead Sciences (@GileadSciences) October 22, 2020

The @US_FDA today approved our antiviral to treat patients with COVID-19 requiring hospitalization. Read more: https://t.co/Z5lO227KVU. pic.twitter.com/NqebDeoWBv

— Gilead Sciences (@GileadSciences) October 22, 2020

We released the following statement today related to the WHO SOLIDARITY trial for the treatment of COVID-19 https://t.co/YzAy1EgnVV.

— Gilead Sciences (@GileadSciences) October 16, 2020

.@US_FDA gave its final nod to @GileadSciences #Remdesivir for treating hospitalised Covid-19 patients. @viswanath_pilla reports. #COVI19 #CoronavirusIndia #COVIDIndia https://t.co/zX7bUsJSES

— moneycontrol (@moneycontrolcom) October 23, 2020

5 Penny Stocks To Watch After Gilead Sciences' Big Remdesivir News https://t.co/fze9H7hBwI

— EIN Presswire: Lung Cancer Newswire (@EINLungCancer) October 23, 2020

NEW: Gilead Sciences has announced that the FDA has approved remdesivir for treating COVID-19. The antiviral drug becomes the first drug to receive full approval from the FDA for treatment against the coronavirus, according to the pharmaceutical company. https://t.co/FGiIkZOtPk pic.twitter.com/m9XIdaVMsE

— WebMD (@WebMD) October 22, 2020

NEW: FDA approves remdesivir to treat Covid-19, making it the first and only drug so far to have received federal approval for the coronavirus. https://t.co/NddlmHEfOo

— MSNBC (@MSNBC) October 22, 2020

BREAKING: FDA approves first COVID-19 drug, remdesivir https://t.co/C5outLVVNF

— CBS News (@CBSNews) October 22, 2020

BREAKING: FDA approves Gilead's remdesivir as coronavirus treatment https://t.co/ryNKPD9vhB

— CNBC Now (@CNBCnow) October 22, 2020

Remdesivir receives FDA approval to treat hospitalized COVID patients @drsanjaygupta reports pic.twitter.com/OxqCn3RKdM

— The Lead CNN (@TheLeadCNN) October 22, 2020

JUST IN: The US Food and Drug Administration has approved remdesivir for the treatment of coronavirus infection, the drug’s maker, Gilead Sciences, says https://t.co/8pg6cHwRoB

— CNN (@CNN) October 22, 2020

Remdesivir is the first and only fully FDA-approved drug in the U.S. for treating the coronavirus. https://t.co/dtYQNytzch

— Axios (@axios) October 22, 2020

The news has barely mentioned it, but Big Pharma company Gilead is charging $3,000 for a coronavirus drug that costs them less than $10 to produce.

Once again, they're set to profit on the people's dime.

— Robert Reich (@RBReich) October 21, 2020

NEW: Gilead Sciences just received FDA approval for remdesivir. This is the inside story of how the company prepared for the pandemic https://t.co/VPXM3GjcbM pic.twitter.com/M4vwD8lNcD

— Businessweek (@BW) October 22, 2020

FDA just approved the first COVID-19 drug AND it's from @OceansideBiz-based@GileadSciences
Details here: https://t.co/pX2vmc6ZiT?

— Innovate78 (@Innovate_78) October 22, 2020

@CityofOceanside's @GileadSciences #COVID19 drug now @US_FDA approved! https://t.co/jYYZjfIVNC

— San Diego North EDC (@SDNorthEDC) October 22, 2020

https://twitter.com/SDRegionalEDC/status/1319400169650073600

Morning Bell: #ASX200 to open flat with all eyes on the #USPresidentialDebate2020 at 11am AEDT. U.S. FDA approves @GileadSciences' #COVID19 treatment. Trading ideas: $ALL, $LBY, $AIS, $NGI, $MYQ & $TSO. #ausbiz #belldirect #tradingideas https://t.co/xblREmVKkU

— Bell Direct (@belldirect) October 22, 2020

The @US_FDA has approved the first drug treatment for #COVID19 in the US, and antiviral by @GileadSciences #remdesivir https://t.co/lrYd1NB3gq pic.twitter.com/byXuRUa4Pe

— Pharmacy Times (@Pharmacy_Times) October 22, 2020

.@US_FDA approves @GileadSciences's remdesivir as the first and only fully FDA-approved drug in the U.S. for treating the coronavirus.https://t.co/QbzL80S6oN #optometry #COVID19 #remdesivir pic.twitter.com/rcDZewIRgk

— Optometry Times (@OptometryTimes) October 22, 2020

#BREAKING Remdesivir becomes first FDA fully-approved coronavirus treatment https://t.co/VAwD4PgPZI

— KTNV 13 Action News (@KTNV) October 22, 2020

Thank you to @GileadSciences for choosing PPD to help support the clinical development program of your important new COVID-19 treatment. https://t.co/xuzXL3Cqpy #ppd #covid19 #coronavirus #pandemic #followthescience #wereinthistogether #wegotthis #relentless #collaborate pic.twitter.com/81yZNEFNcC

— PPD (@PPDCRO) October 22, 2020

ICYMI: The FDA approved Remdesivir for the treatment of coronavirus infection, says the drug's maker, Gilead Sciences. https://t.co/TMDKdaRrw4

— CBS46 (@cbs46) October 23, 2020

JUST IN: The FDA has approved Gilead Sciences’ antiviral drug remdesivir as a treatment for the coronavirus. Remdesivir is now the first and only fully approved treatment in the U.S. https://t.co/tdD2A5IkDB

— NBC Bay Area (@nbcbayarea) October 22, 2020

The FDA has approved #remdesivir for the treatment of #COVID19, Bay Area-based Gilead Sciences, said Thursday. https://t.co/Wix6PGn7vw

— ABC7 News (@abc7newsbayarea) October 22, 2020

JUST IN: The FDA has officially approved remdesivir as a treatment for coronavirus, drug manufacturer Gilead Sciences announced.https://t.co/MZtO88r2eS

— New York Daily News (@NYDailyNews) October 22, 2020

The @NIH has paused a phase 3 study on @LillyPad’s #Covid19antibody treatment on a potential safety concern. The #NIH-sponsored study is testing bamlanivimab (LYCoV555) in combination with @GileadSciences’s #Remdesivir in hospitalized patients. https://t.co/bip662pVW9

— CHEManager International (@CHEManager_EU) October 22, 2020

.@GileadSciences’ Remdesivir Flunks WHO Trial, Gains “Prequalified” Status. Learn more:https://t.co/4LWvAJnhMb pic.twitter.com/xDLUSFqesK

— Genetic Engineering & Biotechnology News (@GENbio) October 19, 2020

News for #pharma #marketers: Mon, Oct 19

-More than 25% of state legislators accepted pharma campaign contributions since 2019
– @Pfizer won’t seek emergency authorization of vaccine until late Nov.
– @GileadSciences Remdesivir failed to prevent deathshttps://t.co/IAaXOVHudQ

— MM+M Magazine (@MMMnews) October 19, 2020

ICYMI: Future of Gilead's #remdesivir for COVID-19 in doubt after WHO reveals trial data @GileadSciences #covid19 #WHO https://t.co/4j6ij1AD6j pic.twitter.com/Ex8jNDr631

— Market Intelligence: Healthcare (@SPGMIHealthcare) October 19, 2020

WHO trial shows @GileadSciences Veklury (remdesivir) has no effect on mortality and hospital stay in COVID-19 – data is inconsistent with US studies used to support Emergency Use Authorization https://t.co/4LZOdhzd8J

— pharmaphorum (@pharmaphorum) October 16, 2020

Results from the WHO’s highly anticipated Solidarity trial found that none of the treatments ‘substantially affected mortality’ or reduced the need to ventilate patients, according to a copy of the study seen by the FT https://t.co/yuKtO8sojn pic.twitter.com/LegWL7ryGI

— Financial Times (@FinancialTimes) October 15, 2020

The US Food and Drug Administration has approved the first drug to treat COVID-19 – Remdesivir. Gilead Sciences Inc says the antiviral medicine, given through an IV for patients needing hospitalisation, cut the time for recovery by five days — from 15 days to 10 on average. pic.twitter.com/gJ5TfeROoY

— Jamaica Gleaner (@JamaicaGleaner) October 22, 2020

@US_FDA approves Gilead’s Remdesivir to treat #COVID19, even though @WHO's study found drug not effective @DrTedros @realDonaldTrump @JoeBiden @KamalaHarris @Mike_Pence @CDCgov @AfricaCDC @NIH @GileadSciences #Election2020 https://t.co/AxP8HjKLz0 via @todaynewsafrica

— TODAY NEWS AFRICA (@todaynewsafrica) October 22, 2020

Investors betting on big profits from #COVID19 treatments may get an unwelcome surprise when @GileadSciences reports quarterly results this month as remdesivir, the first important coronavirus treatment, has not been used as much as first expected. https://t.co/R9ywTIGL7T pic.twitter.com/aiINMXzsuE

— Arab News Japan (@ArabNewsjp) October 17, 2020

FDA approves Gilead Sciences' antiviral drug for treating patients hospitalized with COVID-19. https://t.co/RMKapXSqij

— Arutz Sheva (@ArutzSheva_En) October 22, 2020

Remdesivir has very little effect on Covid-19 mortality, WHO finds https://t.co/ehhGOoTtVV

— The Guardian (@guardian) October 16, 2020

So, has #remdesivir shown a survival benefit? I remember @icer_review suggested that without a survival benefit the price should be about $310. The drug costs $3,120 now. Am I missing something or are we getting price-gouged (again) by @GileadSciences?

— Gregg Gonsalves (@gregggonsalves) October 16, 2020

Gilead received the Solidarity manuscript ruling out a big impact from remdesivir on #covid19 mortality on 28 September according to @WHO.

On 8 October, before the results became public, Gilead signed a billion dollar deal with the EU Commission for remdesivir.

I have questions

— Kai Kupferschmidt (@kakape) October 16, 2020

As #IDWeek2020 spotlights the impact of the #COVID19 pandemic on fighting #HIV, learn how our CARES Grantee Fund is supporting community organizations during this difficult time.

— Gilead Sciences (@GileadSciences) October 22, 2020

The data presented at #IDWeek2020 highlight our commitment and efforts to assess and address unmet needs in #HIV treatment. Learn more here: https://t.co/7p4UfPVE9v pic.twitter.com/OCWbVbaH99

— Gilead Sciences (@GileadSciences) October 21, 2020

#HIV is not a crime. Those living with and at risk for HIV are often held back by laws that discourage people from getting tested or treated.

Learn more from Health Not Prisons Collective, who joined the panel discussion at #2020USCHA.

— Gilead Sciences (@GileadSciences) October 20, 2020

#HealthDisparities can prevent access to HIV care and treatment in Black communities. Progress in ending the #HIV epidemic means not leaving anyone behind.

Join our conversation at #2020USCHA around ending health disparities in HIV.

— Gilead Sciences (@GileadSciences) October 19, 2020

“Peer-to-peer programs work because there’s nothing unreal about it. It’s raw and it’s truth.” Tune in to the #Hepcast, made in collaboration with @Hep_Alliance, to hear how Tony McClure of @HepatitisCTrust helps engage people living with #hepatitisC.

— Gilead Sciences (@GileadSciences) October 16, 2020

This National Latinx AIDS Awareness Day, meet Bamby Salcedo, founder of @TransLatina_C and an advocate for #HIV awareness and prevention. #NLAAD

— Gilead Sciences (@GileadSciences) October 15, 2020

ツイッター検索で上記製薬会社名及び Japan や日本の5製薬会社各社名を入れて出て来たもの

Japan's health ministry included dexamethasone as an option for treatment along with Gilead Sciences Inc's antiviral drug remdesivir. #Japan #Coronavirus #CoronavirusVaccine https://t.co/VM96hBlMJo

— IndiaToday (@IndiaToday) July 22, 2020

Japan on Thursday approved Gilead Sciences Inc's remdesivir as a treatment for COVID-19, making it the country's first officially authorized drug to tackle the coronavirus disease. https://t.co/oZggDtgDyq

— GMA News (@gmanews) May 7, 2020

Japan approves Gilead Sciences' remdesivir as COVID-19 drug https://t.co/EP6Brqywfb pic.twitter.com/7UeR0czgl2

— Reuters (@Reuters) May 7, 2020

Japan approves Gilead Sciences' #Remdesivir as #COVID19 drug. $GILD https://t.co/lJeYKLbitp

— Bio Stocks™ (@BioStocks) May 7, 2020

"Japan on Saturday began to fast-track the approval of remdesivir, Gilead Sciences' antiviral drug intended to treat coronavirus patients… It has also asked the U.S. to ensure Japan receives adequate supplies of the drug."https://t.co/bqxF9ODV9I

— DUTERTENOMICS (@Dutertenomics) May 2, 2020

https://twitter.com/FinancialTimes/status/1258289223121043456

#SunStarWorldNews
TOKYO — Japan has approved Gilead Sciences’ antiviral drug remdesivir for coronavirus treatment in a fast-track review just four days after the US company submitted an application.https://t.co/YoDxFOMWR4

— Sun Star Davao (@SunStarDavao) May 8, 2020

U.S. drugmaker Gilead has an experimental antiviral drug that may work against the coronavirus. It's unapproved for use in humans, but hey it appears to have worked on the first U.S. infection case in Washington state.@joewalkerWSJ https://t.co/zjXUG7rAJY

— Jonathan Cheng (@JChengWSJ) February 1, 2020

Gilead Sciences and Japan Tobacco signed a letter of intent to dissolve their licensing partnership, the cigarette company said Monday, as the U.S. drugmaker prepares to market a new HIV treatment in Japan on its own. https://t.co/WhK2ynVZpX MT @NAR pic.twitter.com/WnfoUz4J9d

— HIV Insight (@HIV_Insight) September 1, 2018

Gilead and Eisai announce co-promotion agreement for investigational rheumatoid arthritis treatment in Japan: https://t.co/ia8aFkxONY.

— Gilead Sciences (@GileadSciences) December 24, 2019

SFBN Feed: Jyseleca® (Filgotinib) Approved in Japan for Rheumatoid Arthritis: FOSTER CITY, Calif. & TOKYO–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) and Eisai Co., Ltd. (Tokyo, Japan) today … #BayArea #Biotech https://t.co/y7JaL4nXwM

— San Francisco Biotechnology Network (@sfbionetwork) September 25, 2020

Gilead Sciences and Eisai Agreed on Distribution and Co-Promotion of Filgotinib – https://t.co/xHtO20gxBa pic.twitter.com/8XM09CgNkO

— GMPnews.Net (@GMPnewsNet) December 30, 2019

Gilead Signs a Co-Promotion Agreement with Eisai for Filgotinib in Japan @GileadSciences @EisaiUS
https://t.co/92Bp0R5v30

— PharmaShots – Incisive news in 3 shots (@Pharmashot) December 26, 2019

U.S.A. アメリカ Vol.118（Illinois イリノイ州 Vol.2: pharmaceutical corporations 製薬会社）

All the below link and tweets are in English.

取り急ぎ以下貼っておきます。

Illinois Vol.11 (corporations: AbbVie)

上記リンク内に無い本日までのツイート

“The beauty of science and medicine is that it is always growing and changing.” Learn what Margot Goodkin on our #ophthalmology clinical development team sees for patients with eye diseases: https://t.co/lfDrwJ1iiA #ScientistsRock pic.twitter.com/DwOiLeQJg6

— AbbVie (@abbvie) October 21, 2020

JUST IN: This morning we announced our @US_FDA and @EMA_News submission in #atopicdermatitis. Learn more: https://t.co/GqBWMkeKiV pic.twitter.com/sf9q9SnSC8

— AbbVie (@abbvie) October 19, 2020

The future of #rheumatology? With a greater understanding of the disease, more people with #RA could have a chance for remission. Read more: https://t.co/F05zmsv9XH pic.twitter.com/TNyEYVpVgg

— AbbVie (@abbvie) October 19, 2020

Read about our combination treatment, which has been granted full approval by the @US_FDA for newly-diagnosed acute myeloid leukemia patients who are ineligible for intensive chemotherapy due to age or comorbidities. https://t.co/E4kEza2Wd2 pic.twitter.com/tbmzfu5A4v

— AbbVie (@abbvie) October 17, 2020

Itchy skin, a symptom of atopic dermatitis – also known as eczema – can cause sleep disruption and lead to symptoms of depression and anxiety. Learn more about this chronic skin condition: https://t.co/zAGqUTbgzf #unhideECZEMA #EczemaAwarenessMonth pic.twitter.com/oD17x7CgQQ

— AbbVie US (@AbbVieUS) October 21, 2020

https://twitter.com/AbbVie_AU/status/1318303724301963264

#Google Spinoff #CalicoLifeSciences Enters its First Clinical Trial with #AbbVie Cancer Drug ABBV-CLS-S579 https://t.co/H7N9CjBX2J #clinicaltrials #cancerdrugs #healthcare #abbvclss579

— TrialSite News (@TrialsiteN) October 22, 2020

In September, $IMAB licensed rights for its anti-CD47 inhibitor to AbbVie. Brad Loncar writes about the deal and what he thinks this means for the CD47 space at large. https://t.co/X11lOh4FTG pic.twitter.com/Dy2Bb9seSh

— Loncar Biotech ETFs (@LoncarFunds) October 21, 2020

AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ™ (upadacitinib) in Atopic Dermatitis >>RFP@ bd@mellalta.com> #mellaltameet https://t.co/HY4h36kXa0

— Mellalta Meets (@mellaltameets) October 21, 2020

AbbVie’s Allergan Aesthetics brand gets a facelift https://t.co/BzvtfloRcG

— cafepharma (@cafepharma) October 21, 2020

#AbbVie Announces Commencement of Registered Exchange Offers https://t.co/V22smFPl6b

— 1stOncology (@1stOncology) October 20, 2020

@abbvie has announced that the @US_FDA approved a new use of its B-cell lymphoma 2 inhibiting drug #Venclexta in the treatment of AML for some patients. https://t.co/QXcLTf8eoC pic.twitter.com/cwanJDKlsb

— LabPulse (@LabPulse1) October 20, 2020

AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ™ (upadacitinib) in Atopic Dermatitis | Small Molecules | News Channels – https://t.co/1KdcMjshu3 https://t.co/M9a8MbW3RL #drug #sting

— US Drug News (@USDrugNews) October 20, 2020

In today's News Briefing: AbbVie and Roche’s Venclexta got a new #FDA thumbs up. And ImmunoGen is picking up $40 million in cash from its new partner, Huadong Medicine.https://t.co/BMgst4quQ8

— Endpoints News (@endpts) October 20, 2020

AbbVie and Roche’s Venclexta (venetoclax) Receive the US FDA’s Approval for Acute Myeloid Leukemia https://t.co/RvvC9uD8wj

— PHARMABOX.in (@pharmabox_in) October 19, 2020

@us_FDA grants full approval to venetoclax @abbvie @genentech regimen for certain patients with newly diagnosed acute myeloid leukemia https://t.co/bGB0NCuYPf with comments from Lee Greenberger, PhD @LLSusa pic.twitter.com/WBiPEpuOjg

— HemOnc Today (@HemOncToday) October 19, 2020

The @US_FDA has fully approved @abbvie #Venclexta in acute myeloid leukaemia (AML).
For full article visit: https://t.co/Nf4Uce07io #cancernews #cancerdata #drugapproval

— Larvol (@Larvol) October 19, 2020

Read: ⁦@abbvie⁩ pipeline drug tested as COVID-19 treatment (via ⁦@CrainsChicago⁩) https://t.co/qSaGdyDneW

— IMA TODAY (@IMA_Today) October 19, 2020

AbbVie’s Venclexta granted full US approval in AML https://t.co/TGQ5rmtlM9 pic.twitter.com/W9n11lTKM3

— PharmaCrowd (@PharmaCrowd) October 19, 2020

Combination therapies involving @Roche and @AbbVie’s cancer drug Venclexta have been formally approved by the FDA in acute myeloid leukaemia, following supportive data from late-stage studies https://t.co/09bS6Cx1fY

— pharmaphorum (@pharmaphorum) October 19, 2020

https://twitter.com/hongkong_israel/status/1318093734387613696

.@abbvie submitted applications for U.S. and European approval of its immunology drug Rinvoq for the treatment of patients with moderate to severe atopic dermatitishttps://t.co/BZKlMihLhS $ABBV pic.twitter.com/GInCcSIIs0

— Market Intelligence: Healthcare (@SPGMIHealthcare) October 19, 2020

.@Roche @abbvie's Venclexta granted full US approval for blood cancer indication https://t.co/JPsTWRDfNb $ROG $ABBV pic.twitter.com/lbXANkZlBV

— Market Intelligence: Healthcare (@SPGMIHealthcare) October 19, 2020

Roche-AbbVie's #Venclexta granted full US approval for blood #cancer indication @Roche @abbvie https://t.co/KBOeUVtWyX pic.twitter.com/eHkLHSU1t2

— Market Intelligence: Healthcare (@SPGMIHealthcare) October 19, 2020

AbbVie, Molecular Partners to withdraw EU, Japan applications for #eye therapy @abbvie @MolecularPrtnrs https://t.co/ynJSf1NVxe pic.twitter.com/Yo6GUuG5L7

— Market Intelligence: Healthcare (@SPGMIHealthcare) July 20, 2020

AbbVie Submits Regulatory Applications to the US FDA and EMA for Rinvoq (upadacitinib) to Treat Atopic Dermatitis @Pharmashot @abbvie https://t.co/ZTUHBymu3B pic.twitter.com/Mn7qfv2Guw

— PharmaShots – Incisive news in 3 shots (@Pharmashot) October 20, 2020

AbbVie and Roche’s Venclexta (venetoclax) Receive the US FDA’s Approval for Acute Myeloid Leukemia @Pharmashot @abbvie @Roche https://t.co/sxljcSi8VT pic.twitter.com/9jZa59Z1oa

— PharmaShots – Incisive news in 3 shots (@Pharmashot) October 19, 2020

.@AlexWestchester reports.@NIAIDNews clinical trial examines .@GileadSciences' remdesivir and antibody candidates by .@humanigen, .@Boehringer, and .@abbvie vs. #COVID19. Read more: https://t.co/DXhw6YJyKo pic.twitter.com/gP0SDRAG0n

— Genetic Engineering & Biotechnology News (@GENbio) October 17, 2020

"We are grateful to AbbVie for helping our city obtain the latest and best technology available to combat gun violence," North Chicago Mayor, Rockingham, Jr. said. "ShotSpotter is one more resource our police department will have to make our streets safer https://t.co/w9GRKNLqd4

— Ralph Clark (@ralphaclark) October 17, 2020

NIH initiates ACTIV trial for COVID-19 immune modulators @NIH @JanssenUS @bmsnews @abbvie https://t.co/YrxhDG2Ti4

— The Science Advisory Board (@ScienceBoard) October 16, 2020

"60% reduction in call volumes to service centers was achieved with the help of MyGuide Digital Adoption Platform" – Sandip Patel,@abbvie. Watch and learn how @MyGuideOrg enabled @abbvie to drive seamless employee software-onboarding experiencehttps://t.co/8Q8siHpI9S @karlmehta

— MyGuide by EdCast – Leader in Digital Adoption (@MyGuideOrg) October 16, 2020

The @uspirg contends @abbvie's patent thicket for Humira (adalimumab) will encourage anticompetitive practices by other manufacturers. $ABBV

Read more: https://t.co/MjnS4LjoQH pic.twitter.com/2qDs4AyMpM

— CenterForBiosimilars (@BiosimCenter) October 14, 2020

Amicus brief filed Monday against the maker of Humira. “As the records demonstrate,…@AbbVie engaged in a patent thicket strategy that allowed the company to prolong its Humira monopoly for years beyond what Congress intended.” #RxDrugs https://t.co/5GKzNe9fMz

— U.S. PIRG (@uspirg) October 14, 2020

Bond like $abbv https://t.co/P0bWzE9igu

— WhiteSands Trader (@contango15) October 22, 2020

https://t.co/NlQbz5M03t $TSCO $INTC $MMM @3M @intel $APO $ABBV @abbvie $BNS $SPG

— StocksDiscovery (@StocksDiscovery) October 21, 2020

AbbVie: Now It's Time To Dollar-Cost-Average On This 5.6% Yield (NYSE:ABBV) – https://t.co/NdKV5dWrWK pic.twitter.com/t7AiNomvQI

— Finanz (@FinanzDK) October 20, 2020

4 AbbVie brands land on pharma's top TV spenders list for September https://t.co/Vy1QJyfN6o pic.twitter.com/RUIc94HBsb

— analyst land news (@analystlandnews) October 16, 2020

Thank you to all who participated in @AbbVieUS SF Bay Area Virtual Partnering Day Plenary Session & Panel Discussion! We heard from AbbVie executives about their approach to partnerships and learned about their areas of interest across several therapeutic areas. pic.twitter.com/CPY22EMH3P

— California Life Sciences Association (CLSA) (@CALifeSciences) October 21, 2020

Explore this new technology! @4P_Pharma @abbvie @LillyPad @EvgenPharma @intlstemcell @Merck @Novartis @GSK @pfizer @PharmaLinkInc @TakedaPharma @zimmerbiomet @FlexionInc

— UF Innovate (@UFInnovate) October 20, 2020

Hosted by @CrohnsColitisFn and sponsored by @abbvie, Dr. Bohm and the IU Team will be participating in a virtual spooky #trivianight! We welcome you to participate to learn what will be happening in #IBD in 2020, as well as some costume contest fun! https://t.co/PaTe76iKlK pic.twitter.com/hCHFBbsaga

— Indiana University Gastroenterology (@IUGastro) October 20, 2020

NIH to test AbbVie, Boehringer Ingelheim drug in combination with remdesivr https://t.co/N6R2gcOqEZ

— Joey Sales (@sales_js) October 21, 2020

NIH to test J&J, AbbVie, Bristol Myers Squibb drugs as COVID-19 treatments

The National Institutes of Health plans to test three drugs from Johnson & Johnson, AbbVie and Bristol Myers Squibb as treatments for COVID-19, The Wall Street Journal reported. https://t.co/5ZMXzeCg7f pic.twitter.com/Dkk4bvloVH

— PharmacyWeek (Kevin) (@PharmacyWeek) October 21, 2020

NIH launches trial to uncover if #immunemodulatordrugs from Johnson & Johnson, Bristol Myers Squibb, and Abbvie can restore balance to overactive immune systems in #COVID-19 patients. https://t.co/x861DOUYLb

— pharmanewsintel (@pharmanewsintel) October 20, 2020

NIH to test J&J, AbbVie, Bristol Myers Squibb drugs as COVID-19 treatments https://t.co/7nkaab5BlS pic.twitter.com/5JZV3vRsZG

— Amber Deese Owens (@AmberOwens18) October 19, 2020

NIH launches COVID-19 test of J&J, Bristol Myers and AbbVie anti-inflammatory drugs | FiercePharma https://t.co/ry1qO7XT7r

— R Mandy Alcuria (@AlcuriaRudolph) October 19, 2020

AbbVie re-ups glaucoma awareness campaign with NFL star Miller https://t.co/oUTvAjxIrc

— NewExpressNews (@NewExpressNews) October 20, 2020

#WeekendReview California AG Joins Coalition Against AbbVie’s Alleged Anticompetitive Practiceshttps://t.co/3MSQWVTrwS

— CPI (@CompPolicyInt) October 18, 2020

CEO of CTYX posted another article on LinkedIn AbbVie to develop and sell China-based I-Mab's cancer drug | Article [AMP] | Reuters https://t.co/SDEsl1OGKs

— Eagle1xOne (@Eagle1xOne) October 21, 2020

Tony Au, general manager of AbbVie China, said, "We are excited about this opportunity and hope to show our commitment to making a remarkable impact on the lives of patients in China." The US firm will participate in the #CIIE for the first time. #WhatTheySay pic.twitter.com/Cd3EpiS5rY

— China International Import Expo (@ciieonline) October 19, 2020

https://twitter.com/fibroidsupport/status/1289126069841399808

Thx to: @abbvie, @accenture, @Aptiv, @Bordbia, @CancilleriaCol, @Entirl, @IDAIRELAND, @InnpulsaCol, @investinbogota, @IrelandiaAvi, @VivaAirCol, @kerryfoodgroup, @MRP_Latam, @Pernod_Ricard, @PlanetPayment, @RubiconCapAdv, @SEPAM_group, @SMBCAVIATION, @smurfitkappa, @PROCOLOMBIACO

— Embajada de Irlanda en Colombia y Panamá (@IrelandColombia) October 20, 2020

#15 position for #AbbVie in the #WorldsBestWorkplaces List by #GreatPlaceToWork!
Congrats! #BestCompany @abbvie @AbbVieItalia #BestCompany2020 #Gptw4all #gptw pic.twitter.com/54Rdw7nKtw

— GPTW Italia (@GPTWItalia) October 14, 2020

ツイッター検索で上記製薬会社名及び Japan や日本の5製薬会社各社名を入れて出て来たもの

A new treatment option in #hepC has just been approved in Japan. Learn more about our exciting news: https://t.co/froz8AgrmO pic.twitter.com/JtQEv0r2gT

— AbbVie (@abbvie) September 27, 2017

#DRG epidemiology report estimates more than 40 million people living with #atopicdermatitis across the United States, Western Europe and Japan @DRGinsights @abbvie #EADV #atopiceczema https://t.co/GzTMBYq1Ve

— DRG Epidemiology (@DRG_Epi) September 14, 2018

Japan awards AbbVie's Skyrizi with first approval, in 4 #psoriasis indications https://t.co/Kfvuazvhrf #pharma pic.twitter.com/safBoeH4EK

— Pharmafocus (@Pharmafocus) March 27, 2019

#Humira's approval in Japan shows that #AbbVie strives to increase its global market share while also increasing the number of indications it can treat with this #biologic. https://t.co/ZZuGEsNTrG

— GlobalData Pharma (@Pharma_GD) March 7, 2019

AbbVie Japan Alters Company Rules for Same-Sex, Common-Law Marriages The Japan arm of AbbVie has changed its company regulations to provide employees who are in same-sex… https://t.co/Xhi9Hp6fVk

— MEDWAVE (@medinfoa2z) August 17, 2020

De momento contento de llevar $ABBV

AbbVie's Psoriasis Drug Approved For Japan, But The Main Event Is Yet To Come $ABBV https://t.co/KRaIiZzu7T

— Josue (@goldesenyo) April 12, 2019

Another great option for people with #psoriasis. #AbbVie gets the first global regulatory approval of #SKYRIZI in Japan https://t.co/Jn6OgT2EbF via @AsiaBioSpectrum

— International Psoriasis Council (@IpcPs) March 27, 2019

$ABBV – AbbVie's Psoriasis Drug Approved For Japan, But The Main Event Is Yet To Come https://t.co/6bTcWFL6WE

— Jeffrey Weber (@jjjinvesting) April 11, 2019

Hats off to all the American companies that are pitching in to help Japan recover from Typhoon Hagibis. Among them are @united, @Merck, @abbvie, and @KEEN. Oregon Governor Brown and I met with representatives of @KEEN_Japan to extend our appreciation. pic.twitter.com/v2ieUTdmvC

— ジョセフ・M・ヤング駐日米国臨時代理大使 (@USAmbJapan) November 21, 2019

Galapagos: Chasing AbbVie, Gilead files for approval of filgotinib in Japan $GLPG https://t.co/4xtyxlLMWR

— Lama Daila (@Lama_Daila) October 8, 2019

#AbbVie receives priority review for new 8-week DAA in Japan https://t.co/R3Lmmj3zG8 #HCV

— Healio Hepatology (@HealioHep) March 15, 2017

AbbVie's Viekirax approved as #HCV treatment in Japan: http://t.co/LwtqdFmT8s @AbbVie RT pic.twitter.com/KPV1ifdAwh

— European Pharmaceutical Review (@PharmaReview) October 1, 2015

With hep C approval app, AbbVie eyes franchise growth in Japan http://t.co/doMYaxyJlM $ABBV #pharma via @FiercePharmAsia

— FiercePharma (@FiercePharma) February 12, 2015

https://twitter.com/galamericas/status/1317122908829908992

AbbVie, Amgen and Takeda team up for joint COVID-19 trial – PMLiVE https://t.co/l47HbqyU9v

— Pharmaceutical Market Europe (@PMLiVEcom) August 5, 2020

AbbVie, Amgen and Takeda test anti-inflammatory drugs in joint COVID-19 study https://t.co/IzrYEnmjmV

— PhRMA (@PhRMA) August 4, 2020

AbbVie, Amgen and Takeda jointly study impact of anti-inflammatory drugs in COVID-19 treatment @ExpPharma https://t.co/jWG55UmxUE

— IJPSonline (@IndianJPharmSci) August 4, 2020

AbbVie, Amgen and Takeda test anti-inflammatory drugs in joint COVID-19 study https://t.co/1IlYuJzeVe

— iBIO (@IllinoisBiotech) August 4, 2020

Rival drugmakers launch joint trial of drugs for #COVID19 https://t.co/LcRNln9jaK @gulf_news #coronavirus @AbbVie @Amgen @Takeda

— Gulf News Business (@GulfNewsBiz) August 3, 2020

AbbVie, Amgen, Takeda launch joint trial of potential COVID-19 drugs https://t.co/J2kmg2aHtE

— FirstWord Pharma (@fwpharma) August 3, 2020

Abbvie, Amgen and Takeda begin patient trial for Coronavirus vaccine https://t.co/j43q68CeRs

— PageOne.ng (@PageOne_NG) August 3, 2020

AbbVie, Amgen and Takeda start testing drugs as COVID-19 treatments https://t.co/d8RdZY3U1g

— MarketsTicker (@MarketsTicker) August 3, 2020

AbbVie, Amgen and Takeda begin testing drugs as COVID-19 treatments https://t.co/3V3KhrwqAT

— MarketWatch (@MarketWatch) August 3, 2020

Rival drugmakers AbbVie Inc , Amgen Inc and Takeda Pharmaceuticals Inc. said they have begun treating patients in a trial. | @reuters https://t.co/5EJHUF7fmQ

— Inquirer (@inquirerdotnet) August 3, 2020

#covid19 cases seem to be reducing in Italy & China. Plus masses of big biotech, pharma & vaccine companies are pouring $bns into finding a cure, eg Gilead, Pfizer, GSK, Takeda, AbbVie, Moderna.

I appreciate no-one has the answer yet, but I suspect they'll get before the y/e pic.twitter.com/haEYH2cUOZ

— PMH Capital (@CapitalPmh) March 4, 2020

Takeda's Entyvio outperforms AbbVie's Humira in moderate-to-severe #UlcerativeColitis https://t.co/RBvxGE4VEN #pharma pic.twitter.com/8duoTU0NH1

— Pharmafocus (@Pharmafocus) September 27, 2019

pH-Dependent Drug-Drug Interactions: Novartis, Merck, Gilead and More Weigh in: Novartis, Merck, GlaxoSmithKline (GSK), Gilead, Bayer, AstraZeneca, AbbVie and Takeda offered their opinions on recent FDA draft guidance on potential drug-drug interactions… https://t.co/usSBncXDwt

— cafepharma (@cafepharma) July 27, 2018

Great opportunities for @ucdscience and engineering students/grads:

☑️NIBRT Careers in Biopharma event in UCD Campus on 13 April

☑️Companies attending include J&J, BMS, Sanofi, Allergan, Amgen, Grifols, Takeda, AbbVie

☑️Further details on https://t.co/zpHbKRFHvq. https://t.co/0N3eoSrKZK

— UCD Chemistry (@ucdchemistry) March 20, 2019

On Saturday, IPhO held its 4th annual Pharma Fair! Student pharmacists from over the country came to network with reps from pharmaceutical companies such as Takeda, AbbVie, & more.

Our students are making key connections that will put them on the path to success! pic.twitter.com/6sGk11Cz4e

— UIC Pharmacy (@UICPharm) October 28, 2019

Takeda buy Shire
BMS buy Cellgene

And now … Abbvie buy Allergan

All are BIG players with significant stakes in current / future therapies for #IBD

It will be very interesting to watch this play out. Hopefully it means more R&D investment that translates to the clinic. pic.twitter.com/EpoUnt9yXD

— Charlie Lees (@charlie_lees) June 25, 2019

MSBE, BT and GCB students check out the Careers in Biopharma event in NIBRT on April 13th 2019. Companies attending include J&J, BMS, Sanofi, Allergan, Amgen, Grifols, Takeda, AbbVie.

Further details on https://t.co/pqVYveVS0o

— Brian Freeland (@BFreelandDCU) March 19, 2019

Big Pharma’s first female CEO is engineering a radical shake-up, taking a different path than Bristol-Myers Squibb, Takeda Pharmaceutical, and AbbVie, which are reinventing themselves with megadeals.

Read more at: https://t.co/kirykEPAe0

— menaka doshi (@menakadoshi) July 18, 2019

8 New drug structures revealed at #ACSOrlando….see them here !
Companies include: Amgen, Abbvie, Novartis, Takeda, Pfizerhttps://t.co/ZE68xbb5r7 pic.twitter.com/tYbPMJ45Gj

— Organic Process Research & Development (@OPRD_ACS) April 5, 2019

Endometriosis Treatment Market New Opportunities For Growth And Profitable Business Development 2026 Evaluated By Global Players Meditrina Pharmaceuticals, Abbvie, PfizerInc, Takeda Pharmaceutica, and Neurocrine Biosciences Inc https://t.co/HhbepHFlxV via @openPR

— Raj Bisen (@Rajbisen210) February 26, 2019

https://twitter.com/AxiomaGroupInc/status/1301584540507439109

J&J may be a little behind with the COVID-19 vaccine, but they may still have an advantage.https://t.co/T4ubxOcCdg #competitiveadvantage #vaccine #strategy #jnj #pfizer #allergan #takeda #abbvie #amgen #moderna #covid19 #pharma #biopharmaceuticals #biopharma #coranavirus #lead pic.twitter.com/OiE3GZXTcX

— Axioma Group, Inc. // Strategy + Innovation (@AxiomaGroupInc) August 12, 2020

https://twitter.com/AxiomaGroupInc/status/1291191015701872643

Prostate Cancer Diagnosis and Treatment Market Supply-Demand, Industry Research and End User Analysis, Outlook 2026 | COVID19 Impact Analysis | Key Players: Abbott Laboratories, AbbVie, Active Biotech, Amgen, Astellas Pharma, etc. https://t.co/SReC9xp1Jy

— mednetnews (@mednetnews) October 2, 2020

https://twitter.com/KNOW_AML/status/1252583034622263297

Cancer Therapeutics Market Estimated to Reach at $178,863 million by 2023 – F. Hoffmann-La Roche,Bristol-Myers Squibb, AbbVie, Johnson & Johnson, Celgene, Astellas, Pfizer, Novartis, Merck, Eli Lilly – Downey Magazine https://t.co/0lBoYnbg4h

— Cross the Creek (@creek_cross) December 26, 2019

Research Segment of Endometriosis Drugs Market (2020 – 2029) | AbbVie, Astellas Pharma, AstraZenecahttps://t.co/Zz5keb7j2s #news #pharma #pharmiweb

— Pharma News (@pharminews) December 23, 2019

Global Idiopathic Intracranial Hypertension Therapeutics Market 2019-2023 | Evolving Opportunities with AbbVie Inc. and Astellas Pharma Inc. | Technavio https://t.co/MScX9lj3gm

— Pharmacutical Daily (@PharmacDaily) November 5, 2019

Don't be left out of the celebrations – Entries from @abbvie @Bayer @astellas @Novartis @JanssenUS already, so don't miss out on your chance to be part of the #efpawards Download your entry pack here https://t.co/Trk5qhLrNR pic.twitter.com/3ibsDJAd67

— Reuters Events Pharma (@RE_Pharma) June 25, 2019

Biopharmaceuticals Market Outlook to 2025 :Inflammatory , Infectious Diseases, Autoimmune Disorders, Metabolic Disorders,| With Top Key Players AbbVie, Amgen Astellas BioPharma, Johnson & Johnson, No https://t.co/EexNJ7Z3l2

— PressRelease.cc (@PressRelease_cc) February 19, 2019

Global Prostate Cancer Drugs Market 2018 Top Intelligence:- AbbVie, Astellas Pharma, Astra Zeneca, Johnson & Johnson, Sanofi https://t.co/OaKEt1Qsin

— Tammy V Wyatt (@tammyvwyatt) January 21, 2019

Hear from Abbvie, Novant Haelth, Astellas, and more at the Strategic Internal Comms for Health Care in April – https://t.co/NUsASWbuVz

— ALI Conferences (@aliconferences) March 16, 2017

NIH launches COVID-19 test of J&J, Bristol Myers and AbbVie anti-inflammatory drugs https://t.co/mmnoWBwa4Y #NIH #JohnsonAndJohnson #BristolMyersSquibb #AbbVie #AntiInflammatoryDrugs https://t.co/vE5QbcsRYJ

— Haybury (@Hayburysearch) October 20, 2020

Bipolar disorder therapeutics market: Top players are Novartis AG, Allergan, Otsuka Holdings, AbbVie etc. – Credence Turbine https://t.co/r9Q5pnDX42

— Schizocidal (@schizocidal) July 10, 2020

Autism Disorder and Treatment Market Growth 2026: Including Key Players Otsuka, AstraZeneca, Pfizer, AbbVie, Johnson & Johnson Services, GlaxoSmithKline https://t.co/8GAlL0MDgR

— Market Research Nest (@marketrnest) April 6, 2020

The $200 discount for the Marketing Disruption Summit ends Friday! Explore the full agenda and get your tickets here: https://t.co/sueo5mBZEd #sanofi #BMS #ferring #boehringeringelheim #merck #teva #gsk #abbvie #astrazeneca #pfizer #bayer #otsuka #us #pharma #marketing #data #it pic.twitter.com/u9P8j4mLcn

— Reuters Events Pharma (@RE_Pharma) August 14, 2019

Japan Oncology Drugs Market Opportunities with Leading Players: Daiichi Sankyo Co Ltd, AstraZeneca plc, AbbVie Inc., Celgene Corporation https://t.co/cTWBLWxisp

— Aditi Desai (@Aditi04986849) November 28, 2019

New post (Humira Market Report Expected Massive Growth By 2020-2025 | AbbVie, Eisai, Torrent Pharmaceuticals) has been published on https://t.co/fdzRB6KRVD – https://t.co/ioErwtJuF5 pic.twitter.com/enQI4mWqu9

— Top News Corner (@topnewscorner) September 15, 2020

Humira Market (2020-2029) : Ranking down the Industry System, Geography and Business sections of the major players AbbVie, Eisai, Cadila Healthcarehttps://t.co/2fA5xvIEqd #news #pharma #pharmiweb

— Pharma News (@pharminews) January 28, 2020

Strategic Overview of the Global Humira Market Exploring the Present and Future State -AbbVie, Eisai And Cadila Healthcare – https://t.co/QnvrzJt4eF #pharma #news

— Pharma News (@pharminews) July 15, 2019

AbbVie and Eisai Announce Fully Human Anti-TNF-α Monoclonal Antibody HUMIRA® is the First in Japan to be Approved for the Treatment of Hidradenitis Suppurativa | News Release：2019 | Eisai Co., Ltd. https://t.co/HE4j8WWYlh

— Krishan Maggon (@kkmaggon) February 22, 2019

AbbVie and Eisai Announce Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA https://t.co/2jOFyHj7qY pic.twitter.com/ZmYb9G36JO

— Haleplushearty.org (@haleplushearty) February 21, 2019

AbbVie and Eisai obtain additional approval for Humira https://t.co/hQFi3njXEo via @NewsNowUK

— francis loos (@claoseun) April 3, 2018

U.S.A. アメリカ Vol.117（New York ニューヨーク州 Vol.3: pharmaceutical corporations 製薬会社）

All the below link and tweets are in English.

取り急ぎ以下貼っておきます。

New York Vol.37 (corporations: Regeneron)

上記リンク内に無い本日までのツイート

We’ve been named one of #AmericasMostJUST companies by @Forbes and @justcapital_ for our commitment to using our resources and expertise to make the world a better place. More on the #JUST100: https://t.co/7uCfrMZ9QD #ResponsibleRegeneron pic.twitter.com/4k7j6Dckzi

— Regeneron (@Regeneron) October 14, 2020

Today, the @EMA_News Committee for Medicinal Products for Human Use (CHMP) recommended the approval of our medicine for children aged 6-11 years with uncontrolled severe #AtopicDermatitis. Learn more: https://t.co/scFqqXQkxS Cc: @sanofi pic.twitter.com/Je5lWmqhZu

— Regeneron (@Regeneron) October 16, 2020

Entered into an agreement with the @Regeneron Genetics Center to advance the goal of the university, along with our partner hospitals @LeBonheurChild, to provide precision medicine tailored to the individual genomic characteristics of patients. https://t.co/NCcDXvzLSn pic.twitter.com/CFLhhDjJjc

— UTHSC (@uthsc) October 19, 2020

Kara and her family are at a standstill with eosinophilic esophagitis management. We’re working with @Regeneron to understand the causes of the disease for families around the world. pic.twitter.com/txk55TyB8i

— Sanofi Genzyme (@SanofiGenzyme) October 14, 2020

Eosinophilic esophagitis (#EoE) is an often misunderstood disease. With @Regeneron, we’re presenting late-breaking pivotal trial data on its management during #UEGWeek. pic.twitter.com/RJkiGhR8z3

— Sanofi (@sanofi) October 13, 2020

Today, our medicine was recommended for approval in children aged 6-11 years in Europe with severe #AtopicDermatitis by the @EMA_News Committee for Medicinal Products for Human Use (CHMP). Cc: @Regeneron Read the news: https://t.co/udUMDRgIws pic.twitter.com/N7eA8DyhE9

— Sanofi (@sanofi) October 16, 2020

Dr David Tucker and the team at @RCHTWeCare worked with @Regeneron to restart a trial of an investigational bio-engineered fully human monoclonal antibody which is being tested in patients with relapsed lymphoma.

Read about the steps they took: https://t.co/jWbzqmawHv @NIHRSW pic.twitter.com/jmkGeXgjTM

— NIHR for Industry (@NIHR_Industry) October 15, 2020

With @Sanofi and @Regeneron, we're seeking ideas to support people living with #AtopicDermatitis (AD). Join the ‘Agents of Change’ Challenge: Navigating Uncertainty to help people with AD feel more in control: https://t.co/FPTNYSphLX pic.twitter.com/3K8CxS5yEZ

— OpenIDEO (@OpenIDEO) October 19, 2020

From academics to CEO: Stephen Russell, the founder of Imanis Life Sciences, chats to us about Vyriad and partnership with @Regeneron https://t.co/vexbqZGWA1 pic.twitter.com/x8w8eGWGNx

— Decision Resources Group (@DRGinsights) October 16, 2020

　https://twitter.com/NewomicsInc/status/1318634515590483971

Thank you to everyone who joined us for the 2020 #GeneExpression and Signaling in the #ImmuneSystem; including co-orgs Diane Mathis, Stephen Nutt, Alexander Rudensky, and Arthur Weiss; and sponsors @NIAIDNews and @Regeneron. #cshlimmune https://t.co/CBlzfEJwkg

— CSHL Meetings (@cshlmeetings) October 19, 2020

Sajith Wickramasekara was an MIT undergrad when he came up with a cloud-based Crispr design tool to help scientists. Eight years later, Regeneron, Gilead and hundreds of other companies use its collaborative software: https://t.co/brNNEmeURD

— Forbes (@Forbes) October 20, 2020

While @Regeneron is pushing its high-dose IV anti-SARS2 mAb cocktail (8g !!), researchers are developing inhaled low-dose anti-SARS2 mAbs (2mg-6mg !!). Potentially much cheaper and more user-friendly! https://t.co/xKzMDOmNar

— Julien Potet (@julienpotet) October 21, 2020

“…REGN-COV2 based therapy may offer clinical benefit in both prevention and treatment settings of #COVID19 disease, where it is currently being evaluated.”

Learn more about the recent findings of .@Regeneron’s antibody cocktail: https://t.co/xblmBjHGQX #SARSCoV2 #coronavirus pic.twitter.com/lRresg4e2S

— Genetic Engineering & Biotechnology News (@GENbio) October 17, 2020

The race we mentioned above got really interesting when we reported that Regeneron’s antibody treatment was tested using cells originally derived from an abortion. https://t.co/lNwUJwbf0R

— MIT Technology Review (@techreview) October 20, 2020

https://twitter.com/chngin_the_wrld/status/1318563734424449024

Today on @TheScienceShed with @SteveTheChemist we delve into the therapeutic that cured Trump, and discuss the insane mouse genetics technology from @Regeneron that allowed it to be made…. https://t.co/O30rIjn5Me

— Nick Evans (@theevanslab) October 19, 2020

.@Regeneron is conducting clinical trials on its monoclonal antibody #COVID19 therapy. If the trials are successful & the therapy receives Emergency Use Authorization from the FDA, Regeneron will provide it for free to Americans suffering from COVID-19: https://t.co/ufzHYm2pMP

— Alliance to Protect Medical Innovation (@ProtectMedicine) October 16, 2020

.@Regeneron asks @US_FDA for emergency clearance for #COVID19 therapy https://t.co/yM0KN6X4Pt pic.twitter.com/Cioxh2lF8X

— The Cancer Letter (@TheCancerLetter) October 13, 2020

A study of the REGN-COV2 #antibody cocktail in rhesus macaques and golden hamsters provides evidence it may offer clinical benefit in both prevention and treatment settings of #COVID19 disease. @Regeneron https://t.co/6E8jJFUTC3 pic.twitter.com/7HAQL4izfm

— Science Magazine (@ScienceMagazine) October 13, 2020

The #SARSCoV2 monoclonal antibody (mAb) rollout is going to be very complicated.https://t.co/0Vm6uvG8Yl @katie_thomas covers many issues here, including potential need for rapid antibody testing. Add this one:
These are outpatient infusions. Where is the mAb infusion clinic?

— Eric Topol (@EricTopol) October 20, 2020

https://twitter.com/DelthiaRicks/status/1317565058998816776

President @realDonaldTrump is working with @US_FDA and @HHSGov to make the antibody treatment Regeneron available to everyone who needs it. pic.twitter.com/YSeT7deNMG

— The White House (@WhiteHouse) October 16, 2020

On the latest #TWiV Ari and Kishana founders of @BlackInMicro join TWiV to discuss goals of organization, then pauses of J&J and Lilly #COVID19 vaccine trials, preclin of Regeneron #SARSCoV2 mAb cocktail, reinfection of a patient in Nevada https://t.co/vIFfxIzZ57 pic.twitter.com/6Xj9jDzWH2

— Vincent Racaniello (@profvrr) October 15, 2020

Took a stab at explaining roughly how the @Regeneron antibody treatment is made. Strange its being dragged into US partisan politics, including controversies over the use of a 50 year old embryonic stem cell line. It represents a massive shift in the way we fix this pandemic: pic.twitter.com/Ycl9MZV9FG

— Kashif Pirzada, MD (@KashPrime) October 13, 2020

Did you know Regeneron's antibody cocktail for #COVID19 is being tested in RI? Here's my Q&A with the principal investigator where we discuss who's getting it and how it's going: https://t.co/dnxFhPA9up

— Kim Kalunian (@KimKalunian) October 20, 2020

.@SavannahGuthrie: "How severe were your symptoms, and in particular did you have pneumonia?"

President Trump: "I didn't feel good, I didn't feel strong … They gave me Regeneron and Remdesivir both and all I know is I felt good the following day."#TrumpTownHall pic.twitter.com/LLLZO5Rwu3

— NBC News (@NBCNews) October 16, 2020

Trump says he feels like 'Superman' after Regeneron COVID-19 treatment https://t.co/PLX4xTkOoS pic.twitter.com/6r0Becmpmn

— New York Post (@nypost) October 14, 2020

Donald Trump told the rally he "felt like Superman" after doctors gave him a COVID-19 antibody cocktail called Regeneron. #9News
https://t.co/SQ1H0jI6pm

— 9News Australia (@9NewsAUS) October 19, 2020

　https://twitter.com/stridermemes/status/1316766718207897601

Regeneron CEO says Trump's experience with the company's COVID-19 drug is the 'weakest evidence you can get' of whether it works https://t.co/DP3HMCz52i via @Yahoo

So much for @realDonaldTrump's infomercial hype.

— The Ghost of Lindsey Graham's Past (@PogoChrestman) October 13, 2020

Local biopharmo co. @Regeneron has been getting a lot of attention this month, though not all of it good. https://t.co/qSf31nsdlE

— Westchester Magazine (@WestchesterMag) October 18, 2020

The Regeneron therapy Trump took is a real menace. It's part of the Operation Warp Speed plan. Trump has promised his miracle cure will be delivered to seniors in nursing homes free of charge. https://t.co/geGZNcWhSq

— Julianne ✝️ ‏ (@KindeandTrue) October 20, 2020

No, Regeneron Did Not Cure Donald Trump of Covid-19 https://t.co/R9R7Pnq9bj

— Sabrina Courtez (@CourtezSabrina) October 19, 2020

Expert doctor on #Regeneron: #Trump also touted bleach for Covid-19https://t.co/mMjW64aa7O via @amjoyshow

— AM Joy on MSNBC (@amjoyshow) October 14, 2020

It takes just 1 sentence to know there's a big problem:
"A White House official told me that the president had “off the charts” antibodies on samples collected after he received the Regeneron infusion."https://t.co/lu05pnLZQp
No need @WhiteHouse or labhttps://t.co/HBCZBv5P8o

— Eric Topol (@EricTopol) October 13, 2020

DON’T RT THIS VIDEO: THE MAGGOTS ARE MAD AT ME: Trump’s lie that Regeneron “cured” his Covid is also a scam: HE OWNED STOCK IN THE COMPANY; the CEO is a pal. And, what matters is Coney Barrett’s lies. Worst Person In The World #4 here: https://t.co/Th9jTg3L8l Short Version below: pic.twitter.com/kpDeJJlosE

— Keith Olbermann (@KeithOlbermann) October 13, 2020

　https://twitter.com/jeff_cranmer/status/1317156952938434561

#Breaking: The FDA has approved our novel anti-viral #antibody medicine for Zaire ebolavirus in adult and pediatric patients. #Ebola Read the full announcement: https://t.co/a8S7QhXMBw pic.twitter.com/nHGrIvrzLH

— Regeneron (@Regeneron) October 14, 2020

Regeneron's #Inmazeb wins US #FDA approval as 1st #Ebola virus treatment @Regeneron https://t.co/AX9YDubXv2 pic.twitter.com/G7f1zrzSSq

— Market Intelligence: Healthcare (@SPGMIHealthcare) October 15, 2020

An antibody cocktail from @Regeneron has been approved by the FDA as the first treatment for Ebola, offering hope that the same approach could be used to combat COVID-19. https://t.co/hDsBWDLueM

— pharmaphorum (@pharmaphorum) October 15, 2020

.@Regeneron's triple-antibody cocktail (REGN-EB3) on Wednesday became the first FDA-approved Zaire ebolavirus treatment: https://t.co/npE95ANizV pic.twitter.com/TlR3RWpugw

— Linksbridge (@linksbridge) October 15, 2020

Exciting news! @BARDA @US_FDA @Regeneron @doddtra https://t.co/HbXWZSMOFk

— CBD S&T Conference (@cbdstconference) October 16, 2020

The @US_FDA has granted approval to @Regeneron’s antibody drug Inmazeb for the treatment of Ebola virus, making it the first treatment for the virulent infection. Read more by @AyeshaR1202 here. https://t.co/l3bnBKhriC #FDA #Ebola #AntibodyDrug

— Xtalks Webinars (@Xtalks) October 19, 2020

This month the U.S. Food and Drug Administration granted formal approval to an antibody cocktail from the pharmaceutical company Regeneron that's been shown to dramatically reduce an Ebola patient's chances of dying. https://t.co/5c34CmtZZl

— NPR (@NPR) October 21, 2020

FDA has approved Regeneron 3 monoclonal antibodies cocktail for treating Ebola

The FDA has approved the first treatment for Ebolahttps://t.co/6TFsIVH1WF

— Randall French (@RandallFrench14) October 19, 2020

Yesterday, @US_FDA announced it has approved @Regeneron's Inmazeb, formerly called REGN-EB3, to treat Zaire ebolavirus infection in adult and pediatric patients — the first-ever FDA-approved treatment for #Ebola.https://t.co/mlJlGvPQTj

— ID News (@InfectDisNews) October 15, 2020

#Biotech #Ebola Regeneron's Inmazeb Becomes First Ebola Treatment To Get FDA Approval https://t.co/v11e1WoHqJ pic.twitter.com/mUPGKSEyAF

— dailytradingapp (@dailytradingapp) October 15, 2020

There's now an approved treatment for #Ebola Zaire, as well as a vaccine. Seemed unimaginable for a long time.
Regeneron's monoclonal cocktail, Inmazeb, was approved today by the FDA. https://t.co/TjAj0Ws6Te

— Helen Branswell (@HelenBranswell) October 14, 2020

FDA approves first treatment for Ebola – it's Regeneron's antibody cocktail, the same approach Regeneron is now taking for #covid19: https://t.co/gn96D5G8WT

— Meg Tirrell (@megtirrell) October 14, 2020

The lines between reality and reality show have become so blurred that the (good!) news of the first #FDA-approved treatment for #Ebola feels like a bizarre cross-promotional product placement for #Regeneron (especially when #Remdesivir was one of the comparators). Still… (1/2) https://t.co/q9vloxSsRv

— Adam R Houston (@HealthLawAdamH) October 14, 2020

ツイッター検索で上記製薬会社名及び Japan や日本の5製薬会社各社名を入れて出て来たもの

#DRG epidemiology report estimates more than 75 million people living with #atopicdermatitis across the United States, Western Europe and Japan. Detailed global reports available now @DRGinsights #RevAtopDerm #SanofiActs @Regeneron @sanofi https://t.co/ClcF0WyNEE

— DRG Epidemiology (@DRG_Epi) April 9, 2020

#DRG epidemiology report estimates more than 20 million people diagnosed with #atopicdermatitis across the United States, Western Europe and Japan. Stay tuned for more epidemiology updates @DRGinsights #atopiceczema @Regeneron @sanofi https://t.co/b3WBojlYkZ

— DRG Epidemiology (@DRG_Epi) August 7, 2019

Japan’s MHLW extended #marketing and #manufacturing authorization for Regeneron’s #DUPIXENT https://t.co/giEc4TlxBi @regeneron pic.twitter.com/0sfqy4ZA8R

— Pharma Journalist (@pharmjournalist) January 24, 2018

.@regeneron has announced that Dupixent, a therapy for adult atopic dermatitis that is inadequately controlled by existing medications, has been granted marketing and manufacturing authorization by the Ministry of Health, Labor and Wealth in Japan.https://t.co/Ys1LSFol8c pic.twitter.com/9j9cu5Dz6R

— Rare Disease Report (@RareDR) January 23, 2018

#Sanofi and @Regeneron gain approval for PCSK9 inhibitor in Japan https://t.co/EnmPRhjXsD

— Sanofi (@sanofi) July 5, 2016

With thanks to Bronze Level Sponsors: Genentech Takeda @TaihoOncology @Regeneron pic.twitter.com/agr98dhoWN

— AA&MDSIF (@aamdsif) October 3, 2020

8-25-2020: Starting 4 months from now, Lilly's LY-CoV555, Regeneron's REGN-COV2, AstraZeneca's AZD7442, or Takeda/Behring/Octapharma might work for early COVID-19, be expensive, be vulnerable to mutations, and be in short supply:https://t.co/s29UYtb9o3 https://t.co/ijHm26afc3

— Ronald M. Chavin (@rmchavin) August 25, 2020

Regeneron has started clinical trials with the dual cocktail, so let's see how that happens. Takeda is taking the approach of hyperimmune polyclonal serum. One issue with the polyclonal preps is maintaining consistency across batches.https://t.co/f7mPK6zNBT

— Thiago Carvalho (@CyrilPedia) July 3, 2020

Adimab broadens R&D deals with Novartis, Regeneron, Takedahttps://t.co/9gF1SqcuEq #R&D #novartis #regeneron #takeda #health #healthcare #pharmaceutical #digitalhealth #vitalyhealth

— Vitaly Health (@HealthVitaly) May 19, 2019

Takeda and Regeneron continue to tap into Adimab’s capabilities https://t.co/lIicDWO57S pic.twitter.com/bUbVGC5pmH

— JackLeckerman (@JackLeckerman) May 13, 2019

13 co's working on Coronavirus treatments/vaccines. Gilead's remdesivir is in late stage testing, GlaxoSmithKline is collaborating with Britain, U of Queensland. See also, Heat Biologics, Inovio, Johnson & Johnson, Moderna, Regeneron, Sanofi, Takeda, more. https://t.co/NyT4jixMES

— Dori Smith (@Dori_TalkNation) March 17, 2020

Biopharma's ever-evolving #COVID19 response, distilled:

Gilead, AbbVie, Pfizer looking at antivirals
J&J, Sanofi, and Moderna on vaccines
Regeneron, Eli Lilly, and Vir on antibodies
Takeda and Emergent on plasma therapyhttps://t.co/8S4Ucbc6ef

— Andrew Dunn (@AndrewE_Dunn) March 13, 2020

and Pfizer Inc., and modest consultant/advisory board fees from Takeda, Medco, AstraZeneca, Resverlogix, Kowa, Abbvie, Eli Lilly, Sanofi, Amgen, Boehringer Ingelheim, Esperion, Cerenis, Akcea, and Regeneron Pharmaceuticals, Inc. https://t.co/NlIG9bHpHu

— Marion Holman (@holmanm) June 15, 2019

Adimab broadens R&D deals with Novartis, Regeneron, Takeda https://t.co/PLAwHC7tjz career medical device pic.twitter.com/cbGNbtODv1

— ThinKeen Global (@thinkeenglobal) May 8, 2019

SSPC GM @denise_croker and team have had a busy week discussing future opportunities for collaboration with Astellas Pharma Ireland, @SKbiotekIreland and @Regeneron @scienceirel #collaboration pic.twitter.com/ezqynt8H75

— SSPC (@SSPCentre) July 25, 2018

Thank you to everyone who support yesterday's Walk to End #Epilepsy, especially our fellow sponsors, including, @Regeneron, @Eisai_SDGs, @GreenwichBio, @EllisMedicine and Supernus. pic.twitter.com/vAAtOaSiw8

— Fingerpaint (@Fingerpainters) September 9, 2019

Great mix of pharma companies represented at @PharmacistsIER careers evening including AbbVie, Alexion, Aspen, Astellas, Bayer, BMS, GSK, Janssen, LEO Pharma, Mallinkcrodt, MSD, Perrigo, Pfizer, Novartis and Regeneron. https://t.co/M5SEwmHPAD

— PIER (@PharmacistsIER) November 1, 2018

Have you seen our @BioCentury Quick Takes? Here’s a look at April 20:

Top-line data for @bmsnews, Idorsia and Ascendis; plus Otsuka-Esperion, @Regeneron and more… https://t.co/ctlZkt7zyV

— matt krebs (@krebs_matt) April 21, 2020

Monday's Quick Takes: top-line data for BMS, Idorsia and Ascendis; plus Otsuka gains Japan rights to Esperioin drugs for $60M upfront and news from Regeneron, Biofourmis and Galapagos $ASND $REGN $BMY $ESPR https://t.co/lu9xn0VCTM

— BioCentury (@BioCentury) April 21, 2020

U.S.A. アメリカ Vol.116（California カリフォルニア州 Vol.2: pharmaceutical corporations 製薬会社）

All the below link and tweets are in English.

取り急ぎ以下貼っておきます。

California Vol.25 (corporations: Amgen)

ツイッター検索で上記製薬会社名及び Japan や日本の5製薬会社各社名を入れて出て来たもの

Since 2011, Amgen has doubled its global presence and, with the addition of Amgen K.K., that now includes Japan. In 2019 alone, we invested more than $4 billion in global research & development to serve more patients. Press release: https://t.co/uBT5FT4fnw 2/2 pic.twitter.com/wstcLnvnnz

— Amgen (@Amgen) April 1, 2020

We’re pleased to introduce Amgen K.K., a wholly-owned affiliate in Japan which will enable Amgen to build a strong presence in the country moving forward. Amgen K.K. will focus on bringing our full global pipeline to Japanese patients. Press release: https://t.co/uBT5FT4fnw 1/2 pic.twitter.com/fkqXj6g6Tm

— Amgen (@Amgen) April 1, 2020

#Amgen’s New #Osteoporosis Treatment Receives First Worldwide Approval in Japan https://t.co/JooD4GUxgK @UCB_News

— Amgen (@Amgen) January 8, 2019

#ICYMI, #Amgen’s medicine for R/R ALL has received marketing authorization in Japan. Learn more: https://t.co/UMrQByPqtD

— Amgen (@Amgen) September 26, 2018

#Amgen receives approval for our R/R ALL medicine in Japan. Learn more: https://t.co/UMrQByPqtD

— Amgen (@Amgen) September 25, 2018

Applications for the #AmgenScholars Program in Europe, Japan & the U.S. are open now: https://t.co/uVtH11AW1w pic.twitter.com/rt3JekGqix

— Amgen (@Amgen) December 13, 2017

The #AmgenScholars Japan Symposium was a global gathering of passionate young #scientists. Learn more: https://t.co/CvuLhtGpQF

— Amgen (@Amgen) January 10, 2017

#Amgen & @UCB_news announce submission of marketing application in Japan for osteoporosis treatment https://t.co/Z27LnrD17x

— Amgen (@Amgen) December 20, 2016

#Amgen submits marketing application in Japan http://t.co/DSa8puB2Ms

— Amgen (@Amgen) March 20, 2015

#Amgen presents new detailed cholesterol data from Japan study at #ACC15 http://t.co/A8Crv951Em

— Amgen (@Amgen) March 14, 2015

Japan’s #biosimilar guidelines aim toward #quality, #safety and #efficacy. Full article: http://t.co/xzDMFOgozN via @GaBIOnline_

— Amgen (@Amgen) September 27, 2013

As the Japan #AmgenScholars Program enters its fifth year, Steve Sugino, Vice President of @Amgen, caught up with its Directors, Dr. Ichiro Sakuma and Dr. Fuyuki Ishikawa about their experience with the program. https://t.co/2opFJZxRUb

— Amgen Foundation (@AmgenFoundation) April 10, 2019

@Amgen establishes a wholly-owned affiliate in Japan by announcing the completion of 49% share buyout in a 7-year-old joint venture with Astellas Pharma Inc.#Japan #Healthcare #GeneOnline https://t.co/rfMMQHKd9e

— GeneOnline (@GeneOnlineNews) April 1, 2020

#Pharma with '#AI friendly' executives will prosper: US, Germany, and Japan-based companies lead the pack, says @DK_Analytics report // @DeepTech_VC

Read: https://t.co/Ra1FDwHAXE @Boehringer @GSK @LillyPad @Evotec @pfizer @Amgen @BayerPharma @Roche @Novartis @bmsnews @Merck pic.twitter.com/df32pzpwpr

— Outsourcing-Pharma (@OutsourcPharma) July 8, 2019

What are the key challenges for #osteoporosis patients in #Japan and how are these affecting their daily lives? Our persona portrait explores the issue. #bonehealthAsia https://t.co/6I7R6gsnr3 (Commissioned By @Amgen) pic.twitter.com/XSzyeHQBpH

— The Economist Intelligence Unit (@TheEIU) March 28, 2019

In Japan, #cardiovascular diseases (CVDs) levy US$24.3bn in direct and indirect costs on individuals, their households and the public finances. What can be done to reduce CVDs costs? Download report> https://t.co/GvIrb2yynd (Via @Amgen) #HearthealthAsia pic.twitter.com/b0syBOLu9W

— The Economist Intelligence Unit (@TheEIU) December 21, 2018

Amgen and UCB's Evenity approved in Japan for #osteoporosis https://t.co/GvzSmOIQv5 #pharma @Amgen @ucb_news pic.twitter.com/gcs0QJ4SJi

— Pharmafocus (@Pharmafocus) January 9, 2019

BLINCYTO® (Blinatumomab) Approved in Japan for the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia @Amgen https://t.co/TxsNrf7oZ1

— Hematopoiesis News (@Hema_News) September 28, 2018

Japan to cut drug prices, @bmsinfo @OnoPharmaOpdivo (nivolumab) & @Amgen Repatha (evolocumab) into the spotlight https://t.co/3xzxFn3muY

— ilS (@ilsintelligence) September 19, 2016

@Amgen's #Repatha wins first PCSK9 OK in #Japan https://t.co/EeEEqDTq40 @FiercePharma #hypercholesterolemia #cholesterol #cardiovascular

— Plexus Ventures (@PlexusVentures) January 25, 2016

@Amgen signs autoimmune pact with Japan's Teijin – Read more via @PharmaTimes here: http://t.co/OlktgphSz9 #autoimmune #Japan #pharma

— Plexus Ventures (@PlexusVentures) August 1, 2013

#Amgen announces approval of Repatha® (evolocumab) in Japan https://t.co/uOn5L1sab3

— Amgen (@Amgen) January 22, 2016

#Amgen and Astellas Announce Japan Alliance http://t.co/oRgJwzycLz

— Amgen (@Amgen) May 29, 2013

Amgen Repurchases Astellas’ Stakes in Amgen Astellas JV to Strengthen its Footprints in Japan @Amgen @AstellasUS https://t.co/9RLS4NdZg2 pic.twitter.com/5eHR6tMorO

— PharmaShots – Incisive news in 3 shots (@Pharmashot) April 1, 2020

@Amgen establishes a wholly-owned affiliate in Japan by announcing the completion of 49% share buyout in a 7-year-old joint venture with Astellas Pharma Inc.#Japan #Healthcare #GeneOnline https://t.co/rfMMQHKd9e

— GeneOnline (@GeneOnlineNews) April 1, 2020

Amgen & Astellas Enter Into Japan Alliance http://t.co/345v46RfBp @amgen @AstellasUS

— Asian Scientist Magazine (@asianscientist) June 7, 2013

#Amgen and @DaiichiSankyoJP announce agreement to commercialize #biosimilars in Japan. https://t.co/bVDl6FJaet

— Amgen (@Amgen) July 14, 2016

#collaboration between @Amgen and @EUdaiichisankyo to #commercialize nine #biosimilars in #Japan.
For more: https://t.co/R2fyWqM00i

— Roots Analysis (@RootsAnalysis) July 18, 2016

@Amgen & @DaiichiSankyo announce agreement to commercialize #biosimilars in #Japan https://t.co/D3xmqmRiJo @WorldPharmaNews #biosim #pharma

— Plexus Ventures (@PlexusVentures) July 14, 2016

.@Amgen agrees deal to commercialise biosimilars in Japan with @EUdaiichisankyo https://t.co/O7cdaYN3Ml

— Pharmafocus (@Pharmafocus) July 14, 2016

Amgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan https://t.co/KsanOqAcmi [h/t @Amgen]

— Endpoints News (@endpts) July 14, 2016

.@Amgen partners with @DaiichiSankyoJP to market biosimilars in Japan https://t.co/fieuGDAidm via @biopharmadive pic.twitter.com/hsWno7fsfd

— NewYork Pharma Forum (@NYPharmaForum) July 23, 2016

.@Amgen partners with @DaiichiSankyoJP to market biosimilars in Japan https://t.co/UpKRfQvYGV via @biopharmadive pic.twitter.com/6H9mg6Ou5y

— NewYork Pharma Forum (@NYPharmaForum) July 22, 2016

AbbVie, Amgen and Takeda test anti-inflammatory drugs in joint COVID-19 study | @AbbVieUS @Amgen @TakedaOncology @WHO #cambridge #massachusetts #thousandoaks #california #covid19 #biotech https://t.co/HAJfTVcTOR

— Pharm2Market (@pharm2market) August 6, 2020

Rival drugmakers launch joint trial of drugs for #COVID19 https://t.co/LcRNln9jaK @gulf_news #coronavirus @AbbVie @Amgen @Takeda

— Gulf News Business (@GulfNewsBiz) August 3, 2020

Our heads of R&D, Takeda's Andy Plump and @Amgen's David Reese, published a @statnews opinion article about the efforts of the COVID R&D Alliance and the power of adaptive trials. Learn how a global network can accelerate the fight against #COVID19 https://t.co/x5gYQT8nVj pic.twitter.com/lXs0YOkkVK

— Takeda (@TakedaPharma) July 23, 2020

Affymax banks $50M milestone on ESA drug approval http://t.co/T5PeWE5y $AFFY $AMGN @Takeda @Amgen

— FierceBiotech (@FierceBiotech) April 10, 2012

#Peptide_Based_Cancer_Therapeutics Market Size Worth $17.18 Billion By 2027

Read More : https://t.co/k5GadYh4D3

major market participants :@AstraZeneca @Allergan @Pfizer @Takeda @Amgen,@JNJNews #peptidetherapeutics #healthcare pic.twitter.com/8LF46fwnPm

— karishma mulani (@karishmamulani5) July 28, 2020

.@TakedaPharma to return molecules/ products for Japan to @Amgen https://t.co/14hGlLgKu6

— Pharmafocus (@Pharmafocus) June 27, 2016

参考．上記linkに無いもの

“The world now recognizes that we need innovation to get out from under the crush of this pandemic.”

Amgen CEO Bob Bradway spoke with @FT's @HannahKuchler about navigating #COVID19 now and preparing for a post-COVID world. #FTUSPharma $AMGN

— Amgen (@Amgen) October 6, 2020

If you’re a provider, visit our updated #COVID19 & cardiovascular resource page which also includes a link to important resources in the @HFSA COVID-19 resource hub to learn more.

Details in the link below.

— Amgen (@Amgen) October 1, 2020

Amgen's Michelle Carillo from our advocacy relations team will join for this discussion. Registration details in link below. #COVID19 https://t.co/wLqtf8dr8A

— Amgen (@Amgen) September 29, 2020

Moderated by MassBio CEO @BobCoughlin, Michelle Carrillo @Amgen, Dr. Meghan Mooradian @MassGeneralNews & Kirsten Sloan @ACSCAN join us now for a discussion on how #COVID19 has impacted cancer care & the path to diagnosis & treatment. Thank you, @Amgen for sponsoring this event! pic.twitter.com/mG5Lb9Hd8f

— MassBio (@MassBio) October 1, 2020

Dr. Steven Galson of @Amgen discussing #COVID19 and the promise of genetic sequencing. A great conversation on how science is meeting this critical moment for our world. #CALeg pic.twitter.com/rn7kDoqWap

— California Biotech (@CABiotech) May 28, 2020

.@PhRMA companies and CMTA members @LillyPad, @TakedaPharma, @pfizer, @JNJInnovation, @Amgen, @Novartis part of coordinated intl. research response for #COVID19 treatments and vaccines. #MakingCA #ProtectingUS https://t.co/K81hC2aHPe

— California Manufacturers & Technology Assn. (@cmta) April 21, 2020

Wonderful news from CLSA members @Amgen and @LillyPad!

The spirit of life sciences collaboration embodies our ability to defeat this pandemic! #innovation > #COVID19 https://t.co/NnfbMCq62H

— California Life Sciences Association (CLSA) (@CALifeSciences) September 17, 2020

In the fight against the pandemic, @LillyPad announced a partnership with @Amgen to #manufacture a new #COVID19 treatment! #CreatorsRespond https://t.co/ihMQVEWabZ

— Friends of Manufacturing (@FriendsofMFG) September 17, 2020

Lilly and Amgen announce manufacturing collaboration for COVID-19 antibody therapies. @WorldPharmaNews @LillyPad @Amgen #COVID19 #antibodies #LYCoV555 #lifesciences #pharma https://t.co/h2TiFilMDl pic.twitter.com/bUbAsek5xs

— Greybridge (@GreybridgeRoles) September 22, 2020

With rising numbers of #diabetic and #chronicdisease #patients, the #wearable #injectors market is growing for ease of #drugadministration. (https://t.co/dNV34tAMEh)
.
.
.#injection #syringe #drugdelivery #medicine #Amgen #BD #Insulet #Medtronic #COVID19 #TBRC #GlobalMarketModel pic.twitter.com/jExYhkjBf7

— TBRC (@tbrc_info) September 22, 2020

Amgen adapts to pandemic with #Prolia home infusion; #Otezla as COVID-19 therapy @Amgen #covid19 #earnings @MichaelHGibney reports https://t.co/lsTmjgdaDz pic.twitter.com/psknF2KIok

— Market Intelligence: Healthcare (@SPGMIHealthcare) July 29, 2020

Discover what it's like to be an outbreak response team member in Amgen #BiotechExperience's new virtual curriculum module that explores the #COVID19 pandemic, Responding to a Mystery Illness.
Read all about it: https://t.co/kecQFvdMA4 pic.twitter.com/TqquQDmqdT

— ABE Program Office (@ABEProgOffice) April 27, 2020

Working with @AdaptiveBiotech, @Amgen is working on a drug to treat #COVID19. #CreatorsRespond https://t.co/BKYN0PgIk6

— The NAM (@ShopFloorNAM) April 3, 2020

First Patients Registered in I-SPY COVID Trial https://t.co/4wzf17dWb6 via @GMP news #AbbVie #Amgen #ClinicalTrials #Covid19 #Takeda #GMPNews

— GMPnews.Net (@GMPnewsNet) August 4, 2020

Tune in as @American_Heart CEO @NancyatHeart and @Amgen CEO Bob Bradway discuss #COVID19 rapid response efforts, especially for heart disease and stroke patients who are at higher risk & rightfully concerned. https://t.co/rAOt9UJFD4

— American Heart News (@HeartNews) May 19, 2020

Thank you @Amgen Canada for your donations, supplies, and expertise to our Canadian communities to help fight against #COVID19. #CanadaResilient Learn more > https://t.co/70V9BlXh29 pic.twitter.com/Mo34pp6FPg

— Mississauga Business (@MississaugaEDO) May 6, 2020

At shareholder meetings this spring investors asked #BigPharma to commit to freeze prices on key drugs in light of the #COVID19 pandemic. Tomorrow the industry is set to again raise prices. CEO Bradway of @Amgen – will you commit? https://t.co/Aratl9g4iU

— ICCR (@ICCRonline) June 30, 2020

#NasdaqListed @Amgen marks a major milestone with a note of gratitude to #healthcare workers.

How they're stepping up to address the #COVID19 pandemic: https://t.co/PBb1vBMhAd https://t.co/0pWytEJcHp pic.twitter.com/R9aolBQRET

— Nasdaq (@Nasdaq) April 8, 2020

Boehringer Ingelheim-backed COVID researchers identify new antibodies to fight the virus | @boehringerus @UniCologneNY @DZIF_ @lillypad @Regeneron @Amgen @AstraZeneca #immunesystem #covid19 #biotech #research https://t.co/T8Y9zaIVX0

— Pharm2Market (@pharm2market) July 11, 2020

U.K. イギリス Vol.30（pharmaceutical corporations 製薬会社）

All the below link and tweets are in English.

取り急ぎ以下貼っておきます。

UK Vol.169 (pharmaceutical corporations: AstraZeneca)

追加（本日までのツイート）

White blood cells produce antibodies in response to infection. Over 25 years, @croweje and @VUMC_Vaccines have pioneered techniques for isolating human “monoclonal” antibodies to neutralize pathogenic viruses with a laser-like focus. #COVID19 @AstraZeneca https://t.co/yomHmoGDpW

— VUMC Insights (@VUMC_Insights) October 14, 2020

Read Heather Macdonald-Tait’s account of what motivated her to volunteer for a trial of the #COVID19 vaccine developed by @UniofOxford and @AstraZeneca, and her experiences so far: https://t.co/LYpCFkxVbE

— Gavi, the Vaccine Alliance (@gavi) October 14, 2020

US Signs Deal With @AstraZeneca to Develop, Make #COVID19 Antibody Treatment

Learn more: https://t.co/oJncXqIEB1 pic.twitter.com/Bb8LWIbq5o

— AJMC (@AJMC_Journal) October 10, 2020

We’re partnering w/ @JPEOCBRND & @AstraZeneca under #WarpSpeed on clinical trials and large-scale manufacturing of a monoclonal antibody therapeutic to prevent #COVID19. With @US_FDA authorization, the doses could be used to help fight the pandemic https://t.co/ugxfm9LQyw pic.twitter.com/TUHAQMtLNU

— BARDA (@BARDA) October 9, 2020

.@BARDA, @JPEOCBRND & @AstraZeneca are working together at #WarpSpeed on clinical trials and large-scale manufacturing of a medicine to prevent #COVID19. The government will own these first doses and can make them available with authorization from @US_FDA. https://t.co/7LP5tF4rCf pic.twitter.com/924YcaCEvW

— ASPR (@PHEgov) October 9, 2020

Due to a month-long halt of the trial imposed by #US regulators investigating potential side-effects, volunteers have only been given one dose of the vaccine #COVID19 #Oxford @AstraZeneca https://t.co/NYt8lWVaHM

— Arab News (@arabnews) October 7, 2020

US Govt has awarded $486 million to @AstraZeneca PLC to develop & secure supplies of up to 1 lk doses of #COVID19 antibody treatment, a similar class of drug that was used in treating President #Trump: US Health Dept@realDonaldTrump @AstraZenecaUS pic.twitter.com/ahDVDSne3n

— ET NOW (@ETNOWlive) October 12, 2020

The U.S. government and @AstraZeneca have teamed up to develop 100,000 doses of #COVID19 antibody treatments for high-risk populations, with the possibility for the U.S. to acquire an additional 1,000,000 doses in 2021.

Learn more, via @CNBC https://t.co/A22Y0hOkLp

— Solomon McCown & Cence (@solomonmccown) October 12, 2020

A #COVID19 #vaccine trial by @UniofOxford and @AstraZeneca was paused last month due to a reported side effect in a patient.
But how common is pausing a vaccine trial? How does the trial resume? Do vaccine companies really treat safety seriously?@Dr_Banika explains: pic.twitter.com/3nkwwA9pLy

— hospital research (@hosp_research) October 13, 2020

.@AstraZeneca received $1.2 BILLION to develop a #COVID19 vaccine from the US government. But that didn't satisfy their greed.

Since their Texas-sized payday, the company announced price hikes on many of their products TWICE. https://t.co/GdaTXQnzJk

— Texans For Affordable Rx (@TX4AffordableRx) October 8, 2020

After @Novartis & @AstraZeneca J&J puts on hold it’s #COVID19 trial due to unexplained illness in participant… All this isn’t surprising. Beyond the hype, reality of #clinicaltrials catches up with us… It’s a long, risky & unpredictable endeavor. https://t.co/YWV56CNFqA

— Amine Korchi MD (@AmineKorchiMD) October 13, 2020

#US, @AstraZeneca sign pact for #COVID19 antibody treatment used to treat #Trump https://t.co/ulVrswN2gD | #pharma #pharmanews #IndiaIncfightsCovid19

— ExpPharma (@ExpPharma) October 11, 2020

Let's talk about some real COVID19 drugs for a moment. The one drug that really helped me in my own COVID19 infection was Symbiocort by @AstraZeneca. I already had some at home for my asthma: my doc in Canada had given me a free sample he'd gotten from his drug rep. 1/ https://t.co/AKb6IAi6Y2

— Shawn Wenzel (@shawnwenzel) October 8, 2020

“Front-runners @Pfizer and @AstraZeneca say they have no plans to do challenge studies. Other #vaccine makers like @JNJNews are eyeing them cautiously… @moderna_tx has started manufacturing a strain of the virus that could be used for challenge studies…” #COVID19 #compliance https://t.co/McIgobW16i

— Mark Warner (@MAAWLAW) October 13, 2020

US backs @AstraZeneca #COVID19 antibody drug with $486M in funding. Read more at: https://t.co/tsxzEXmJIv

—#biomanufacturing #biopharma #pharmaceutical #pharma #vaccine pic.twitter.com/feSd63P3Qm

— American Biomanufacturing (@BioMfg) October 13, 2020

Pharma continue to hold the reins. "MoU between @AstraZeneca and a Brazilian manufacturer, which has been seen by @financialtimes, defines the “Pandemic Period” as ending on July 1 2021." #COVID19
https://t.co/2iBoiiC4Gz

— Shailly Gupta (@Shaillytweeting) October 7, 2020

Mergers & Acquisitions explores 5 ways the #coronavirus is changing #dealmaking, as pharmaceutical companies such as @sanofi and @astrazeneca scramble to develop vaccines, diagnostic tools and treatments https://t.co/wvz94Eh9iZ

— Mergers&Acquisitions (@TheMiddleMarket) October 7, 2020

EMA begins real-time review of @AstraZeneca's #COVID19 vaccine: https://t.co/lHiEaN1tfE @EMA_News #clinicaltrials #COVID #CoronaVirus #Vaccine

— Teckro (@teckroofficial) October 9, 2020

Cambridge trio accelerate COVID-19 initiatives https://t.co/cLkjZ8M5oH @AstraZeneca @GileadSciences @sanofi @UniofOxford #COVID19 #coronavirus #Remdesivir pic.twitter.com/pfmZB60RxB

— Business Weekly (@businessweekly) October 8, 2020

Great news. The two vaccines for COVID-19: One is being developed by the company @AstraZeneca, Cambridge, UK, in collaboration with the University of Oxford, the other by @BioNTech_Group, Mainz, Germany, in collaboration with @pfizer, NY, USA. #COVID19. By @ChemistryViews https://t.co/sNXkzsF82d

— Química y Sociedad (@ForoQyS) October 8, 2020

Staffordshire is set to receive 600,000 doses of coronavirus vaccination from as early as November! It's great to hear that a vaccine to combat #COVID19 is being manufactured @KeeleUniversity following an agreement between @CobraBiologics & @AstraZeneca UK https://t.co/eXw21WRYO5

— Croft Architecture (@CroftArchitects) October 8, 2020

AstraZeneca eligible for provisional registration of Covid-19 vaccine after ruling by Therapeutic Goods Administration. News via @CanberraIQ for your daily news digest. For a free trial: https://t.co/jLzrWSAOYG @TGAgovau @AstraZeneca #COVID19 #pandemic https://t.co/hGDtvFgyl5

— Canberra IQ (@CanberraIQ) October 11, 2020

A vaccine to treat COVID-19 globally is imminent but its likely effectiveness has been laid bare. @AstraZeneca @pfizer @JennerInstitute #COVIDVaccine #Vaccine https://t.co/iir1So9X2O

— The CEO Magazine (@TheCEOMagazineG) October 14, 2020

ツイッター検索で上記製薬会社及び Japan や日本の5製薬会社各社名を入れて出て来たもの

We are thrilled to be building on our long-standing heritage in breast cancer through our collaboration announced today with Daiichi Sankyo. To learn more about why we believe pioneering new treatments in this area are so important, click here: https://t.co/1Haz3gHlud pic.twitter.com/pkXJnovNgz

— AstraZeneca (@AstraZeneca) March 29, 2019

AstraZeneca-Daiichi Sankyo's gastric cancer drug wins approval in Japan @AstraZeneca #daiichisankyo https://t.co/n2VmONPEKA pic.twitter.com/oaN0SVZtB1

— Market Intelligence: Healthcare (@SPGMIHealthcare) September 28, 2020

AstraZeneca to pay Daiichi Sankyo $1B up front in #cancer drug collaboration @AstraZeneca @DaiichiSankyo #dealmaking https://t.co/HjFewEzOS1 pic.twitter.com/8gdC72bRiM

— Market Intelligence: Healthcare (@SPGMIHealthcare) July 27, 2020

AstraZeneca-Daiichi Sankyo drug gets US FDA breakthrough tag for lung #cancer @AstraZeneca #enhertu https://t.co/8JOmhiH3dh pic.twitter.com/Gg2Bcxhuat

— Market Intelligence: Healthcare (@SPGMIHealthcare) May 18, 2020

COVID-19 Vaccine: AstraZeneca AZD1222 phase 1/2 trials to begin in Japan @AstraZeneca,@DaiichiSankyo #astrazeneca #astrazenecanews #clinicaltrial #coronavirus #covid-19 #coronavirusvaccine #azd1222 #daiichisankyo #jcrpharma https://t.co/ndeokzCfcI

— Medical Dialogues (@medicaldialogs) September 6, 2020

AstraZeneca, Daiichi Sankyo gets USFDA Breakthrough Therapy status for lung cancer drug Enhertu @AstraZeneca,@DaiichiSankyo #astrazeneca #cancer #enhertu https://t.co/6pyPdJqecP

— Medical Dialogues (@medicaldialogs) May 19, 2020

.@AstraZeneca has agreed a global development and #commercialization deal with @DaiichiSankyoUS, worth up to $6 billion for the Japanese #pharma. The deal centers on Daiichi Sankyo’s TROP2-directed antibody drug conjugate DS-1062 https://t.co/VC2DGKjyWP pic.twitter.com/BA6qSTSzWf

— CHEManager International (@CHEManager_EU) August 6, 2020

.@AstraZeneca has agreed to develop .@DaiichiSankyoUK Phase I cancer antibody drug conjugate DS-1062 worldwide except Japanhttps://t.co/jeq0LARzDm
DS-1062 is a trophoblast cell-surface antigen 2 -directed ADC for non-small cell lung cancer and triple negative breast cancer.

— Decipher Analytics (@DecipherAnalyt2) July 30, 2020

@AstraZeneca bets up to $6 billion on new Daiichi cancer drug.https://t.co/CvDOIuBdVj

— TheNewsPanels (@TheNewsPanels) July 29, 2020

A look at some of the success factors behind yesterday's mammoth ADC deal with @AstraZeneca #pharma #biotech

Oncology Deal-Making The Daiichi Way https://t.co/NPnpZgejGG

— Ian Haydock (@ScripIanHaydock) July 28, 2020

AstraZeneca bets $1B on Daiichi rival to Immunomedics' Trodelvy | @AstraZeneca @ImmunomedicInc @Pfizer @DaiichiSankyo #pancsm #lungcancer #cancer #breastcancer #Biotech #NewJersey https://t.co/QV27IJeUjW

— Aspen Biosciences (@aspenbio) July 27, 2020

AstraZeneca & Daiichi Sankyo enter collaboration to develop and commercialise new ADC https://t.co/c3BBGtcTba @AstraZeneca @EUdaiichisankyo More European life science business news at [LSE] at https://t.co/df6Gi5dTPT pic.twitter.com/E3kdckFgzF

— [iito] Life Science (@iitoLifeScience) July 27, 2020

.@AstraZeneca pays $1B upfront & ~$5B milestones to codevelop DS-1062 w/ @DaiichiSankyo outside of Japan

TROP2-directed DXd #antibody-drug conjugate is currently in Ph1 #clinicaltrials vs #NSCLC & #TNBC https://t.co/pXa46t3W6S #immunooncology #ADC #LungCancer #BreastCancer pic.twitter.com/jjm8bKCcyb

— DDNews Online (@DDNewsOnline) July 27, 2020

@AstraZeneca strengthens Daiichi Sankyo partnership with new development of a novel antibody drug conjugate (ADC) for the treatment of a number of multiple tumours which express the cell-surface glycoprotein TROP2https://t.co/aUefWC4btv vía @pmlivecom

— Jose Antonio Gasquet (@jagasquet) July 27, 2020

.@AstraZeneca & Daiichi have also been in talks over the supply of the British company's potential coronavirus vaccine in Japan.https://t.co/k1kqx6uYuL

— CNBC-TV18 (@CNBCTV18Live) July 27, 2020

.@AstraZeneca could pay up to $6 billion to #Japan's Daiichi Sankyo to develop and market a type of targeted cancer treatment in the second multi-billion dollar #cancer drug collaboration between the two companies.https://t.co/5CoLjHOdY9

— The Jerusalem Post (@Jerusalem_Post) July 27, 2020

AstraZeneca Collaborates with Daiichi Sankyo to Evaluate the Combination of Patritumab Deruxtecan (U3-1402) + Tagrisso for EGFR-Mutated Non-Small Cell Lung Cancer @AstraZeneca @DaiichiSankyoUS https://t.co/GegHhaEVis pic.twitter.com/y5XRj56gWY

— PharmaShots – Incisive news in 3 shots (@Pharmashot) August 7, 2020

Daiichi Sankyo in Talks with AstraZeneca for the Supply of AZD1222 to Combat COVID-19 in Japan @AstraZeneca @DaiichiSankyo https://t.co/xcsgbutsPz pic.twitter.com/T6p9mCQ6YE

— PharmaShots – Incisive news in 3 shots (@Pharmashot) June 29, 2020

AstraZeneca and Daiichi Sankyo Provide Updates of Enhertu (fam-trastuzumab deruxtecan-nxki) in HER2-Positive Metastatic Colorectal Cancer and HER2-Mutant Non-Small Cell Lung Cancer #ASCO20 @AstraZeneca @ASCO https://t.co/ukMWYKFZfo pic.twitter.com/SjMNX4tMH6

— PharmaShots – Incisive news in 3 shots (@Pharmashot) June 1, 2020

AstraZeneca Signs a Worldwide Development and Commercialization Agreement with Daiichi Sankyo for $6.9B @AstraZeneca
https://t.co/zV274HcNZW

— PharmaShots – Incisive news in 3 shots (@Pharmashot) April 1, 2019

One of @AstraZeneca's most decisive moves last year came when it signed a multi-billion dollar deal with @EUdaiichisankyo, focused on just one breast cancer drug. We spoke with Daiichi's @GillesJAGallant about the future plans for the drug https://t.co/C4VAEammCR pic.twitter.com/6NeXkiU5Kf

— pharmaphorum (@pharmaphorum) January 30, 2020

Results from a piviotal study of @AstraZeneca and Daiichi Sankyo’s trastuzumab deruxtecan, showed that women with breast cancer who had not responded to around six prior treatment courses saw no further progression for a median of 16.4 months https://t.co/TL1sLOmgf6

— pharmaphorum (@pharmaphorum) December 12, 2019

AstraZeneca, Daiichi Sankyo get Orphan Drug Designation for gastric cancer drug Enhertu @AstraZeneca #astrazeneca #enhertu #usfda #daiichisankyo #gastriccancer #trastuzumabderuxtecan https://t.co/ofKbiL4T8M

— Medical Dialogues (@medicaldialogs) May 25, 2020

Rare disease: Enhertu of @AstraZeneca and Daiichi Sankyo now with Orphan Drug Designation in the US for treatment of gastric cancer https://t.co/IZqqD1DNTf #gastricCancer #rarediseases #cancers #oncology pic.twitter.com/npY2FpPoZF

— EuropaWire (@europawire) May 22, 2020

From the Center for Biosimilars, @AstraZeneca + Daiichi-Sankyo win @US_FDA OK for #trastuzumab antibody conjugate #Enhertu https://t.co/s2E3s6bSr8

— AJMC-Oncology (@EBOncology) December 23, 2019

FDA accepts BLA from AstraZeneca and Daiichi for targeted chemotherapy@AstraZeneca @DaiichiSankyo #oncologydrugs #targetedchemotherapy https://t.co/NB0YHsLwUI

— Pharma Tech Focus (@PharmaTechFocus) October 18, 2019

AstraZeneca and Daiichi Sankyo sign $6.9bn cancer drug development deal @AstraZeneca @EUdaiichisankyo #cancerdrugdevelopment #bigpharmadealts https://t.co/lWXBRDSHS8

— Pharma Tech Focus (@PharmaTechFocus) March 29, 2019

Full house at AstraZeneca Exchange event at the Judge Business School, University of Cambridge. Fascinating insight to the recent AZ/Daiichi Sankyo deal from the people who made it happen @AstraZeneca @CambridgeJBS pic.twitter.com/CaN7n8PAw2

— Milner Institute (@TheMilnerInst) July 3, 2019

@AstraZeneca and Daiichi's #HER2 ADC hits goal in pivotal trial https://t.co/E0rhjfKnGX

— Miles Collier (@MilesCollier) May 8, 2019

.@AstraZeneca has signed a $6.9bn collaboration with Daiichi Sankyo to co-partner on cancer drug DS8201. Read full note here @LiberumToday #aim #shares https://t.co/R2styv9Pxs pic.twitter.com/trsEc3uZiW

— Research Tree (@research_tree) April 5, 2019

@AstraZeneca signs $6.9B deal with Daiichi Sankyo for #cancertherapy #healthcare #news https://t.co/kw2IhwuIBT

— Healthcare Opportunities (@HealthcareOppo1) April 3, 2019

.@AstraZeneca will pay up to $6.9 billion in #cancer drug deal with Daiichi and more for #pharma #marketers to know. #drugprices #DTC $JNJ $AZN $GILD https://t.co/CIJqaYE6LJ pic.twitter.com/j6VKJgbvgW

— MM+M Magazine (@MMMnews) April 1, 2019

.@AstraZeneca and Daiichi Sankyo brought us a huge deal last night. We worked on the Top 20 #cancer deals with @JohnCendpts at @endpts with data from @DealForma $AZN https://t.co/HJjEAS19Gz

— Chris Dokomajilar (@ChrisDoko) March 29, 2019

.@AstraZeneca sought to buy Japan's Daiichi Sankyo last year https://t.co/BQ6IFBwu8l pic.twitter.com/s933R4Glvb

— The Business Times (@BusinessTimes) August 31, 2017

#AZN £85.95 #AI #PHARMA $AZN & Daiichi Sankyo enter collaboration to develop & commercialise new #antibody drug✅
Calquence recommended for approval in the EU for chronic #leukaemia✅
Imfinzi recommended for approval in the EU for small cell lung #cancer✅https://t.co/pRRm18hjeI pic.twitter.com/uHD3PLkvay

— Peter Higgins (conkers) (@conkers3) July 27, 2020

#AZN-4% £62.05 $3.5Bn #Placing & collaboration w/ Daiichi Sankyo for #HER2 ADC #trastuzumab deruxtecan (DS-8201) w/ upfront payment of $1.35B, plus up to $5.55B include $3.8B for regulatory & other milestones, as well as $1.75B for sales-related milestones https://t.co/Lj8lTxIsdL pic.twitter.com/YmjCiZF2TR

— Peter Higgins (conkers) (@conkers3) March 29, 2019

AstraZeneca Resumes Clinical Study of its COVID-19 Vaccine in Japan @AstraZeneca https://t.co/l8IrrMu0oz pic.twitter.com/Wyn0BkNSKz

— PharmaShots – Incisive news in 3 shots (@Pharmashot) October 5, 2020

AstraZeneca and MSD’s Selumetinib Receive MHLW’s Orphan Drug Designation for Neurofibromatosis Type 1 in Japan @AstraZeneca @Merck https://t.co/azsnR93iP5 pic.twitter.com/34oe5UGj9p

— PharmaShots – Incisive news in 3 shots (@Pharmashot) June 30, 2020

.@AstraZeneca Plc said on Friday clinical trials of its experimental COVID-19 #vaccine resumed in Japan.https://t.co/enubUg9VQ6 pic.twitter.com/bSDa4lRQTp

— Arab News Japan (@ArabNewsjp) October 3, 2020

Major British drugmaker @AstraZeneca PLC said Friday that it has agreed with the Japanese government to launch negotiations on supplying #Japan with a #coronavirus vaccine currently under development with University of Oxford.https://t.co/OTrkWJzmHn pic.twitter.com/MYMrK1ZReE

— Arab News Japan (@ArabNewsjp) June 27, 2020

Japan's Prime Minister @AbeShinzo said Sunday that the country is in talks with pharmaceutical firms overseas to secure vaccines for the novel #coronavirus towards the end of the year.@AstraZeneca https://t.co/k41GZj2afH pic.twitter.com/hKODrfAh5O

— Arab News Japan (@ArabNewsjp) June 14, 2020

.@AstraZeneca resumes #COVID19 #vaccine trial in Japan, U.S. still paused. https://t.co/reQEFIZw5M

— A Voice For Choice Advocacy (@avoiceforchoice) October 2, 2020

https://twitter.com/moneycontrolcom/status/1311949554284023808

Kudos to @AstraZeneca whose Breztri Aerospher has become the first triple-combination therapy for #COPD in a pressurized metered-dose #inhaler device to be approved in Japan. https://t.co/9KlWUm8B8t #NoblePharma #GoNoble

— Noble (@NoblePharma) August 9, 2019

Latest newsletter highlights: VivaGel BV European & AU launch, $SPL’s 2nd @AstraZeneca agreement, VivaGel condom launch in Japan w/ @Okamototown & our DEP programs https://t.co/mOVSIwGRZ6 #ASX pic.twitter.com/jK9jN33tY9

— Starpharma (@Starpharma_ASX) July 1, 2019

#AstraZeneca Reports Approval Of #Tagrisso In #Japan https://t.co/yEwHkUDRvG @RTTNews @AstraZeneca #osimertinib #NSCLC

— Plexus Ventures (@PlexusVentures) August 22, 2018

In industry news: Lynparza Approved in Japan for BRCA-Mutated Metastatic #BreastCancer @AstraZeneca @Merck https://t.co/rYdVMDnSfm pic.twitter.com/GEOQrnCUeQ

— Mammary Cell News (@MammaryCell) July 6, 2018

What possibilities for business with the #EU #Japan free trade agreement? Highly relevant seminar in Stockholm today by @BusinessSweden and @SweMFA, with opening by @AnnLinde. @AstraZeneca @BabyBjornSweden @Virtusize @Kommerskoll pic.twitter.com/D9A92vi2tC

— Anna Stellinger (@AnnaStellinger) March 28, 2018

Inflammatory Intestinal Diseases Findings: Efficacy & Safety of Oral #Budesonide in Patients with Active #Crohn's Disease in Japan: A Multicenter, Double-Blind, Randomized, Parallel-Group Phase 3 Study #Crohns @AstraZenecaSE @AstraZeneca @S_Karger_Japan https://t.co/bejGi7Mmg5 pic.twitter.com/hZnd8trekI

— Karger Open Access (@KargerOpen) November 28, 2017

Our employees from around the globe did their bit for #EarthDay at the weekend, with teams from Serbia, to Japan & the US joining the #EarthDayCleanUp19. Find out more about our approach to environmental protection as part of our sustainability strategy: https://t.co/1wtTM2Z3xp. pic.twitter.com/N2xBB4hMvh

— AstraZeneca (@AstraZeneca) April 25, 2019

Did you know that we have committed to moving 100% of our vehicle fleet across Europe, North America & Japan to hybrid, plug-in or electric by 2025? This is one of the ways we are working to #ActOnClimate earning us a spot on the @CDP #CDPAList: https://t.co/1g9MJYeXD3 pic.twitter.com/1KbqbupS7C

— AstraZeneca (@AstraZeneca) February 25, 2019

https://twitter.com/BCCJapan/status/1193767882334687232
https://twitter.com/BCCJapan/status/1071924366328258560

Phase III and Phase II/III clinical trials studying immunization for #RSV disease prevention for all infants have launched in Japan. We are pleased to partner with @AstraZeneca in an effort to reduce the burden of #RSV worldwide. Learn more here: https://t.co/a7KpuD4M4Z pic.twitter.com/7ven9yqeHK

— Sanofi (@sanofi) October 11, 2019

Astrazeneca Pharma initiates the commercial launch of XIGDUOA XR tablets in India. XIGDUOA XR is a product of @AstraZeneca Group approved in 61 countries including US, EU & Japan. It is used to treat type 2 diabetes mellitus pic.twitter.com/JqEBOjh5dJ

— CNBC-TV18 (@CNBCTV18Live) February 12, 2018

.@AstraZeneca enters agreement with Kyowa Hakko Kirin to commercialise antibody to treat asthma/COPD in Japan http://t.co/3yBVniGTW0 #pharma

— SartoriusRoyston (@TAPBiosystems) July 18, 2015

Grünenthal to Acquire AstraZeneca’s European rights to Nexium & Global (ex US & Japan) Rights to Vimovo for up to $922m https://t.co/uAVjxWY3IX @grunenthalgroup @AstraZeneca More European life science business news at [LSE] at https://t.co/8to5cxePG5 pic.twitter.com/lceOUo8wHH

— [iito] Life Science (@iitoLifeScience) October 30, 2018

AstraZeneca: Tagrisso Approved in Japan for 1st-line EGFR-mutated NSCLC https://t.co/FRUMYxZIYx @AstraZeneca More UK & Irish life science business news at [LSE] at https://t.co/ShKV2svWTv pic.twitter.com/XDjdQn2XTd

— [iito] Life Science (@iitoLifeScience) August 21, 2018

#AZN £63.74 After positive news: #Calquence trial✅#Lynparza approved in the #EU✅#Bevespi #Aerosphere approved by the #Japanese MH✅
Lynparza approved in #Japan✅
Breztri Aerosphere (PT010) approved in Japan✅https://t.co/pRRm18hjeI #COPD #PHARMA #AI pic.twitter.com/z0rSyl0eqz

— Peter Higgins (conkers) (@conkers3) June 19, 2019

#AZN £59.90 #Tagrisso approved in #Japan for 1st-line treatment of EGFR-mutated non-small cell lung #cancer.
1st-line Tagrisso offers a potential new standard of care for Japanese lung cancer patients✅https://t.co/C8ZDZK9cuV #PHARMA #BIOTECH #BIOPHARMA #MEDTECH #AI #ML #SCIENCE pic.twitter.com/vCp7Y2yiWn

— Peter Higgins (conkers) (@conkers3) August 21, 2018

#AZN +2% £53.59$AZN Regulatory submission in #Japan for #Forxiga in type-1 #diabetes✅ https://t.co/TLiZLg7L6I

US regulators finally approve @AstraZeneca' potential blockbuster #LOKELMA drug✅https://t.co/GDxPfuUR0D #PHARMA #BIOTECH #INVESTING #QARP pic.twitter.com/0P5FEP3J0E

— Peter Higgins (conkers) (@conkers3) May 21, 2018

#AZN+1% £50.36 @DigitalLookNews #AstraZeneca gets approvals for #Fasenra & #Lynparza in #Japan✅Lynparza is the first poly ADP-ribose polymerase (PARP) inhibitor to be approved in Japan✅ https://t.co/ErNbKkH0YE #bronchial #asthma #COPD $AZN #PHARMA #BIOTECH #BIOPHARMA #MEDTECH pic.twitter.com/QLyA8r41IC

— Peter Higgins (conkers) (@conkers3) January 19, 2018

.@AstraZeneca Q1 Results http://t.co/eYQpCrJ12W Growth platforms (Brilinta, diabetes, respiratory, Emerging Markets & Japan) +13% to $3.4Bn

— Peter Higgins (conkers) (@conkers3) April 24, 2015

#DRG epidemiology report estimates more than 35,000 newly diagnosed cases of #chroniclymphocyticleukemia across the United States, Western Europe and Japan. Detailed global reports available now @DRGinsights #CLL #leukemia chronic #lymphocyticleukemia @AstraZeneca https://t.co/c93A2A45xs

— DRG Epidemiology (@DRG_Epi) December 2, 2019

#DRG epidemiology report estimates more than 3.5 million people affected with #hyperkalemia across the United States, Western Europe and Japan. Detailed report available now @DRGinsights #kidney #KidneyWk #chronickidneydisease @AstraZeneca https://t.co/PV3qywDoqv

— DRG Epidemiology (@DRG_Epi) November 18, 2019

#DRG epidemiology report estimates over 35,000 newly diagnosed cases of #chroniclymphocyticleukemia across the United States, Western Europe and Japan. Detailed global reports available now @DRGinsights #CLL #leukemia #lymphocyticleukemia #BloodCancerAwarenessMonth @AstraZeneca https://t.co/a86N2RqLkg

— DRG Epidemiology (@DRG_Epi) September 11, 2019

More than 7000 newly diagnosed #ovariancancer cases have #BRCA #mutations across the United States, Western Europe and Japan. Watch this space for more updates on #DRG global epidemiology data @DRGinsights #ovarian #cancer #biomarkers #tumors #genetictesting @AstraZeneca https://t.co/X2aYXDRkqQ

— DRG Epidemiology (@DRG_Epi) September 3, 2019

#DRG epidemiology report estimates more than 35,000 newly diagnosed cases of #chroniclymphocyticleukemia across the United States, Western Europe and Japan. Detailed global reports available now @DRGinsights #CLL #leukemia chronic #lymphocyticleukemia @AstraZeneca https://t.co/dIbsLkOrVa

— DRG Epidemiology (@DRG_Epi) August 22, 2019

More than 3.5 million people are affected with #hyperkalemia across the United States, Western Europe and Japan. Follow us for more updates on #DRG epidemiology data on #hyperkalemia #CKD @DRGinsights @AstraZeneca #KidneyWk https://t.co/xOVhUSaqVL

— DRG Epidemiology (@DRG_Epi) October 25, 2018

#DRG reports more than 10 million cases living with #Alzheimers across the United States, Western Europe and Japan https://t.co/r92nrjx1mO @DRGinsights @AstraZeneca https://t.co/xk3LFosS3Q

— DRG Epidemiology (@DRG_Epi) August 3, 2018

Thanks to our @ANZUPtrials #bestofGUoncology #ANZUPGU19 sponsors – @IpsenGroup Astellas Oncology @AstraZeneca @MSD_Aus pic.twitter.com/WtTfQE1djd

— ANZUP (@ANZUPtrials) November 6, 2019

Thanks also to our #APCCC APAC Satellite Symposium sponsors Astellas @AstraZeneca @IpsenGroup @JanssenANZ and Tolmar #APCCCinAPAC18 pic.twitter.com/AnrhNOAxuu

— ANZUP (@ANZUPtrials) February 23, 2018

.@MeetingsShow’s healthcare education speakers to include @AstraZeneca and Astellas: http://t.co/EtOBMyb9Q5 #TMS15 pic.twitter.com/xlnTvYk3fr

— Soaring Worldwide (@SoaringWW) June 16, 2015

United States Shingles Vaccine Market @SanofiPasteur,@GlaxoSmithKline,@Merck,@Pfizer,@AstraZeneca,@Mitsubishi,@EmergentBiosolutions,@Astellas,@Valneva,@Seqirus,@BavarianNordic,@Sinovac,@Panacea,@BharatBiotech #shingles #zoster #vaccine https://t.co/DIBnqocTp0 via @dpiresearch

— DPI Research (@DPIResearch) October 14, 2020

Vaccines Market Booming Worldwide With Leading Players https://t.co/yVs3yTmMC8 @SanofiPasteur,@GlaxoSmithKline,@Merck,@Pfizer,@AstraZeneca,@Mitsubishi,@EmergentBiosolutions,@Astellas,@Valneva,@Seqirus,@BavarianNordic,@Sinovac,@Panacea,@BharatBiotech

— DPI Research (@DPIResearch) September 28, 2020

United States Influenza Vaccines Market Forecast 2020 – 2027 https://t.co/ovFvfMYYfI @SanofiPasteur,@GlaxoSmithKline,@Merck,@Pfizer,@AstraZeneca,@Mitsubishi,@EmergentBiosolutions,@Astellas,@Valneva,@Seqirus,@BavarianNordic,@Sinovac,@Panacea,@BharatBiotech

— DPI Research Official (@dpi_research) August 28, 2020

I just published US Influenza(Flu) Vaccine Market https://t.co/I0te2HEkCW @SanofiPasteur,@GlaxoSmithKline,@Merck,@Pfizer,@AstraZeneca,@Mitsubishi,@EmergentBiosolutions,@Astellas,@Valneva,@Seqirus,@BavarianNordic,@Sinovac,@Panacea,@BharatBiotech

— DPI Research Official (@dpi_research) August 27, 2020

Analyst Keshalini Sabaratnam @Pharma_GD on the #sales #forecast for @Merck and #Otsuka 's #Keytruda (pembrolizumab) projected to be top drug by 2023 and what does this mean for their #contractmanufacturers #CDMO #CMO @AstraZeneca @BoehringerDE https://t.co/R6Wmwcm2Qb

— GlobalData PharmSource (@PharmSource) October 2, 2019

#Innovation #Index #Pharma @baxter_intl @Celgene #Otsuka @AstraZeneca @Roche @Novartis… https://t.co/zzzaGWoCii pic.twitter.com/sbAEuYm54a

— Biotechin.asia (@biotechinasia) April 10, 2016

AstraZeneca and Eisai make EMA demands:
The European Medicines Agency will relocate from the UK in light of Brexit. https://t.co/plD7JJnH1z @AstraZeneca #Eisai #EMA @EMA_News #Brexit #medicine #health #Lifesciences

— LifeSciencesIPReview (@LifeSciencesIPR) January 10, 2018

.@AstraZeneca and Eisai support continued @EMA_News oversight of drugs and safety on both sides of the Channel. Minimum demand is “mutual recognition” of medicines standards. #Brexit https://t.co/2RNHEIPPMA

— RegMedNet (@RegMedNet) January 9, 2018

On #WorldNTDDay we celebrate our industry partnerships to #beatNTDs including the innovative Drug Discovery Booster to discover new drugs with @abbvie @AstellasUS @AstraZeneca @bmsnews @Eisai_SDGs @merckgroup Shionogi & @TakedaPharma. pic.twitter.com/j4Xgs60vO2

— Drugs for Neglected Diseases initiative (@DNDi) January 30, 2020

DNDi partners with Eisai, Shionogi, Takeda, and @AstraZeneca to find new treatments for #Chagas and #leishmaniasis http://t.co/ZA64pVAEhE

— Drugs for Neglected Diseases initiative (@DNDi) May 29, 2015

Huge thanks to @wellcometrust for having confidence in us. Terrific to be working in partnership with @turinginst to combine scientific excellence with commitment to improve the working environment for trainees with @NHSDigital @eisai @gsk @AstraZeneca @Microsoft @intel @iqvia https://t.co/bjIYmMhDH0

— Andrew Morris (@profadmorris) September 16, 2019

Excellent dialogue b/t #GlobalHealth leaders, philanthropic pharm. cos. @AstraZeneca @Eisai and NGOs @DND about partnerships to #CombatNTDs pic.twitter.com/jQwl8S8XAP

— MAP International (@mapintl) October 27, 2017

The 2020 Pharmaceutical Innovation and Invention Index is live at @FortuneMagazine: https://t.co/dLQhy8vDMF
2020 Innovation Index
1 @Roche
2 @abbvie
3 @Novartis
3 @VertexPharma
5 @LillyPad
6 @AstraZeneca
7 @AlexionPharma
8 @Merck
9 Shionogi
10 @JNJNews
10 @Regeneron

— Mike Rea, IDEA Pharma (@ideapharma) April 6, 2020

.@purduepharma and Shionogi take on @AstraZeneca, @Valeant in opioid-induced constipation. https://t.co/KaqgT4sAnO #DrugApproval $AZN $VRX pic.twitter.com/LlFIXx79wf

— FiercePharma (@FiercePharma) March 24, 2017

Vaccines Market Booming Worldwide With Leading Players @SanofiPasteur @GSK @Merck @Pfizer @AstraZeneca @Mitsubishi @emergentbiosolu @AstellasPharma @Valneva @Seqirus @CSLLimited @BavarianNordic @Sinovac @PanaceaBiotec @Dynavax @Grifols https://t.co/G6av4krbos via @dpiresearch

— DPI Research (@DPIResearch) October 5, 2020

Check out my latest article: Flu Vaccines Market Worth $7.5bn by 2027
https://t.co/ZbzwVCpnrq via @LinkedIn @SanofiPasteur @GSK @Merck @Pfizer @AstraZeneca @Mitsubishi @EmergentBioSolutions@AstellasPharma @Valneva @Seqirus @CSLLimited @BavarianNordic @Sinovac @PanaceaBiotec

— DPI Research (@DPIResearch) October 7, 2020

https://t.co/6rgVwPyvqg @SanofiPasteur @GSK @Merck @Pfizer @AstraZeneca @Mitsubishi @EmergentBioSolutions@AstellasPharma @Valneva @Seqirus @CSLLimited @BavarianNordic @Sinovac @PanaceaBiotec @Dynavax @Grifols

— DPI Research (@DPIResearch) October 11, 2020

#ImaginAb joins with #AstraZeneca, #Pfizer and #Takeda to develop #tumourimaging #tech https://t.co/ccUgDG0BiV via @pharmaphorum @AstraZeneca @pfizer @TakedaPharma #technology #immunotherapies

— Plexus Ventures (@PlexusVentures) October 14, 2019

“@Novavax has signed similar deals with the UK, India, the Czech Republic, South Africa & Japan to supply doses of the potential #vaccine… [The Canadian government] is also in the final stages of negotiations with drug firm @AstraZeneca…” #COVID19 https://t.co/1qusqAiqJQ

— Mark Warner (@MAAWLAW) August 31, 2020

Takeda teams up with Novavax to introduce its coronavirus vaccine in Japan | @Takedapharma @Novavax @Pfizer @BioNTech @AstraZeneca @UniofOxford #Vaccines #Covid19 #Biotech #MatrixM #Maryland #OperationWarpSpeed @JNJ https://t.co/82tpoKazFb

— Aspen Biosciences (@aspenbio) August 9, 2020

Experts at @Astrazeneca, @Takeda and @Novartis tell us how to strengthen the collaboration and improve trust with patient community https://t.co/2sffvRXmJE #patients #patientcentricity #efppatients pic.twitter.com/QCW22ABoH2

— The Pharmaceutical Marketing Group (@PharmaMKTnet) September 28, 2019

Wrote about @AstraZeneca's new $1 billion plan to go carbon-zero by 2025 (carbon-neutral by 2030), and just how bad US-based big Pharma is

(Other Pharmas with near-term carbon-neutral plans: Novo Nordisk, Takeda and Novartis, all 3 EU or Japan-based)https://t.co/eqmNeLflQv

— Jason Mast (@Jasonmmast) January 23, 2020

U.S.A. アメリカ Vol.115（Indiana インディアナ州 Vol.2: pharmaceutical corporations 製薬会社）

All the below link and tweets are in English.

取り急ぎ以下貼っておきます。

Indiana Vol.8 (corporations: Eli Lilly)

追加

COVID-19 SETBACKS: As hospitalizations climb in America – with a field hospital set to open in Wisconsin Wednesday – Johnson & Johnson and Eli Lilly are reporting setbacks on vaccine and antibody treatment trials, respectively. @sramosABC reports. https://t.co/GnnUv1Mazk pic.twitter.com/PpPYNsCWBP

— World News Tonight (@ABCWorldNews) October 14, 2020

Eli Lilly says it is pausing the trial of its coronavirus antibody treatment because of a safety concern https://t.co/1H99MmaraN Johnson & Johnson said on Monday it would pause its COVID-19 vaccine trial due to an unexplained illness https://t.co/fTnt6q7uwa pic.twitter.com/EQzoQcBoX0

— Reuters (@Reuters) October 13, 2020

“This is an indication that the system is working as it was designed to work to protect human subjects in clinical trials,” said Lawrence Gostin, a public health and legal expert at Georgetown and Johns Hopkins universities. https://t.co/pZkPkzRSt2

— Statesman Journal (@Salem_Statesman) October 14, 2020

Coronavirus update: Regeneron, Eli Lilly seek FDA approval of antibodies, boosted by Trump's bout with COVID https://t.co/OdhsKigIwu by @AnjKhem pic.twitter.com/m05Ue3NYJi

— Yahoo Finance (@YahooFinance) October 11, 2020

Coronavirus update: Eli Lilly eyes emergency use for antibodies; Trump fumes over FDA vaccine guidelines https://t.co/g84f6tDmOI by @AnjKhem pic.twitter.com/ykVbjTX68x

— Yahoo Finance (@YahooFinance) October 8, 2020

The US pharmaceutical firm Eli Lilly announced it had applied for an emergency use authorization (EUA) for a lab-produced antibody treatment against Covid-19, after early trial results showed it reduced viral load, symptoms and hospitalization rates https://t.co/lOiibBnhLm

— AFP news agency (@AFP) October 7, 2020

ICYMI: @BillGates explains how the Bill & Melinda Gates Foundation has been “working with the companies doing antibodies” research for Covid-19 treatment. #MTP

Gates: “We’re partnered with Eli Lilly, who with Regeneron, has been the fastest to get these antibodies ready.” pic.twitter.com/JjAHoYGZPf

— Meet the Press (@MeetThePress) October 12, 2020

Project warp speed dropped the ball on antibodies. Was a mistake to focus mostly on vaccines and not enough on scaling up antibodies production (beyond what Regeneron and Eli Lilly can do) https://t.co/33zCOgkzMy

— avidresearch (@avidresearch) October 12, 2020

Monoclonal Antibodies for #SARSCoV2 #COVID19
(Regeneron, Eli Lilly, and Prometheus)
Great report by @apoorva_nyc

[1] Monoclonal antibodies are artificially synthesized copies of the most effective antibodies produced naturally by patients. https://t.co/cIh0ylmaIo

— Rajeev Chitguppi MDS (@chitguppi) October 13, 2020

Based on what's in the press release, these are impressive data and will surely lead to EUA for antibodies.

Reduction in ER or hospital visits from 5.8% in placebo to 0.9%. This is first demonstrated efficacy on clinical endpoints.https://t.co/HG4aWLS7nI via @statnews

— Walid Gellad, MD MPH (@walidgellad) October 7, 2020

Was it a blessing or a curse for Eli Lilly & Co. that President Donald Trump was treated with coronavirus antibodies made by rival Regeneron? https://t.co/ZS9tEO0lgv

— Bloomberg (@business) October 13, 2020

Eli Lilly has paused its monoclonal antibodies clinical trial after a participant got sick.

"They can produce infusion reactions and may be associated with everything from mild fever or rashes to anaphylactic shock,” @angie_rasmussen told me https://t.co/cXMPK37b0l @newrepublic

— Melody Schreiber (@m_scribe) October 13, 2020

An update on the Eli Lilly pause: researchers found a difference in the "clinical status" between people getting the placebo and the antibodies. We don't yet know what that means. But it's possible hospitalized patients may not benefit from the treatment.https://t.co/77byH7seUF

— Katherine J. Wu, Ph.D. (@KatherineJWu) October 14, 2020

Eli Lilly halts COVID-19 antibody treatment trial over 'safety concern' https://t.co/bbb5EJsIZm via @nypost
President Trump was given an experimental cocktail of manufactured antibodies to help in his bout with the virus and has since called his treatment a “miracle” and “cure”

— Muhammad Zafrullah (@mzafrullah) October 13, 2020

A Regeneron spokesman said its manufacturer "expects to begin delivering product in the first quarter of 2021," and that another company pursuing an EUA for monoclonal antibodies is working to meet demand. That company, Eli Lilly, just paused its trial. https://t.co/tPG7mTo5gO

— Michael Wilner (@mawilner) October 13, 2020

Eli Lilly press release* suggests monoclonal antibodies reduce COVID symptoms and hospital visits

*ie data not yet peer reviewed https://t.co/iP0431dweT

— Tim Lahey (@TimLaheyMD) October 7, 2020

Earlier today, I predicted that Trump would be treated with one of the experimental antibody treatments for #COVID19 (either from Regeneron or Eli Lilly). These work by providing “passive immunity,” similar to convalescent plasma, but are manufactured.https://t.co/ZnPrctsgMr

— Dena Grayson, MD, PhD (@DrDenaGrayson) October 2, 2020

IU and Eli Lilly are working together on potential therapies that range from using plasma from infected people to treat those hospitalized to developing drugs with antibodies to fight coronavirus. https://t.co/TxUYjQKJq3

— IndyStar (@indystar) May 6, 2020

ツイッター検索で上記製薬会社及び Japan や日本の5製薬会社各社名を入れて出て来たもの

New post (Cytotoxic Drug Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026| Roche, Eli Lilly, Celgene, Sanofi, eisai, Sumitomo Dainippon Pharma – Apsters News) has been published on FUNDSWIFT – https://t.co/4yzfwj7wW4 pic.twitter.com/fEus7AeoVx

— FundSwift (@fundswift) July 8, 2020

Who would want a simple solution?

"thank the leadership of AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eisai, Eli Lilly, Evotec, Gilead, GlaxoSmithKline, Johnson & Johnson, KSQ Therapeutics, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda, and Vir"https://t.co/V20z6DAu2U

— sandeep chakraborty (@sanchak74) June 12, 2020

Great to see so many pharma companies sharing assets and expertise to support research into COVID-19…Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Eli Lilly, Gilead, GSK, J&J, Merck, Novartis, Pfizer, and Sanofi. https://t.co/wtWagRqEV5 pic.twitter.com/6pq6mPl4Cm

— Jennifer Harris (@jnharris1189) March 26, 2020

Sanofi and Eisai Pharma are joining Eli Lilly in a lawsuit to overturn a ruling to end the patent protection of Cialis. Read more to find out the implications for patent claims for other pharmaceutical companies: https://t.co/kojTpbi2cl

— INCUBATE (@incub8coalition) July 17, 2019

Breast Cancer Therapeutics Market Factors That Can Have A Sizable Impact On Industry Growth With Players Like AstraZeneca plc, Eli Lilly and Company, Eisai, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Pfizer https://t.co/fizvl2Uiuq via @openPR

— Dr. Maddys (@Maddys53920205) April 18, 2019

Rectal Cancer – Pipeline Review, H2 2018 Featuring AbbVie, Amgen, Eisai, Eli Lilly, Merck, and more – ResearchAn.. https://t.co/7K2X5TDpLA

— Financial Buzz (@financialbuzz) October 19, 2018

The key industrial players in the anti-migraine drugs sales market include Abbott Laboratories, Inc., Eisai Inc., Eli lilly and Company, Pfizer Inc., Astra Zeneca plc. and Glaxo SmithKline Plc. https://t.co/POypY1bebe

— Amit Rade (@Market_Updates_) February 22, 2018

Other companies in the life sciences #COVID19 consortium are @BDandCo, @Boehringer, @biomerieux, Eisai, @LillyPad, @GileadSciences, @GSK, J&J, @Merck, @merckgroup @Pfizer and @sanofi

— Jim Sheldrake (@jimsheldrake) March 26, 2020

It was great to start day two at Biopharma mission presenting #Stemnovate to leadership in India @AstraZeneca, @GSK, @Sanofi, @Abbott, @Amgen, @NestleSkin, @LillyPad , @Serdiapharma, @Roche, @Oppilotech , @Eisai……looking forward to the next phase of meetings at Ahmedabad. pic.twitter.com/epxYmUC8uB

— Stemnovate Limited (@StemnovateL) September 25, 2019

Next for our #BIO2015 coverage: @Baxalta @PanCAN @BioCentury & ECL Eisai Co on the 5 P's of Successful Stakeholder Engagement.

— Eli Lilly and Company (@LillyPad) June 16, 2015

Latest Research Report on Bipolar Depression Treatment Market| GSK, Pfizer, Janssen Inc., Eli Lilly and Company, Allergan, Novartis, AbbVie, AstraZeneca, Otsuka Pharmaceutical Companies – Dagoretti News – Dagoretti News https://t.co/ohlTIlHYDa

— BipolarDays.com (@BipolarDaysNews) January 20, 2020

#SmallMoleculeCancerDrugs Market Rapid Growth And Development In Pharma & Biotech Industries 2018-2026 By Key Players Otsuka Pharmaceutical Co. Ltd, Eli Lilly and Co, Janssen Research and Development, Novartis AG, Pfizer, SANOFI AVENTIS US https://t.co/iuaAxGjYQC

— Michael Jaikishan (@Michaeljaikish1) July 5, 2019

"Editor’s note: The author did not initially disclose having received payments from Boehringer Ingelheim, Eli Lilly, Hoffmann-La Roche, Lundbeck, Merck, Sharpe, and Dohme, Otsuka, Pfizer, and other companies." You have to ask – why the delay? @AmerGeriatrics https://t.co/RWpZYRJ7zK

— James Richardson, MD, MPH (@DocRock54) March 10, 2018

.@TheDDFund $350M raise included $60M from @AARP as part of its #DisruptDementia initiative; fund spearheaded by #biopharma group that included @biogen @LillyPad @GSK @JNJNews Otsuka @pfizer @TakedaPharma

— BioWorld (@BioWorld) June 25, 2018

Otsuka inks deal for rights to migraine drug candidate fremanezumab https://t.co/AcRfmaGiro #biotech @LillyPad

— The Pharma Letter (@ThePharmaLetter) May 17, 2017

Interesting, head of #BorisJohnson's #COVID19 '#Vaccine Task Force', Kate Bingham, on board of DDF Investment Committee – created by 6 leading Pharma giants #GSK, Biogen, Johnson & Johnson, Eli Lilly, Pfizer, Takeda. https://t.co/ZOZ6Re3rxK

— Patrick Henningsen (@21WIRE) September 24, 2020

Biogen, Eli Lilly, Takeda ask staff to work from home to limit coronavirus spread https://t.co/IylUkp7Qse $BIIB $LLY

— FirstWord Pharma (@fwpharma) March 9, 2020

As Biogen grapples with coronavirus crisis, Big Pharmas like Eli Lilly, Takeda hunker down, tell staffers to work from home https://t.co/imJyrr1EQ3

— Endpoints News (@endpts) March 9, 2020

this is new
As Biogen grapples with coronavirus crisis, Big Pharmas like Eli Lilly, Takeda hunker down, tell staffers to work from homehttps://t.co/t6nrWWkjEJ

— John Carroll (@JohnCendpts) March 9, 2020

Fujifilm's flu drug Avigan improves COVID-19 recovery time, setting up filing in Japan | @WHO @FujifilmUS @drreddys @ResponseAid @GileadScience @Lillypad @Roche #Covid19 #pneumonia #Biotech #Valhalla #NewYork #Indianapolis #FosterCity #California #Biotech https://t.co/XfSqvA4Xp2

— Aspen Biosciences (@aspenbio) September 24, 2020

The key players in Non-Small Cell Lung Cancer #market include @Novartis, @Merck, @LillyPad, Hoffmann-La-@Roche, @Xcovery, @beyondspring26, @OSEIMMUNO, @sanofi, @Takeda, @abbvie and others.

For more detailed information visit: https://t.co/RWk90xqKhl #LungCancer #Cancer

— DelveInsight (@delve_insight) May 12, 2020

Congratulations again to all finalists in the 2019 @PharmaAwardsIRL and well done to all those in our sponsored category Astellas @bmsnews @LillyPad and @MSDInvents. Looking forward to October 24th.@IrishTimes https://t.co/ijZAo6krPM

— BioPharma Engineering (@BioPharmaE) September 16, 2019

#DRG epidemiology report estimates over 1.5 million people living with #ankylosingspondylitis across the United States, Western Europe and Japan. Check out our detailed global reports for more updates @DRGinsights #spondylitis #FDAapproval @US_FDA @LillyPad https://t.co/0CjXXNZN4T

— DRG Epidemiology (@DRG_Epi) August 27, 2019

#Pharma with '#AI friendly' executives will prosper: US, Germany, and Japan-based companies lead the pack, says @DK_Analytics report // @DeepTech_VC

Read: https://t.co/Ra1FDwHAXE @Boehringer @GSK @LillyPad @Evotec @pfizer @Amgen @BayerPharma @Roche @Novartis @bmsnews @Merck pic.twitter.com/df32pzpwpr

— Outsourcing-Pharma (@OutsourcPharma) July 8, 2019

Eli Lilly (@LillyPad) has had a mixed few days, posting promising trial results for mid-stage Crohn’s disease drug mirikizumab, undercutting a key insulin from Sanofi in the US, but facing safety concerns over a new breast cancer drug in Japan https://t.co/FEpzrbD2aM

— pharmaphorum (@pharmaphorum) May 22, 2019

#DiabetesCellTherapy
Scientists from US and Japan have devised a #newTissueEngineering method to tackle #vascularity problem of transplanted cells
Companies like @LillyPad @Sigilon_Inc are involved in Diabetes cell therapy development
For details click https://t.co/oJMBgdLQ2l

— Roots Analysis (@RootsAnalysis) May 9, 2018

@LillyPad keeps #Alimta patent in Japan for now, new challenges on the way$LLY https://t.co/bplSR75D4o

— Pharmacutical Daily (@PharmacDaily) February 2, 2017

The #ChicagoOsaka Women’s Leadership Forum featured our CEO Andy Zopp, @1871Chicago CEO @BetsyZEO, Mie Kitano of @LillyPad Japan, President Sachiko Morita of Terrace, and @UnivKansai faculty Masumi Shiraish to discuss global gender equality and #womenleaders in business. pic.twitter.com/tbYDfed5MT

— WorldBusinessChicago (@WorldBizChicago) October 24, 2018

Last week, we helped commemorate @LillyPad’s new office in Kobe, Japan. The company has been headquartered in Indianapolis for more than 140 years. #INJapan pic.twitter.com/Ik6MeY96az

— Indiana in Japan (@InvestIN_Japan) July 17, 2018

Indiana is home to 280+ Japanese businesses & Hoosier firms like @LillyPad, @Cummins, @CookMedical, @zimmerbiomet have facilities in Japan. pic.twitter.com/5RkAw6fv24

— Indiana Economic Development Corp. (@Indiana_EDC) September 12, 2017

#EDGEX2018 Speaker Fun Fact: Newt Crenshaw served as the president of @LillyPad in Japan, where he and his wife also helped establish a new @YoungLife ministry. Join us on October 5 as Newt shares his #leadership journey with us! https://t.co/nSglOE045U pic.twitter.com/r8EBLtRKv4

— EDGE Mentoring (@EDGEMentoring) June 13, 2018

@LillyPad #Drug Receives #Approval in #Japan https://t.co/X7VKcQ3DEi pic.twitter.com/w4Mgo6jIKK

— IMA (@IMA1901) July 7, 2017

#TPP "Allied for Innovation" Experts discuss US/Japan common #IP values @globalIPcenter @ITIFdc @USCC_Asia @LillyPad pic.twitter.com/V0yb52OMcW

— Patrick Kilbride (@pjkilbride) April 24, 2015

The U.S., Japan and China were standout markets in Q2 2016. Find out more: https://t.co/4KIV3ZB3nm $LLY pic.twitter.com/d1GMjXxAcQ

— Eli Lilly and Company (@LillyPad) July 27, 2016

Drivers of our Q1 #earnings results include the United States and Japan. Learn more: https://t.co/N0eQxNMDXJ $LLY pic.twitter.com/MRA9JrIGtV

— Eli Lilly and Company (@LillyPad) April 27, 2016

We celebrated Lilly #Japan Day by getting down to the art of the matter. https://t.co/oZFXQWVgrg pic.twitter.com/A54opqm4qq

— Eli Lilly and Company (@LillyPad) December 1, 2015

Speakers shared Lilly #Japan's importance on our 2nd-largest affiliate's 40th anniversary. https://t.co/Ix2v1clkrP pic.twitter.com/23lN8dkp3H

— Eli Lilly and Company (@LillyPad) November 29, 2015

Our #Japan affiliate just marked its 40th anniversary. We held Lilly Japan Day in its honor! https://t.co/Ix2v1clkrP pic.twitter.com/l1SMDRnvWI

— Eli Lilly and Company (@LillyPad) November 25, 2015

Performers took center stage as we celebrated our #Japan affiliate's 40th anniversary! https://t.co/Ix2v1clkrP pic.twitter.com/M61jKy49jf

— Eli Lilly and Company (@LillyPad) November 27, 2015

We're glad to share growth in the U.S. and Japan in Q3. https://t.co/aAFVq1fpjY #earnings $LLY pic.twitter.com/HqKjUjRSdQ

— Eli Lilly and Company (@LillyPad) October 22, 2015

　https://twitter.com/LillyPad/status/459766514456215552
　https://twitter.com/LillyPad/status/458323201479946240

https://twitter.com/Roxann_Minerals/status/975914779859701762

$LLY Here are the Accord Healthcare/Daiichi Sankyo/Eli Lilly IPR final determination docs. https://t.co/bckhh1Qaw8 https://t.co/iCIt9roKAz

— TradeHawk (@TradeHawk) September 12, 2016

Global Cardiovascular Therapeutics Market 2020-2024 | Evolving Opportunities with Astellas Pharma, Inc. and Eli Lilly and Co. | Technavio https://t.co/w46yHRXwvw pic.twitter.com/z9bYWSGkzP

— Latest News from Business Wire (@NewsFromBW) April 10, 2020

Ependymoma Market Future Innovation Strategies by 2029 | Eli Lilly, Astellas and DNAtrixhttps://t.co/kXAemzI6Mt #news #pharma #pharmiweb

— Pharma News (@pharminews) March 30, 2020

Cancer Treatment Drugs Market Size, Growth, Share and Top Players to 2026: Amgen, Roche, Novartis, Johnson & Johnson, Pfizer, Eli Lilly, Astellas https://t.co/9tASuYljgR pic.twitter.com/CxDF4MHAOF

— PressRelease.cc (@PressRelease_cc) October 1, 2019

Astellas, Eli Lilly must face lawsuit alleging underpaid Medicaid rebates https://t.co/VPhVGWIRf9 @nateraymond ($) pic.twitter.com/1HovatBRq7

— Reuters Legal (@ReutersLegal) April 5, 2019

Antibiotics Market Future Outlook to 2025 – GSK, Sanofi, Novartis, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Astellas Pharma, Pfizer, Janssen Inc. and Abbott https://t.co/gErVJuGW0d via @openPR

— Mohammed Alsogaih (@MAlsogaih) September 1, 2018

Eli Lilly, Astellas, China’s ShangPharma and Simcere helped raise $171M for Partners HealthCare System's life science fund. https://t.co/5wJ6YPKUJj

— FierceBiotech (@FierceBiotech) November 9, 2017

Great news! Sekisui has been named in the 2018 Global 100 World’s Most Sustainable Corporations: https://t.co/IQZWtjm4cy Congratulations to UCB, Merck, Allergan, Sanofi, AstraZeneca, Eli Lilly, Takeda, GSK, Novartis, J&J and others who also placed! pic.twitter.com/y6cmX0BRiX

— Sekisui XenoTech (@XenoTechllc) January 26, 2018

Breaking: Jury hits Eli Lilly, Takeda with $9 billion penalty. http://t.co/EIqfJ7JDRl

— IndyStar (@indystar) April 8, 2014